Treatment of inoperable hepatocellular carcinoma: from systemic to regional, from conventional to novel. by Leung, Wai-Tong. & Chinese University of Hong Kong Graduate School. Division of Medicine.
TREATMENT OF INOPERABLE HEPATOCELLULAR 
CARCINOMA 
- FROM SYSTEMIC TO REGIONAL, 
FROM CONVENTIONAL TO NOVS{=~A 
. ' . • ,' < . \~~, • • ~,,~ ,<, 
'l" 
. :' ~ <~: :~ \ '.~ :' \ \ 
. . - - - - -.-, ~. -\ ' l 
\ ': 
l ' · J. 
: ' .. ! 
BY 
WAI-TONG LEUNG, M.B.B.S. (H.K.) 
A Thesis submitted to The Chinese University of Hong Kong for the degree of 
Doctor of Medicine 
1995 
i 
o 7 MAY H91 
Dedicated to my wife, Rita, 
" "ti " • 
and my children, Lydia and Caleb, 
for their continuedsuppo~t, 




Table of Contents 
Precis to the thesis 
TABLE OF CONTENTS 
Glossary of abbr~yiation used in the thesis 
List of Figures and Pictures 
List of Tables 
Acknowledgments 
Statement of Originality 
PART ONE Introduction 
Chapter 1 Background for Hepatocellular Carcinoma 
1. History 
2. Epidemiology - World wide, China, Hong Kong 
3. Pathology 
4. Aetiology 
5. Clinical Manifestation and Diagnosis 
6. Natural History 
7. 




















Chapter 2 Hepatocellular Carcinoma in Hong Kong 
1. Clinical Study of 1119 cases of Hepatocellular Carcinoma 
PART TWO Conventional Treatm'ent for Hepatocellular 
Carcinoma 





Review of the Literature in Systemic Chemotherapy 
Phase IT Trials of Systemic Chemotherapy 
a. VP16-213 
b. Low Dose 4'-Epidoxorubicin 
c . . High Dose 4'-Epidoxorubicin 
d. 5-FU and High Dose Folinic Acid 
e. High Dose Ifosfamide 
Review of the Literature in Intra~'Arterial Chemotherapy 
Intra-Arterial Chemotherapy Trial Performed in PWH 
a. An Early Phase IT Trial. on Treatment of Inoperable 











with Lipiodol and 4'-Epidoxorubicin 131 
b. Phase 11 Trial of Treatment of Inoperable Hepatocellular Carcinoma 
by Intra-Arterial Lipiodol and High Dose 4'-Epidoxorubicin, a 
Comparison with Intravenous 4'-Epidoxorubicin 137 
iv 
PART THREE Novel Treatment for Hepatocellular 
Carcinoma 
Chapter 4 Selective Internal Radiation Treatment for 
Hepatocellular Carcinoma 
1. Review of the Literature in Radiotherapy for Liver Tumours 
2. Selective Internal Radiation with 131Iodine-Lipiodol in HCC 
a. Background and Review of the Literature 
b. Physical Aspects of 131Iodine-Lipiodol 
c. Bio-distribution of 131I_L in one HCC Patient 
d. Clinical Study on the Use of 131I-Lipiodol in the Treatment 
of Inoperable HCC 
3. Selective Internal Radiation with 90Yttrium-Microspheres in HCC 
4. 
a. Background and Review of the Literature 
b. Physical Aspects of 90Yttrium-Microspheres 
c. Treatment of Inoperable Hepatocellular Carcinoma with 
Intrahepatic-Arterial 90Yttrium Microspheres - An Early 
Phase 11 Study 
d. Treatment of Inoperable Hepatocellular Carcinoma with 
Intrahepatic-arterial 90Yttrium Microspheres through 
Hepatic Angiography 
Selection of Patients for 90Yttrium-Microspheres Treatment 
a. Diagnostic Scintigraphy with Hepatic Intra-Arterial 
Technetium-99m Macroaggregated Albumin in the 
Determination of Tumour to Non-Tumour Uptake Ratio 
in Hepatocellular Carcinoma 
b. Measuring Lung Shunting in Hepatocellular Carcinoma with 
















Correlation of Tumour Vascularity Grading by Selective 
Hepatic Angiography with TIN Ratio from Tc-MAA Scan in 
Hepatocellular Carcinoma 
Pulmonary Complications from 90Yttrium-Microspheres 
Treatment 
Conclusion of the Thesis 
.. .. . 1 
References to Chapter 1 
References to Chapter 2 
References to Chapter 3 
References to Chapter 4 
Appendix: 
1. Recommendations for Grading of Acute and Subacute Toxicity in 
Cancer Treatment 
2. Recommendations for Grading of Response Criteria 













Precis to; the M.D. thesis 
Background 
Hepatocellular Carcinoma (HCC) is the most frequent primary malignant tumour of the 
liver worldwide. The disease has high prevalence al!long Orientals. In Hong Kong, there are more 
than 1,200 new cases of HCC every year, according to the local Cancer Registry, amongst a 
population of 6,000,000. 
It is one of the most aggressive types of cancer. Patients suffering from the disease survive 
.. .., t .. 
on average 2 to 3 months from presentation. Most patients tend to present late and early detection 
is difficult because of the aggressive nature of the disease. The number of patients that can benefit 
from surgical resection is small (less than 15%), most patients having unresectable disease at 
presentation. By then, they usually have huge, multiple tumours and compromised liver function 
due to co-existing chronic liver disease. Even with definitive surgical resection, most patients still 
die of the disease because of recurrence. Their hope of cure is remote and they usually die 
miserably because of metastases or expanding local tumours. Therefore, there is a need to find a 
non-surgical treatment which can offer palliation, improve quality of life and, hopefully, prolong 
their survival or even produce a cure. Furthermore, since some patients after resection will have 
tumour recurrence, some form of additional post-operative adjuvant treatment may improve their 
prognosIs. 
Non-surgical treatment of HCC can be either chemotherapy or radiotherapy. 
Chemotherapy can be delivered systemically, or regionally through the hepatic artery. 
Radiotherapy can be delivered externally by megavoltage linear accelerator, or internally by 
unsealed radio-isotope sources. However, HCC is resistant to most of the conventional cytotoxic 
chemotherapeutic agents. External radiotherapy is not able to deliver an adequate radiation dose 
to the tumour because of the relatively low radiation tolerance of normal liver . Because of these 
\, 7 
obstacles, various forms of targeted therapy have been developed. These involve either the 
"tagging" of drugs (intra-arterial targeted chemotherapy) or radio-isotopes (selective internal 
radiation) to ,Lipiodol, microspheres or intravenous tumour-specific monoclonal antibodies. These 
modalities improve the therapeutic ratio through tumour-targeting and thus overcome cellular 
resistance. Although they have not yet been shown to cure HCC, they can prolong survival in 
cases that respond to the treatment, provide palliation of symptoms, and delay progression of the 
, disease. 
In order to improve patient management and coordinate research in the treatment of HCC, 
the Joint Hepatoma Clinic (JHC) was set up in the Prince of Wales Hospital (PWH) in 1985. The 
clinic sees every HCC patient that comes through PWH, organises investigations, enters patients 
into appropriate treatment protocols and follows up all patients on trial protocols. With an 
improved central registry of all HCC patients from PWH, we are able to understand more about 
the disease , and evaluate efficacy of various forms of treatment in a large number of patients. The 
author has completed 6 different phase 11 clinical trials with both systemic and regional 




The present study, started in 1985, has been trying to find a form of non-surgical 
treatment for inoperable HCC that could improve the outlook in terms of tumour response, 
tolerance and survival. The new form of treatment which is under test is selective internal 
radiation treatment. The hypothesis is "improvement in loco-regional control of the disease by 
this new treatment is feasible, effective, safe and can significantly improve outlook of patients 
with inoperable HCC". 
Scope and Outline of-the Study 
The present study will focus on treatment for inoperable HCC and exclude 
cholangiocarcinoma and secondary liver cancer. It starts by giving an account of the clinical and 
pathological features of HCC, the course of the disease and the outcome after conventional 
treatments. It is then followed by author's personal observation of the disease and all the phase 2 
trials of treatment done by the author from 1985 to date. This section defines the current status of 
conventional treatment. The study goes on to test the feasibility of selective internal radiation 
therapy by 13110dine-Lipiodol and Yttriurri90-microspheres, through studies of the distribution of 
the radioisotopes within non-tumourous liver and HCC. This is then followed by an assessment of 
the effectiveness and safety on the use of selective internal radiation therapy in treatment of 
inoperable HCC in clinical early phase 11 studies. Methods to select patients in order to improve 
effectiveness and safety of the treatment are described. The results are compared with current 
conventional treatments so that the research hypothesis can be judged to be accepted or rejected. 
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Objectives of the Study 
1. To have a better understanding of the problem of HCC epidemiologic ally. 
2. To have a bette! understanding of the behaviour of HCC in terms of outcome of disease 
and prognosis. 
3. To perform a literature reVIew of current non-surgical treatment of HCC, including 
chemotherapy, radiotherapy, arterial embolisation and local tumoural injection, in terms 
of technique, tumour response, toxicity and survival benefit. 
4. To review, on .a similar basis, all completed clinical studies on conventional treatments 
that were conducted by the author between 1985 and 1993. 
5. To test the feasibility, safety and effectiveness of a new form of treatment, selective 
internal radiation radiation treatment with Lipiodol-Iodine131 and Yttrium90 
micro spheres. 
6. To suggest future direction for research with selective internal radiation treatment in the 
management of HCC. 
Research Methods 
The method employed to test a new treatment for inoperable HCC was similar to that of 
phase 11 clinical trial. The end-points are: 
1. Treatment toxicity. Treatment toxicity were reported according to the W.H.O. 
recommendations for grading of acute and subacute toxicity. 
2. Tumour response rates. Response to treatment was measured objectively by radiological 
assessment of tumour size and biochemical measurement of changes in serum alpha-
fetoprotein and other relevant tumour markers. Definition of response was according to 
the W.H.O. recommendations. 
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3. Duration of remission and overall survival. Survival duration or duration of remission 
was calculated either from the date of diagnosis or first treatment to date of last event 
(death, default or alive). Survival probability was plotted according to the Kaplan-Meier 
method and comparison of survival obtained by using log-rank: tests. 
Overview of the Thesis 
Part I of the thesis provides background information, from the literature, regarding the 
history, epidemiology," pathology, aetiology, clinical features and diagnosis of HCC. The present 
status of treatment and prognosis is described. This section ends with a clinical study done by the 
author of 1119 patients of HCC seen in the Joint Hepatoma Clinic from 1984 to 1993. The study 
summarises the clinical features, biochemical characteristics on blood test results of all HCC 
patients, and reports patients' outcome and survival duration following various forms of palliative 
treatment. Both univariate and multivariate analysis were done to establish the prognosticators for 
HCC. 
Part 11 of the thesis gives an account of the present status of conventional treatment from 
the literature. It starts With a review of systemic chemotherapy and proceeds to a summary of 
various phase 11 trials of new drugs or combination chemotherapy that were done by the author. It 
is followed by a discussion of regional intra-arterial chemotherapy including details of two 
studies completed by the author. Other ~pecialised modalities such as absolute alcohol injection 
and hepatic arterial embolisation are also described. 
Part III of the thesis describes a new loco-regional treatment for HCC known as Selective 
Internal Radiation (SIR). Regional administration of radio-isotopes that are able to target the 
tumour is a new concept quite different from conventional treatment, and involves the use of the 
isotopes, 131 Iodine and 90Yttrium. The section starts with a review of the literature on 
radiotherapy for liver tumours. It is followed by a discussion of the physical properties and 
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preparation of the therapeutic materials and the technique of administration, and finishes with the 
results of treatment. Important radiological observations and new procedures for patient-selection 
using diagnostic radio-isotopic scans are discussed. Pulmonary complications of SIR will also be 
presented. The evidence presented in this thesis is consistent with the original hypothesis that 
selective internal radiation therapy is feasible, effective and safe in the treatment of inoperable 
HCC. 
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Summary of results done by the author 
1. Clinical study on 1119 cases of HCC that were seen in the Joint Hepatoma Clinic from 
1984 to 1993(1). This study sets in perspective problems we are now seeing in the 
treatment of HCC. 
1. There were 989 male and 130 female patIents. The sex ratio was 7.61 (M:F). 
2. The median age at presentation was 56 (range 13-87) years. 
3. Only 10% of the patients had operable disease and were offered resection as definitive 
treatment:'", . 
4. 43% of the patients presented with advanced disease and were not suitable for any 
form of treatment. 
5. 47% of the patients entered into various trials of non-surgical treatment, including 
systemic and/or regional treatment, with the use of cytotoxic drugs or radio-isotopes. 
6. 822 patients had survival data available. 787 patients have already died at the time of 
writing. The median . survival of the whole group of patients was 2.23 ' months (range 
0.03 to 92.37). The long-term survivors had all received surgical resection of their 
tumours. 
7. The levels of AFP (p=0.0036), haemoglobin (p=0.02S6), albumin (p=0.0487), 
bilirubin (p=O.OOOI), alkaline phosphatase (p=O.OOOI), are found to be prognostically 
important on multivariate analysis. 
Thus, although surgical resection offers the best chance of cure, most patients (90%) 
with HCC are not suitable for this form of treatment at presentation. 
11. Results on non-surgical treatment of inoperable HCC 
1. Phase II studies using different systemic chemotherapy 
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a. High dose 4'-Epidoxorubicin(7): objective response in 14.2% (4 out of 28 patients. 
Median survival 14 weeks. 
b. 5-Fluorouracil and high dose folinic acid(3): no objective response. Median 
survival 15 weeks. 
c. High dose Ifosfamide(4): no objective response. Median survival 13 weeks. 
2. Intra-arterial chemotherapy trials 
a. Early phase 11 study with intra-arterial Lipiodol-4'-Epidoxorubicin(5,6): uSIng 
escalatipg dose of 4'-Epidoxorubicin (50-90mg/m2), there was an objective 
response rate of 15.4% (2/16 patients) and a median survival of 10 weeks. 
b. Phase 11 study with Lipiodol-4'-Epidoxorubicin(7): using an uniform dose of 4'-
Epidoxorubicin (90mg/m2), there was an objective response rate of 6.7% (2/30 
patients) and a median survival of 18.9 weeks. There was no difference in terms of 
tumour response and survival when compared with a control group receiving the 
same dose of 4'-Epidoxorubicin intravenously. 
Ill. Study on the use of 131Iodine-Lipiodol 
1. Bio-distribution of 131Iodine-Lipiodol in an patient with Hee 
The results suggested 131Iodine-Lipiodol was mainly concentrated within tumour and 
had a longer biological half lif~ than normal liver. Other organs received relatively 
small amount of radiation. The radiation dose should be tumouricidal and safe to 
normal organs. 
2. Phase IT studies using intra-arterial 131 Iodine-Lipiodol (8) 
In this study, 26 patients with inoperable Hee were treated with this novel modality 
and achieved an objective response rate of 52% and a median survival of 6 months. 
Treatment toxicity was minimal. 
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IV. Study on the use ofYttrium-90 microspheres 
1. Early phase IT study with intra-arterial 90Yttrium-microspheres(9) 
In this early phase 1111 study, intra-arterial 90Yttrium microspheres was used to treat 
15 patients with inoperable HCC. The treatment was delivered through laparotomy in 
order to obtain dosimetry data. The data correlates well with pre-treatment simulation 
with Technetium-99m labeled macroaggregated albumin (Tc-MAA, discussed below). 
A 66% obJ~ctive response rate was documented and a median survival of 8 months 
was observed. 
2. Phase IT study with percutaneous intra-arterial 90Yttrium-microspheres 
In this study, using Tc-MAA scan to select patients for SIR treatment, intra-operative 
dosimetry was not necessary. The treatment was then delivered through hepatic 
angiography. Forty-seven patients were treated. The objective response rate was 67% 
with a minimal median survival up to 6.05 months. 
V. Study on case selection and complications of selective internal radiation therapy 
1. Study on lung-shunting after intra-arteIial injection of Technetium-99m 
macroaggregated albumin (Tc-MAA)(10). 
This method was designed to, detect percentage of lung-shunting by gIvIng a 
diagnostic dose of intra-arterial Tc-MAA. Those with high -lung-shunting were 
excluded from further treatment with SIR because it may cause radiation pneumonitis. 
In this study, the percentage lung-shunting from 125 patients varied between 8.1 % to 
67.2% with a median of 8.1 %. The degree of shunting depended on the vascularity of 
the tumour but not on the tumour size. The effect of angiotensin lIon lung-shunting 
was tested on 6 patients and there was no significant difference between those with or 
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without angiotensin 11 pre-treatment. The shunting was thought to be due to new 
vessel growth arising from within the HCC. 
2. Study on tumour-to-normal ratio after intra-arterial injection of Tc-MAA(ll). 
Intra-arterial T~-MAA scan was also used to predict tumour-to-normal ratio (TIN 
ratio) after SIR and select those with optimal TIN ratio for SIR therapy. The TIN ratio 
varied from 0.7 to 19.3 with a median of 3.8 among 124 patients. Twelve patients who 
entered the_,~arly phase 1/11 study with intra-arterial 90Yttrium had verification of TIN 
ratio by intra-operative dosimetry and scintillation count of liver biopsies. These all 
correlated well with the TIN ratio predicted by Tc-MAA scan. 
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3. Determination of tumour vascularity using selective hepatic angiography as compared 
with intra-arterial Tc-MAA scan in HCC (12). 
Fifty-one patients with HCC were also studied to determine the tumour vascularity by 
selective hepatic angiography (HAG) and compared with intrahepatic-arterial Tc-
MAA scan. The grades of vascularity on HAG were: grade 1 in 5 patients, grade 2 in 
13 patients, grade 3 in 24 patients and grade 4 in 9 patients. The tumour vascularity on 
scintigraphy was represented by the TIN ratio which was 0.9 to 11.1, with a median of 
3.7. There was no correlation bet~een the tumour vascularity grading on HAG and the 
TIN ratio on the Tc99m-MAA scan (Wilcoxon rank test: p=0.83). Thus, it was 
concluded that HAG can neither reveal the true vascularity nor reflect the TIN ratio in 
HCC. Tc-MAA scan remains the most important pre-treatment investigation in case-
selection for SIR treatment. 
16 
4. Radiation pneumonitis after internal irradiation(13) 
Five cases who had radiation pneumonitis after 90Yttrium-microsphere treatment were 
also documented. They all had high lung-shunting before treatment. The radiologfcal 
and pathological findings are described in the thesis. It is concluded that those patients 
with high lung-shunting should not be selected for SIR treatment. Attempts have been 
made to reduce lung-shunting by partial embolisation of the hepatic artery. These 
attempts will form the basis of a future prospective study, the rationale of which is 
also discuss,~d in this thesis. 
Author's role and contribution 
The author is responsible for the design of trials, collection and interpretation of data of 
all the trials mentioned in the thesis that were conducted between 1985 and 1994. 
Research Grants for the project 
The JHC group was granted by the UPGC grant committee an Earmark grant of 
HK$340,OOO in 1989 to carry out research .into the use of SIR, a novel therapy for inoperable 
HCC, which is still under investigation. I have been chief investigator on the project "A Study of 
131 lodine-Lipiodol injected into the Hepatic Artery for the treatment of Hepatocellular 
Carcinoma "RGC Ref No.: CUHK 44/89'~ since March 1992. I was also granted a direct grant for 
research on the project "The Study of Lung Shunting and Tumour/Normal Ratio of Liver in 
Hepatocellular Carcinoma after Intra-Arterial Technetium-99m macroaggregated Albumin". 
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Glossary of abbreviation used in the thesis 
131 I-E 131 Iodine-E thiodol 




AFP , Alpha Fetoprotein 
APTI 'Activated thromboplastin time 
Bq . Becquerel 
BCNU Bischloroethylnitrosourea 
CBP Complete Blood Picture 
CEA Carcino-embryonic Antigen 
CR Complete Remission 
CT Computerised Tomography 
CUHK Chinese University of Hong Kong 
GBq Gega-Becquerel 
HAG Hepatic Angiography 
Hb -Haemoglobin 
HBV Hepatitis B virus 
BCC Hepatocellular Carcinoma 
BCV Hepatitis C virus 
ICD International Classification of Disease 

























Magnetic Resonance Imaging 
Milli -Curie 
Percutaneous Ethanol Injection' 
Pro gressive Disease 
Partial Remission 
~~othrombin time 
Prince of Wales Hospital 
Renal and liver function test 
Static Disease 
Selective Internal Radiation 
Single Photon Emission Computerised Tomography 
Technetium-99m-Macroaggregated Albumin Scan 
Tumour Node Metastasis 
Tumour to non-tumour ratio 
Union Internationale Contra le Cancer 
Ultrasonogram 
World Health Organisation 
White blood cell 
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Background for Hepatocellular Carcinoma 
Hepatocellular ~arcinoma (HCC) is the most frequent primary malignant tumour of the 
liver. It was first described in text by Galen and Aretaeus, physicians in ancient Greece, in the 
second century AD( 1). Although at that time there was no distinction between a primary and 
secondary tumour, this is considered to be the oldest record of liver cancer. From the early 
eighteenth century when autopsies became common, many cases of hard nodules in the liver were 
described. These could have been cirrhosis, metastatic cancer or even primary liver cancer. 
Matthew Baillie(2) for example, described metastatic nodules in the liver and called them 
"tubercles". Cancerous livers were also described by Bayle in 1812(3), Rokitansky in 1855(4) and 
Cruveilhier in 1892(5). Virchow(6), in 1862 .. was the first to draw a clear distinction between 
primary and metastatic liver cancer. The first detailed description of primary liver cancer was 
probably by Kelsch and Kiener(7) in the late nineteenth century. In 1890, von Hansemann 
reviewed a total of 258 cases of malignant hepatic tumours at the Berlin Pathological Institute and 
reported that the incidence of primary liver cancer was far less than that of metastatic liver cancer 
in Europe(8). In 1911, the term hepatocellular carcinoma was coined by Goldsieher and von 
Bokay(9) and in the same year, Yamagiwa clearly differentiated two types of primary liver 
cancer, hepatocellular and cholangio, carcinoma, although he sowed the seeds of subsequent 
confusion by naming these hepatoma and cholangioma (10). 
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The first gross classification of primary liver cancer into nodular, solitary and diffuse 
types was first proposed in 1888 by Hanot and Gilbert(ll) and refined by Eggel in 1901(12). A 
histological classification of primary liver cancer was first proposed by Yamagiwa(13), 
Goldzieher and Bokay(9). As the clinical, macroscopic and microscopic features of primary liver 
cancer gradually became well recognised, large serie"s of cases were reported. Rosenberg and 
Ochsner in 1948 reported one case of their own and reviewed the world literature citing 1048 
cases(14). They commented "It (primary liver cancer) is no longer as uncommon as used to be 
thought". 
The epidemiology and causation of these tumours have also been widely studied. Berman 
in 1951 was the first to note the high incidence of primary liver cancer in Asia and Africa(I). 
This made researchers focus attention on the possible role of environmental factors or diseases 
specific to tropical countries. The discovery of aflatoxin in the early 1960s, a mycotoxin 
contaminant responsible for fatal liver disease in poultry, led to the possibility of chemical 
hepatocarcinogenesis. Another important risk factor was viral hepatitis. The association with 
primary liver cancer was first suggested by Payet in 1956 who noted high incidence of viral 
hepatitis in high risk primary liver cancer areas( 15). However, identification of specific viruses 
was not achieved until hepatitis B antigen was discovered by Blumberg in 1965(16a). The virus 
responsible for hepatitis A and hepatitis C (so called "non-A-non-B" hepatitis) were also 
identified, but only the latter can cause primary liver cancer(16b). 
In terms of diagnosis, clinical methods were the only tools available in the early years. 
Plain radiography was of little more benefit than a pair of sensitive hands in palpation of the 
tumour. Stirrett et al in 1954 described the first successful liver scans using an automated 
rectilinear scanner and gold-198 colloid( 17). Friedell and others demonstrated the use of iodine-
131. Rose Bengal and gold-198 colloid several years later in 1957(18). Technetium-99m sulfur 
colloid was introduced by Harper et al in 1965(19). These imaging techniques aided diagnosis 
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, and localisation of the tumour which is crucial in the planning of surgical resection as the 
definitive treatment. However, the most important discovery was a blood test for the disease 
which was discovered in 1963. Abelev and co-workers(20) detected a fetal protein, a-fetoprotein 
(AFP), in mice with chemically-induc~d Hee. AFP was shown to be present in serum of patients 
with Hee by Taratinov in 1964(21). The test is now' widely used in diagnosis, screening and 
follow up of Hee patients after treatment. 
Despite the rapid increase in understanding of the epidemiology, aetiology, pathology and 
improvement in diagnos'is of the disease, progress in treatment was relatively slow. Liver 
resection has been the only rational and scientific treatment for the disease. Planned hepatic 
resection only became possible with the advent of anaesthesia in the late nineteenth century. The 
first reported planned hepatic resection was probably done by Langenbuch in 1888 who excised a 
"corset tumor" (possibly a liver adenoma) from a 30-year-old woman(22). The first resection of a 
liver cancer was done by Lucke in 1891 (23). In 1899, Keen summarised the recorded experience 
of liver resection for tumours of 76 cases(24). Although the results were not satisfactory mainly 
because of bleeding and other complications, there were a few long term survivors. The results of 
surgical resection were further improved with . ~etter understanding of intra-hepatic structures so 
that hepatic resection could be done through anatomical planes. Improvement of surgical 
technique also helped in haemostasis which was the most difficult obstacle in the early times. 
These advances have made liver resection safer and more definitive for liver cancer. 
Surgical resection has still remained the only form of treatment, that can potentially 
produce cure of liver cancer. Despite the success of chemotherapy and radiotherapy in treating 
some other cancers, Hee has proved relatively resistant to these modalities, and it has been 
shown that they have only a small role to play if any in the curative treatment of HCC.Cure thus 




HCC is the most frequently occurring primary malignant tumour of the liver. World-wide, 
HCC is the seventh most common form of cancer in males and the ninth in females(25). The 
annual incidence of HCC has been estimated to be around 1 million a year with a male to female 
ratio of about 4: 1 world-wide(25). It is relatively common in South Africa, Southeast Asia, 
Taiwan, China, Japan, and the Pacific islands and uncommon in the white populations of western 
countries. The highest incidence rates for HCC have been documented in the black male 
population of Mozambique (98.2/100,000) and in the African males of Bulawayo in Zimbabwe 
(64.6/100,000). It is the second most common cancer in sout~ern Africa and Southeast Asia, and 
the third most common among males in China. HCC is relatively rare in America, northern 
Europe, northern Africa, and southeast Asia. 
In Asia, HCC is reported to be highly prevalent in China, Hong Kong, Korea, the 
Philippines, Indonesia, certain areas of Japan, Singapore, Thailand and Burma. In North America, 
the Chinese populations in the San Francisco Bay area and Los Angeles and the Eskimos in 
Canada have relatively high rates of occurrence. In most of Europe, the rates are low except in 
countries like Rumania, Switzerland, Poland, Italy, and Spain where the incidence rate is 
intermediate. The age-adjusted incidence rates of HCC among different countries are listed in 
Table 1.1. The age-adjusted death rates of HCC in males for some countries are listed in Table 
1.2. The age-adjusted incidence rates for HCC among male migrants are shown in Table 1.3. 
The overall incidence of HCC over the past 2 decades has been · stable and significant 
changes in individual populations are rarely found. From the 4 volumes of Cancer Incidence in 
Five Continents(26-29), 13 populations were identified for which a significant increasing trend in 
male HCC incidence was found. Most of these countries fall in the low risk areas. Two 
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populations show decreasing trend but they both belong to the very low risk areas (Table 1.4). 
The changes may be due to changes in diagnosis and registry. Among the high risk areas, isolated 
areas in sub-Saharan Africa have shown a decline in HCC incidence rates. The South African 
goldminers in Johannesburg have shown a rather steep and continuous downward trend in the 
incidence of HCC. The estimated figures were 80.5/100,000 in 1964 and 30.8/100,000 in 
1979(30,31). Van Rensburg et al(32) documented a decline in HCC incidence rates between 1968 
and 1975 in the general population of the Inhambane Province of Mozambique. The reasons for 
this decline are still unkn9wn, but it has been suggested to be due to a reduction in aflatoxin 
exposure with safer handling of crops and improvement in living conditions(30,32). The time 
trends of HCC in males abstracted from the 4 volumes of Cancer Incidence in Five 
Continents(26-29) are listed in Table 1.4. 
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Registry Male Females 
Los Angeles 
Chinese 12.0 3.8 
Spanish 4.1 1.4 
Black 3.9 0.9 
Japanese 2.7 1.6 
White 1.8 0.8 
New Orleans 
Black 4.2 2.0 
White 3.3 0.9 
Connecticut 2.0 1.0 
Hawaii .. ... . 
Hawaiian 10.3 7.2 
Filipino 9.5 1.8 
Chinese 7.8 3.1 
Japanese 5.7 2.2 
White 2.7 1.4 . 
Canada 
Eskimos 6.9 3.7 
Saskatchewan 1.5 0.6 
Alberta 1.3 0.5 
Europe 
Rumania, County Cluj 11.8 7.9 
Switzerland 
Geneva 9.7 1.3 
Vaud 6.3 1.9 
Poland 
Warsaw 8.3- 4.9 
Cieszyn 7.5 4.4 
Cracow 5.9 4.3 
Italy, Varese 6.9 2.7 
Spain 
Zaragoza 6.9 5.1 
Navarra 0.5 0.6 
France 
Bas-Rhin 4.9 0.7 
Doubs 1.9 1.1 
FRG,Hamburg 3.6 1.6 
German Dem. Republic 3.6 1.5 
Sweden 3.4 1.8 
Finland 3.2 1.7 
Czechoslovakia, Slovakia 3.1 2.6 
Denmark 2.9 1.6 
. Hungary 
Szabolcs 2.9 1.2 
Vas 2.9 1.4 
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Registry Male Females 
Yugoslavia, Slovenia 2.0 0.9 
UK 
East Scotland 2.1 0.8 
West Scotland 1.3 0.7 
Birmingham 1.4 0.4 
Oxford 1.1 0.4 
Asia 
Hong Kong 34.4 8.9 
People's Rep. China, Shanghai 31.7 9.1 
Singapore " " ' 1 
Chinese 32.2 7.1 
Malay 17.1 3.1 
Indian 14.0 4.8 
Burma, Rangoon 25.5 8.8 
Philippines, Manila 19.9 6.2 . 
Korea,~at. Reg. 13.8 3.2 
Japan 
~agasaki 11.9 2.9 
Fukuoka 7.2 2.2 
Osaka 5.6 1.2 
Miyagi 2.5 0.9 
Kuwait 
~on-Kuwaiti 9.6 1.8 
Kuwaiti 1.9 1.0 
Indonesia, Semarang 9.5 2.8 
Thailand, ~at. Reg. 6.8 2.3 
India 
Bangalore 4.7 1.6 
Bombay 2.7 1.0 
Madras 2.1 0.7 
Poona 1.3 0.8 
Israel, Jews 2.9. 1.3 
Iran, Fars 2.8 1.1 
Pakistan, all centers 0.7 0.8 
Turkey, ~at. Reg. 0.7 0.3 
Oceania 
~ew Caledonia 
Melanesian 18.7 5.7 
European 7.9 1.1 
Vanuatu (~ew Hebrides) 9.4 3.0 
~ew Zealand 
Maori 8.7 2.5 



















* All figures taken from Cancer Incidence in Five Continents(26-29) or Cancer Occurrence in 
Developing Countries(35) 
Table 1.2 Age-Adjusted Combined Death Rates of HCC In Males for Selected Countries 









Rates adjusted to the World Standard Population. 










Table 1.3 Age-Adjusted Incidence Rates for HCC Among Male Migrants(37,38) 
Population No. of patients per 100,000 population 
Chinese 
China 31.7 
Hong Kong 34.4 
Singapore 32.2 
United States 
San Francisco 18.1 
Los Angeles 12.0 
Hawaii 7.8 
Jews 
Born in Israel 
Born in Europe and U.S.A. 

















Table 1.4 Time Trends of HCC In Males and Age-Adjusted Incidence Rates (AAIR) For All Ages 
Country AAIR Country AAIR 
Populations showing a significant increase 
Gennan Democratic Republic Denmark 
1964-66 2.28 1953-57 2.68 
1968-72 3.17 1958-62 2.18 
1973-77 3.57 1963-67 3.14 
1968-72 2.85 
Hungary, Szabolcs--Szatmar 1973-76 2.91 
1962-66 0.85 
1969-71 0.93 UK, Birmingham 
1973-77 2.87 1960-62 0.80 
1963-66 0.80 
Finland 
.... { ~ 1968-72 0.95 
1956-61 1.39 1973-76 1.42 
1962-65 1.22 
1966-70 2.12 Canada, Alberta 
1971-76 3.16 1960-62 0.41 
1963-66 0.76 
Norway 1969-72 1.40 
1959-61 1.01 1973-77 1.19 
1964-66 0.95 
1968-72 1.51 Israel, Jews 
1973-77 1.56 1960-66 1.79 
1967-71 2.50 
Sweden 1972-76 2.90 
1959-61 1.79 
1962-65 2.45 Israel, Jews born in Europe/USA 
1966-70 2.91 1960-66 1.45 
1971-75 3.38 1967-71 1.95 
1972-76 3.08 
Japan, Miyagi 
1959-60 6.01 Puerto Rico 
1962-64 1.25 1962-63 2.74 
1968-71 1.75 1964-66 2.48 






Populations showing a significant decrease 
UK, southwestern USA, Connecticut 
1960-62 1.95 1960-62 2.37 
1962-65 1.71 1963-65 4.15 




HCC is the third most common malignant neoplasm in China causing approximately 
100,000 deaths annually and being responsible for about 40% of world liver cancer mortality(39). 
The age-adjusted death rates for liver ,cancer showed that the highest rate (more than 30/100,000) 
occurred in the south-east sea coast of China, particularly in Shanghai, Fusui (county province of 
Guang-Xi), Qidong (county province of Jiang-Su), Zhoushan, and Tongan counties (in Guang-
dong province)(40). The age-specific incidence rate of HCC in Shanghai was 39.29/100,000 for 
males in 1982 and HCC'is the third most common malignancy in males and fourth in females. 
The Qidong province has an even higher incidence up to 50/100,000 annually. In some high-risk 
areas, the age-specific incidence of HCC has nearly doubled over the past 2 decades: Shanghai 
from 8.96/100,000 (1959) to 13/100,000 (1982), Qidong from 20.45/100,000 (1958) to 
47.41/100,000 (1982). This may be due to more case findings with the screening method that was 
widely practised in these areas. Reasons for the clustering of cases around these areas are 
uncertain but it is thought to be related to hepatitis infection as well as hereditary. The 
geographical distribution of HCC frequency is listed in Fig 1.1. 
Chinese people in other areas outside mainland China also have high incidence rates. The 
age specific incidence in Taiwan which is among the high risks areas was 55.3/100,000(33). 
Chinese in Singapore (34.2/100,000), California (21.1/100,000), and other areas such as 
Malaysia, Indonesia, the Philippines, and Curacao also have high rates of occurrence. Rates in 








" Hong Kong 
HCC is the second most common cancer in males and seventh in females in Hong Kong 
. (Fig 1.3, 1.4). It accounts for 8 .. 5% of all newly diagnosed cases of malignant disease and 12.5% 
of all cancer deaths(36) . Compared with other areas, Hong Kong is thus in the highest risk zone 
world-wide (Table 1.2). The incidence rates per 100,000 and number of new cases of HCC from 
1984 to 1989 are shown in Figures 1.5 and 1.6 according to the Hong Kong Cancer Registry 
data(36). In 1989, there were 1,404 total number of new cases and a total incidence rate of 48.7 
per 100,000 population~ !· The age-specific incidence rates of HCC of males and females over the 
years 1984 to 1989 are shown in Figures 1.7 and 1.8 respectively. Since the cancer registry of 
Hong Kong Hospital Authority is run on a basis of voluntary notification by doctors, the figures 
tend to underestimate the real situation. However, there is still a slightly increasing trend over the 
years which is probably due to an increase in awareness and diagnosis of the disease. 
In view of this serious health hazard, the JHC was established in 1984 and had been seeing 
an increasing number of HCC patients (Fig 1.9). The reason for the increase is establishment of 
the service attracts referrals from other hospitals or private doctors. A detailed study of the 

















































































































































































































































































































































































































































































































































































































































































































































































































































Primary malignant tumours of the liver are classified according to whether they are 
mesenchymal or epithelial in 9rigin(41)(Table 1.5). HCC constitutes more than 90% of all 
primary malignant tumours of the liver. In the W.H.O. classification, HCC is grouped under 
malignant epithelial tumours and coded "155" in the International Classification of Diseases(42). 
Table 1.5 Different Types of Primary Malignant Hepatic Tumours 
1. Primary Malignant Epithelial Tumours 
a. Hepatoce/{ular carcinoma 
b. Hepatocellular carcinoma variants: childhood, fibrolamellar, combined, spindle 
cell, clear cell, giant cell, carcinosarcoma, sclerosing 
c. Hepatoblastoma 
d. Cholangiocarcinoma 
e. Hepatic cystadenocarcinoma, squamous cell carcinoma. 
2. Primary Malignant Mesenchymal Tumours 
Angiosarcoma, haemangioendothelioma, leiomyosarcoma, malignant schwannoma, 
fibrosarcoma, malignant fibrous histiocytoma, lymphoma, osteosarcoma, 
rhabdomyosarcoma,mesenchymalsarcoma 
(modified/rom Armed Forces Institute 0/ Pathoiogy,/ascicies 22 and 26,1989) 
Macroscopically, the tumour is either encapsulated or non-encapsulated, soft, of light 
brown colour and usually haemorrhagic because of the high vascularity. The non-tumourous part 
of the liver is often involved by cirrhosis which is present in more than 80% of patients (Fig 
1.10). Bile staining is occasionally seen which is due to bile produced by the tumour or secondary 
to biliary tract obstruction. The gross ~natomical classification of HCC, first introduced by 
Eggel(12) in 1901, is still widely used today. He classified HCC into 3 types according to the 
gross appearance: nodular (solitary or multinodular), massive or diffuse forms(12) (Fig 1.11-
1.13). 
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Fig 1.10 HCC in a background of cirrhosis 
Fig 1.11 Multinodular type HCC 
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.... ... .. : ........... . .. . . 
Fig 1.12 Massive type HCC 
Fig 1.13 Diffuse type HCC 
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The nodular form occurs as a solitary nodule or multiple nodules which vary in size and 
are sharply demarcated. Tumours that involve the entire right or left lobe, or which are as large as 
a single lobe, are designated as the massive form. This type is very commonly accompanied by 
multiple smaller nodules over other parts of the liver and are considered to be metastatic nodules. 
, The diffuse form consists of numerous small foci (about the size of cirrhotic nodules) scattered 
throughout the liver and can be difficult to be differentiated from cirrhosis macroscopically. The 
massive solitary forms encompass more than half of the patients having HCC. 
Microscopically;the tumour cells are often well-differentiated and in some show features 
resembling normal hepatocytes (Fig 1.14). They form a trabecular pattern lining the vascular 
sinuses. The tissue stroma is typically scanty. Bile production is usually present and is 
characteristic. Blood vessel invasion is frequent and a tumour thrombus may be the only clue to 
the malignant nature of the lesion. The presence of cirrhosis in the non-tumourous area is again 
found histologically in over 80% of patients. W.H.O. classifies HCC into 5 histological types: 
1. Trabecular type (sinusoidal) 
The tumour cells grow in cords of variable thickness separated by prominent 
sinusoids lined by flat endothelial cells ... The endothelial cells, usually inconspicuous, may 
sharply define the trabeculae. Fibrous connective tissue is absent between the tumour 
cords and cells, but a few collagen fibres may sometimes be detected in the sinusoidal 
walls. 
2. Pseudo glandular type (acinar) 
A variety of gland-like structures may be seen in this type. Canaliculi, with or 
without bile, are often recognisable and may be dilated into gland like spaces. Larger 
cystic spaces, lined by a layer of cells, are apparently formed by central degeneration and 
breakdown in otherwise solid trabeculae. 
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3. Compact type 
This is basically a trabecular pattern, but the tumour cells grow in apparently solid 
masses and the blood spaces are rendered inconspicuous by compression. 
4. Scirrhous type 
Areas with abundant fibrous stroma separating cords of tumours cells are most 
often seen following radiation exposure, chemotherapy or infarction. 
5. Other variants 
Other cyto.l~gical variants are listed as: pleomorphic, clear cells, tumour cells with 
scanty cytoplasm, spindle-shaped tumour cells, bile production, glycogen, fat, and 
cytoplasmic inclusions. 
The fibrolamellar type HCC is a histologically distinct type of HCC that deserves special 
consideration because of its distinct clinical behaviour. It was first reported by Edmondson in 
1956(43) and followed by 5 additional cases by Peters in 1976(44). The histology is characterised 
by polygonal cells with eosinophilic cytoplasm and pyknotic nuclei within a background of 
abundant lamellar fibrosis. This kind of HCC constitutes about 1 % to 2% of all HCC(45) and 
40% of cases seen in patients under 35 years of age are of this type( 46). The tumour is commonly 




Fig 1.14 HCC Histology 
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HCC is an aggressive disease. Spread is mainly haematogenous and appears to be a late 
I, phenomenon in the course of the disease. This is reflected by excellent treatment results for small 
HCC after surgical resection( 46). The disease can extend locally to invade the portal vein, inferior 
vena cava and hepatic vein. Hepatic vein involvement is usually suggestive of systemic 
dissemination. Hepatic artery and bile duct involvement are also common and the latter may 
result in obstructive jaundice. Distant metastasis occurs most commonly in the lungs. Bone, brain, 
skin and lymph node metastases are also documented. Patients die of the disease mainly because 
of cachexia, liver failure.and loss of organ function due to systemic metastases. 
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Aetiology 
The aetiology of HCC is still largely obscure. Causative agents for HCC have been sought 
using two general approaches. Firstly, by studying the epidemiologic association of HCC with 
other human diseases, and secondly, by examining the effect of carcinogens which are thought to 
be present in the human environment, in experimental animals. 
Looking at the wide geographical variation in the incidence of HCC outlined above, it is 
likely that environmental factors are playing an important part. First of all, the high risk areas for 
.. .. f · 
HCC coincide very well with those which have a high incidence of hepatitis B virus infection. 
This suggests that hepatitis B infection is one of the important aetiologic factors for HCC. The 
correlation between the incidence of HCC and that of hepatitis B virus carrier status is listed in 
Table 1.6( 48). Case control studies have also shown a strong association between chronic 
hepatitis B carriage rates and an increased incidence of HCC (Table 1.7). There was up to a 200-
fold excess incidence of HCC found in Taiwan among chronic HBV carriers(33). In Japan, 
hepatitis C virus (HCV) infection is an important causative factor for development of HCC which 
may explain a steady increase in HCC incidence rates in the last 3 decades(49) (Table 1.8). HCC 
patients in Hong Kong had a low incidence of HCV infection which is not as prevalent as in 
Japan(53). However, since HCV has no reverse transcriptase activity and is not a retrovirus it 
should, in theory, have no direct oncogenic potential. Most authors have therefore attributed the 
association with HCC to the chronic liver disease which chronic HCV infection may cause. 
Strong evidence for a relationship between HBV infection comes from molecular biology 
and animal model studies. Integration of human HBV DNA into the tumour tissue genome was 
first detected in 1980(50-53) and is very supportive of the epidemiological findings. The main 
animal model is the woodchucks. Hepatitis B-like viruses (hepadnaviruses) having the same 
morphology, biologic properties and genomic organization as human HBV have been identified 
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in animals which cause acute and chronic hepatitis as well as HCC in woodchucks(S4,SS). In 
view of the close relationship between HBV and HCC, large scale vaccination against HBV 
infection may reduce HCC incidence. 





































·, Table 1.7 Role of Hepatitis B in Case-Control Studies of HCC(57) 
NU. u{ patients HBsAg pusitiye 
Study HCC Controls HCC Controls Relative Risk Attributable 
Population (%) (%) (95% Cl) Risk (%) 
High-Risk 
. Areas 
Senegal 165 328 61.2 11.3 12.4 (7.7-19.3) 56.3 
South Africa 289 213 61.6 11.3 12.6 (7.7-20.1) 56.7 
Hong Kong(52) 107 107 82.0 22.0 21.3 (10.1-45.9) 78.5 
China 50 - '1 ' , 50 86.0 22.0 17.0 (4.3-99.4) 77.9 
Philippines 104 84 70.0 18.0 10.83 (5.3-20.9) 63.9 
Intermediate-
Risk Area 
Greece 194 451 45.9 7.3 10.7 (6.8-16.6) 41.6 
Low-Risk Area 
USA 86 161 17.9 0 (10.0-100) 
Table 1.8 Global Epidemiol59) of Hepatocellular Carcinoma and Association with Hepatitis 
C Virus Infection( ) and HBsAg Status 
Area, Country Overall HCV Anti-HCV according to HBsAg Anti-HCV in 
positivity rate in Status Controls 
HCC patients without HCC 
(%) Positive (%l Negative (%l 
Central Japan 73.5 (61/83) 35 (10/29) 94 (51/54) 0.9-1.2 
North Italy 65 (86/132) 54 (22/41) 70 (64/91) 
Sicily, Italy 76 (152/200) 58 (18/31) 79 (134/169) 
Barcelona, Spain 75 (72/96) 55.5 (5/9) 77 (67/87) 7.3 
Miami, USA 52.5 (31/59) 61.1 (11/18) 48.8 (20/41) 0.5 
South Africa 28.9 (110/380) 25.5 (47/184) 32.1 (63/196) 0.7 
Taiwan 33.3 (22/26) 16.7 (7/42) 62.5 (15/24) 0.95 
Hong Kong(59) 7.3 (31/424) 3 (15/341) 4 (16/83) 
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Liver cirrhosis is commonly a concomitant feature in the background of HCC and is a 
, known risk factor for HCC. Worldwide, 60% to 80% of HCC are associated with liver cirrhosis. 
The incidence may be even higher in Southeast Asia. In the study by Lai et al of 186 HCC 
Chinese patients, 95% of males and 71 % females with HCC had histological evidence of 
cirrhosis(60). This may be due to more prevalent HBV infection which is a common cause of 
cirrhosis. However, it is still not clear whether cirrhosis itself is a predisposing factor to the 
development of subsequeQt. HCC or whether the underlying causes of the cirrhosis are actually the 
carcinogenic factors. About 20% of North American patients with HCC do not have underlying 
cirrhosis,and probably not more than 20% have associated hepatitis B. Other conditions that 
predispose to liver cirrhosis such as alcohol, autoimmune chronic active hepatitis, cryptogenic 
cirrhosis, HCV infection may all possibly predispose patients to develop HCC. Hereditary 
metabolic diseases like genetic haemochromatosis and hereditary tyrosinaemia run a high risk of 
development of HCC. Possible conditions associated with HCC are listed in Table 1.9. 
Among all the chemical carcinogens, aflatoxin B1 is the best studied and most potent one 
to induce HCC. Aflatoxin B 1 is a product of the mould, Aspergillus fungus, and is found in a 
variety of stored grains, particularly in hot humid parts of the world where grains such as rice are 
stored in unrefrigerated conditions. The study by Linsell and Peers has established the 
relationship between intake of aflatoxin B1 and the incidence of HCC(61). Although aflatoxin 
was shown to be very potent, there are marked differences of susceptibility among different 
animal species. The rat was the most commonly used experimental animal in aflatoxin induced 
hepatocarcinogenesis. A study in the United States using mortality ratios and projections of 
aflatoxin contamination of food for 1910-1960 did not show the difference in mortality 
anticipated from either experimental or previous epidemiological studies in Africa and Asia(62). 
65 
Other carcinogens like Thorotrast, polyvinyl chloride monomer and arsenic are also known to 
induce primary liver tumours, particularly angiosarcomas and cholangiocarcinoma. 
Table 1.9 Conditions Associated With HCC 
Cirrhosis 
Hepatitis B virus 
Alcohol 
Autoimmune chronic active hepatitis 
Cryptogenic cirrhosis '" . 




Alpha I-antitrypsin deficiency 
Ataxia telangiectasia 
Types 1 and 3 glycogen storage disease 
Galactosaemia 
Citrullinaemia 
Hereditary haemorrhagic telangiectasia 











N -nitrosylated compounds 


























(modified from DeVita VT , Hellman S, Rosenbery SA ed (1993). Cancer, Principles and 
Practice of Oncology, 4th edition, Philadelphia, 1.B. Lippincott. P.887) 
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Although many causative factors have been identified in the development of HCC, the 
cause of the disease is probably multi-factorial. These factors operate differently in terms of 
weighting in different ethnic groups, geographical areas and other predisposing factors in the 
development of HCC. Cirrhosis may just be a common pathway rather than the cause of the 
disease. Similarly, HBV or HCV infections may just be by-standers which immortalise the liver 
and allow the latter to be exposed to the true culprit of carcinogenesis. 
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Clinical Manifestations and Diagnosis 
Clinical features 
Although HCC can present clinically in many diverse ways, most cases are already at an 
advanced stage when the patient is fir'st examined. This is due to the rapid growth rate of the 
tumour, which in some instances has a doubling time of as little as 10 days(63). In addition, the 
liver is a relatively large organ and the abdominal cavity can accommodate a sizable hepatic 
tumour before it becomes symptomatic. Therefore, patients tend to present late in the course of 
" "'! ' 
the disease. This makes early detection difficult and prognosis very poor. 
Most symptomatic patients with HCC present with abdominal pain, mainly in the right 
upper quadrant and epigastrium. Sometimes, the symptoms are attribu'ted to gall stone or peptic 
ulcer disease so that the diagnosis is delayed. Other symptoms such as anorexia, weight loss and 
abdominal distension are also common and usually suggest very advanced disease. Asymptomatic 
cases are also seen occasionally. They are mainly detected through health check-up or during 
follow-up for chronic liver disease. The disease may present acutely because of tumour rupture or 
upper gastrointestinal bleeding due to varices. The less common presentations are fever of 
unknown origin, bone pain and symptoms of hepatic failure. In Hong Kong where HCC is a very 
prevalent disease, HCC is the major differential diagnosis of hepatic enlargement. 
However, clinical features of patients in high-incidence areas are different from those 
patients in low-incidence areas. The median age tends to be younger in high-incidence areas and 
the course is more fulminant in young black Africans(64). Symptoms of upper abdominal pain, 
weight loss, weakness, anorexia, and abdominal swelling are more common and the duration may 
be as short as 4-6 weeks. The liver can develop into a huge mass in a short period of time and the 
presence of a bruit is commonly the predominant physical finding. Liver tenderness is usual~y not 
severe unless haemorrhage or necrosis has occurred within the tumour. Lai et al(65) who 
68 
reviewed 211 Chinese patients in Hong Kong :with HCC, also found abdominal discomfort a 
frequent complaint and hepatomegaly and ascites were common physical findings. In patients 
from low-incidence area such as North America, the stigmata of chronic liver disease are more 
common. However, the incidence of cirrhosis among HCC patients is the same between high and 
low risk areas(66,67) although the cause of cirrhosis is not the same. The cause of cirrhosis in low 
risk areas is commonly alcoholic or cryptogenic, and in high risk areas, viral hepatitis. The 
proportion of patients having positive Hepatitis B surface antigen status or high serum AFP level 
is also smaller in high risk,. ~reas(66,67) (Table 1.10). 
Table 1.10 Clinical Features of HCC Patients in High- and Low-Incidence Areas 
High-incidence Low-incidence 
Geographic location Asia, Africa North America 
Race Orientals, blacks Mostly whites 
Median age Orien tal, 40-50 50-60 
Black, 20-30 
Duration of symptoms Usually short, especially in Can be indolent 
young blacks 
Abdominal pain or discomfort 70-90% 50-70% 
Anorexia and weight loss Common Common 
Cirrhosis 60-80% 60-80% 
Stigmata of chronic liver Uncommon Common 
disease 
Haemorrhage secondary to 10-20% <10% 
ruptured tumour 
Positive HBsAg status 70-90% 15-40% 
AFP >400J.Lg/L 70-85% 30-65% 
Hepatocellular carcinoma is also known to be associated with many paraneoplastic 
features. Most of them are biochemical changes rather than clinically recognisable. However, 
these findings may herald a clinical illness. The paraneoplastic features include hypoglycaemia, 
erythrocytosis, hypercalcaemia and hypercholesterolaemia(68). Rare syndromes are porphyria 
cutanea tarda, feminization, carcinoid syndrome, hypertrophic osteoarthropathy, hypertension and 
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hyperthyroidism(68). There are at least 2 reports from Hong Kong which reported high 
:. prevalence of hypoglycemia(69) and erythrocytosis(70) in Chinese HCC patients. 
Attempts have been made to correlate certain clinical features with survival. However, 
many prognosticators may only operate in one geographical area and not in others. The single 
biochemical value found consistently to be of prognostic importance is the bilirubin level on 
presentation(64,65,7l), the higher the level the worse the prognosis. Fibrolamellar type HCC also 
has a better prognosis and has already been discussed in the previous section. 
The pattern of sp;'~ad of HCC is commonly systemic to the lungs and regional lymph 
nodes. Involvement of other areas such as adrenals, bone and brain is also common. The cause of 
death is usually cachexia, liver failure, haemorrhage from oesophageal variceal bleeding or 
ruptured tumour. When there is recurrence after definitive surgical resection or effective loco-
regional treatment, death is often a result of metastatic disease, presumably due to longer survival. 
Tumour markers 
Alpha feto-protein is a serum <ll-globulin with a molecular weight of approximately 
65,000-70,000 daltons. It is normally detected in the human foetus older than 6 weeks and 
disappears in the blood a few weeks after birth. AFP was first detected by Abelev and co-
.workers(20) in mice with chemically-induced HCC. Taratinov, in 1964, detected AFP in serum of 
patients with HCC(2l). Depending on the sensitivity of testing method for AFP, it is found to be 
abnormal in 70-90% of patients with HCC(72). Therefore, it can be used as a diagnostic test for 
HCC and is also useful in screening for HCC among patients with cirrhosis. It is also used in 
follow up of patients who received treatment for HCC. The profile of serum AFP level after 
treatment is a good indicator of response. However, AFP is also raised in patients with chronic 
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liver disease or cirrhosis even if HCC is not present, although at a lower level. Therefore, a cutoff 
value of 400ng/ml to 500ng/ml is usually chosen to make the test more specific to HCC(73). 
The prognostic value of serum AFP level is controversial. One report by Ch un et al(71) 
found that patients with AFP < 10,000ng/ml and >lO,OOOng/ml were 8.9months and 4 months 
'. respectively which was statistically significant. Shiu et al studied 340 HCC patients in Hong 
Kong and did not find serum AFP level to be prognostically significant(74). 
There are other tumour markers that can be detected in HCC but these are not as specific 
" ,!( . 
as AFP. Carcinoembryonic antigen (CEA) has been reported to be abnormal in as many as 39-
70% of HCC patients(7 5). However, CEA is also positive in other gastrointestinal malignancies 
and in patients with cirrhosis, so that its use in HCC is limited. 
Radiological Investigations for HCC 
The best diagnostic tool to image HCC is ultrasonography (USG) or a good quality 
computerised tomography (CT). USG is particularly useful for the diagnosis of portal venous 
thrombosis and is thought to be more sensitive in this respect than a CT scan or even an 
angiogram. The presence of portal vein thrombosis usually precludes a patient from surgical 
resection. HCC produces a typical "ring sign" on USG which consequently can detect lesions as 
small as 1 cm. It can also differentiate whether the HCC is of the nodular, massive or diffuse 
type. The procedure is widely used in screening programmes for high risk patients. Furthermore, 
USG-guided needle biopsy of HCC is commonly performed to establish diagnosis histologically. 
CT scan appears to display tumour extent better than USG and is crucial when planning for 
resection. Localized HCC usually appears as a slightly to moderately hypodense mass and 
occasionally as an isodense mass on plain CT scanning. Additional features suggestive of 
cirrhosis may also be noted. Hepatic angiography (HAG) is the next essential investigation before 
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;, surgery or any form of intra-arterial treatment. HCC is typically hypervascular with tortuous 
" blood vessels within it. Localisation of tun10ur and detection of small lesions is more sensitive by 
HAG than USG or CT scan. Furthermore, the detection of arterio-portal shunts, portal vein 
thrombus or the presence of any arterial anomaly may be crucial for future intra-arterial 
treatment. Besides using conventional X-ray contrast media during angiography, Lipiodol, which 
is a poppyseed oil and radio-opaque, is specifically taken up by HCC and remains in tumour 
tissue for longer than in normal liver tissue(76). It is now widely used as a diagnostic test for 
small lesions of uncertaiD--p.,ature. 
Hepatic scintigraphy is sometimes used in the diagnosis of HCC but has no added benefit 
over conventional USG, CT or angiography. The inherent limitation of scintigraphic imaging for 
HCC is its inability to detect lesions less than 2cm. Technetium 99m labeled tin or sulfur colloid, 
which is taken up by the hepatic reticuloendothelial system after intravenous injection, results in 
photopenic areas in HCC imaged by a gamma camera(77). Single photon emission CT (SPECT) 
can give more precise spatial orientation and clearer images after sulfur colloid 
administration(78 ,79) . SPECT is also capable of detecting smaller lesions than is possible with 
planar scintigraphy. 
Magnetic resonance imaging (MRI) is a new technique to image hepatic tumours. It is 
particularly good at detecting intra-hepatic lesions, especially in T2-weighted images. One of the 
major problems with this technique is the requirement for long data acquisition time and poor 
anatomic definition because of low signal-to-noise ratio and patient movement. The use of 
paramagnetic contrast agents such as gadolinium and the use of Tl-weighted sequences appear to 
provide somewhat better contrast(80). 
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Work-up/or HCC 
In patients with hepatomegaly and symptoms suggestive of HCC (pain and weight loss), 
investigation usually starts with blood tests for hepatitis Band C, serum AFP levels, clotting 
profiles and baseline liver function tests. A pos~tive serum AFP level> 500ng/ml together with a 
confirmed hepatic tumour by one of the imaging methods are virtually diagnostic of HCC. 
Patients with negative AFP or AFP < 500ng/ml require liver biopsy for diagnosis and this is 
normally performed under usa guidance. A confirmed case of HCC needs further work-up to 
plan treatment. Initial screen for extrahepatic disease includes chest radiograph and usa 
examination of other parts of the abdomen and pelvis. As surgical resection is still the mainstay of 
treatment, further investigation has to determine whether the disease is operable or not. This is 
done by detailed usa or CT scan examination of the liver together with hepatic angiography to 
show the exact location of the tumour. Disease localised to one lobe of the liver without any 
major vascular involvement or extrahepatic disease is usually resectable provided the liver reserve 
is good. Inoperable cases usually run a rapid downhill course and they should be put on best 
supportive care or entered into a clinical trial protocol. 
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, Natural History 
Hepatocellular carcinoma is one of the most aggressIve types of cancer. Even with 
surgical resection, most patients will still die of the disease because of either local or systemic 
recurrence. In Africa and the Far East, the tumour behaves particularly aggressively. Geddes and 
Falkson reported a mean duration of symptoms of 5 months in South African Bantu mine 
workers(81). Shiu's study on 340 Chinese Hong Kong patients only had a median duration of 
survival of 8 weeks(74) (most of whom did not receive any anti-cancer treatment). In the West, 
those without underlying "cirrhosis seem to survive longer(82). The fibrolamellar type of HCC 
probably is the only histological type associated with a better prognosis. Because of higher 
resectability rate, the median survival is up to 6 years. 
With better understanding of the disease and its high risk groups, screening programmes 
for HCC are currently ongoing in various countries, especially China and Japan. From these 
programmes, more early stage HCCs are found. The definition of a small HCC is a tumour less 
than 3cm in diameter. They were commonly picked up during follow-up for chronic liver disease 
when a high serum AFP level or a space occupying lesion on USG was found. The behaviour of 
these early stage small HCCs is different from symptomatic advanced cases of HCC. They were 
highly amenable to surgical resection and curative in a high percentage. Recurrence of tumour 
after resection is usually local and amenable to repeat surgery. The study from Shanghai on 
Chinese HCC patients showed that 60% of asymptomatic HCCs were resectable(83). The 5-year 
survival rates of asymptomatic small HCCs were reported to be from 40% to 70%(84) which is 
much better than symptomatic cases. Another study from Hong Kong, reviewing 17 cases of sub-
clinical HCC showed a high operability rate (76.5%) with median survival of 36 months (85). 
Progression of HCC is from local extension to systemic metastasis. Local infiltration to 
invade the hepatic arteries, hepatic and portal veins causing tumour thrombus within the blood 
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vessels is common In advanced diseases. Multiple secondary deposits within the liver 
" accompanying a huge solitary HCC is also common. It can also extend into the biliary system 
causing obstructive jaundice and was called "icteric hepatoma", a term coined by Lin(86). In 
Kojiro's review of 439 cases of HCC, 27 (6.1 %) cases had prominent tumour growth into the 
hepatic and/or common bile duct(87). 
Extrahepatic spread from HCC occurs usually in late stage except when the portal or 
hepatic vein is invaded early in the course of disease. The study by Mori et al found 52.8% of 
extrahepatic metastases from HCC were haematogenous and commonly involved the lungs and 
bone, while 29.8% were lymphatic and involved lymph nodes of the hepatic hilum, 
retroperitoneum, mediastinum and the para-aortic nodes as well(88). The lungs are the most 
common site of metastases from HCC, a figure of 40% being reported in an autopsy study by 
Willis et al(89). In more than half of these cases the tumour was only detectable microscopically. 
Systemic metastases are more likely to occur if there is hepatic vein thrombus which sheds 
tumour emboli into the systemic circulation. The extreme form of extension of tumour growth 
into the right atrium has also been reported(90,91). 
With local extent of the tumour, cirrhosis may be worse and complications arise. Variceal 
bleeding and hepatic failure commonly result in morbidity and mortality. Tumour rupture into the 
peritoneal cavity is a well recognized complication which carries a high mortality rate(92,93). 
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. Conventional Treatment for HCC 
Surgical resection 
Surgical treatment has long been the mainstay of treatment for HCC and is the only 
treatment modality that can offer the possibility of cure in HCC. Therefore, the possibility of 
surgical resection should be the first treatment considered for every .HCC patient. However, the 
number of patients that can be cured by surgery is small because most patients are deemed 
inoperable at presentation due to advanced disease or cirrhosis. Even with surgical resection, most 
" " f' 
patients will still die of tumour recurrence. During recent years, new surgical techniques have 
been developed to limit blood loss and to preserve hepatic function. The use of an ultrasonic 
dissector, vascular isolation and intraoperative ultrasound have contributed significantly to the 
safety of liver resection. Although these new techniques have reduced surgical morbidity and 
mortality, the number of patients that can benefit from surgical resection is still small. The rate of 
resection for patients presenting with symptoms is low, between 9% (Hong Kong Chinese, Lee et 
al)(94) and 27% (Japanese, Okuda et al)(95). The rate is higher in reports from Western 
countries, probably because of different referral patterns. Liver resection carries an operative 
mortality of around 5% in non-cirrhotic and 10-15% in cirrhotic patients. The 5-year survival rate 
of 225 Japanese HCC patients with liver resection was reported by Ozawa et al in 1991 to be 
35%(96). The prognosis tends to be better for non-cirrhotic patients. A multi-centre analysis of 
surgical treatment by stage from Japan showed a 3-year survival of 50% for surgically resected 
stage I disease and 25% for stage 11 disease using Okuda's staging classification(97). There were 
high intra-hepatic recurrence rates after resection(98,99) and patients often need a second 
operation for local recurrence(100). The size of the tumour is probably the most important factor 
affecting the success of resection. The significant influence of the size of tumour on the prognosis 
after hepatectomy was noted from Asian series(101) but not in Western patients(102). · This 
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discrepancy may be due to the fact that resection of HCC in Western countries is commonly 
performed on non-cirrhotic livers. Other factors which predispose HCC patients to have 
recurrence after resection are: close surgical margin of less than 10mm, intrahepatic metastases, 
tumour emboli in the portal vein and lack of capsule formation. 
Multi-modality approaches including resection 'have been studied. The influence of pre-
operative cytoreductive therapy on survival was explored by Tang et al (103) in China who 
reviewed 345 patients treated with a variety of pre-operative regimens: hepatic artery infusion of 
chemotherapy, cryosurgery; regional radiotherapy, hepatic artery ligation or radioimmunotherapy. 
An impressive 5-year survival rate of 63% was achieved in 32 patients who underwent sequential 
resection. However, due to heterogeneity of initial treatment and lack of a control group for 
comparison, it is difficult to draw any conclusion at the present stage. 
With improvements in screening and early detection of HCC, small HCCs are found more 
often than before. The prognosis after surgical excision of these patients is excellent. Zhou et al 
from Shanghai reported 14 patients with small HCC and produced 100% 5-year survival after 
resection(104). However, another study from Hong Kong by Lai et al(105) who reported 39 
patients with small « 5cm) HCCs receiving hepatic resection had no difference in 1, 3 and 5 year 
survival rate (59%, 28%, 11 %) when compared with those having tumours larger than 5 cm. The 
difference is difficult to explain. 
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, Liver Transplantation 
The pattern of recurrence after resection suggests that liver transplantation would be a 
more definitive way of tumour removal which may improve on the results of surgery. Actually, 
, most of the first patients to receive transplants had primary hepatic malignancy. However, the 
results were not satisfactory. In a group of HCC patients treated in Germany, 61 patients 
underwent transplantation as their primary operation and 6 after initial resection and recurrence. 
There were only 3 patients alive at 5 years post-transplantation(106). Most patients failed because 
of local and systemic recurrences. In an attempt to find prognostic factors after orthotopic liver 
transplantation for HCC, Yokoyama et al reviewed histopathologic features in 106 cases that 
received liver transplants in Pittsburgh (107). Tumour recurrence was reported in 51 % of patients 
who survived longer than 3 months. Eighty-five percent of recurrences occurred within 12 
months of transplant. Favourable factors included tumour size less than 5 cm in diameter, single 
tumour, no vascular invasion, no lymph node metastases, presence of a pseudo-capsule, 
circumscribed tumour, absence of margin invasion, and unilobar involvement. A more recent 
review by McPeake et al of 87 patients with HCC who received orthotopic liver transplantation 
showed that recurrence rate was higher for large (> 8 cm) and multifocal tumours(108). 
When comparing resection and transplantation, results were similar and poor for both 
treatments( 109). The results were even wors~- for transplantation in Ringe' s review of 131 cases 
of HCC treated by resection and 61 cases by orthotopic liver transplantation from the same 
centre. The study showed that survival at 5 years was 36% for resection and 15% following 
transplantation(106). A summary of the literature on results of liver transplantation for HCC is 
listed in Table 1.11. The poor treatment from transplantation in general suggests that when the 
disease has become symptomatic, there are already circulating tumour cells that lead to 
subsequent systemic metastases and local recurrences as well. Therefore, surgical resection when 
the disease is symptomatic or advanced does very little to benefit HCC patients as a whole in 
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\; terms of cure. Penn et al who reviewed all the liver transplant cases done at the University of 
. Cincinnati, found that for patients with asymptomatic hepatomas, the 2 and 5 year survival was 
. 57% which is better than those with symptomatic hepatomas(110). A favourable prognosis was 
also found for those with fibrolamellar type HCC who had 2 and 5 year survival rate of 60% and 
55% respectively. 
Surgical resection or transplantation still carry their own morbidity and mortality. The 
benefit of surgical resection is probably achieved only when the disease is still early. This relies 
on a cost effective screening programme of high-risk group patients. Whether liver 
transplantation can improve the outlook of those early-stage patients remains to be proved. 
Table 1.11 Liver Transplantation For HCC: A Review of the Literature 
Centre Patients (n) Overall survival 
I-year 2-year 5-year median 
Vienna, Funovics et al (111) 26 2.96 
(1977-1986) months 
Cambridge, O'Grady et al(112) 50 
(1968-1987) 
. Paris, Bismuth et al(113) 30 81% 
(1985-1989) 
Boston, Jenkins et al(114) 88 
(1983-1987) 
Hannover, Ringe et al (106) 65 22.8% 9.4 
(1972-1988) months 
Pittsburgh, Yokoyama et al(116) 80 64% 37% 37% 
(1980-1988) 
Birmingham, Ismail et al(117) 21 11.5 
(1982-1989) months 
Los Angeles, Olthoff et al (117) 16 40% 
(1984-1989) 
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, Systemic Chemotherapy 
BCC is well known to be resistant to most conventional cytotoxic drugs. Most cytotoxic 
drug protocols produce no more than a 20% objective response rate and response duration is 
usually short. The treatment also involves substantial toxicity for the patients. Therefore, systemic 
cytotoxic chemotherapy does not seem to be promising in HCC treatment. The study by Shiu on 
340 Chinese patients with HCC only showed a median survival of 8 weeks for patients treated 
with various forms of systemic chemotherapy and virtually no cure(7 4). The use of systemic 
chemotherapy in treatment' of BCC is mainly limited to inoperable cases, of palliative intent or in 
a protocol setting. Recently, there are many reports on using regional chemoembolisation 
suggesting an improvement in response rate and survival. However, they were not controlled 
studies and difficult to compare with systemic treatment. The discussion on chemotherapy and 
chemoembolisation are presented in Chapter 3. 
Radiotherapy 
Radiotherapy is feasible as a palliative treatment for inoperable HCC, mainly to relieve 
pain due to bony secondary deposits. Irradiation of the liver has been severely limited by the 
radiosensitivity of normal hepatocytes. External radiotherapy is not able to deliver an adequate 
radiation dose to the tumour because of relatively low radiation tolerance of normal liver. 
Therefore~ radiotherapy to the liver is not very often practised. New approaches to the use of 
radiation in HCC treatment are available now using radiolabeled antibodies, microspheres and 
Lipiodol. These will be discussed in Chapter 4. 
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Percutaneous Ethanol Injection 
Percutaneous ethanol injection (PEI) is another form of loco-regional treatment for small 
, HCC. Absolute ethanol immediately fixes or coagulates tissue in a dose-dependent manner. It also 
, causes occlusion of blood vessels and results in, coagulative necrosis of a tumour nodule and to a 
small extent the adjacent hepatic parenchyma. Systemic side-effects are usually minimal. It is 
done under ultrasound guidance, percutaneously, and requires an experienced ultrasonographer. 
An early study by Ebara et al treated 95 patients and reported 41.8% complete response after PEI 
for tumours less than 3cni>The 5-year survival rate was 28%(119). The side-effects are mainly 
pain, fever and a transient rise in liver enzymes. Livraghi et al(120) recently published the largest 
series of 2,485 PEI treatment in 207 patients with cirrhosis and HCC. The 1 year, 2 year and 3 
year survival rates were 90%, 80% and 63% respectively. For patients with lesions less than 5 
cm, prognosis was similar to that of a matched group of historical controls who underwent 
resection. 
Size of tumour is one of the limitations of PEI due to limited penetration distance of 
ethanol within liver tissue. It is indicated only in tumours less than 3cm in diameter(121). The 
technique is difficult for multiple tumours and , only suitable for patients with limited disease. 
These patients are usually not considered for surgical resection because of poor liver function due 
to cirrhosis. It is also indicated for isolated recurrence after surgery when further surgery cannot 
be done. Success of treatment is related to initial size of tumour. The procedure has also been 
found to be useful during laparotomy to control bleeding HCC(122,123). There are at least 1 non-
randomised(124) and 1 randomised trial(125) to compare PEI with surgical resection for small 
HCC «3cm) showing a similar treatment result. This suggests that surgery can probably be 
delayed and PEI can be the first treatment for small HCC. It also confirms the observation that 
small HCC behaves very much as a local disease with a low systemic metastasis rate. Therefore, 
an effective loco-regional treatment which is well tolerated may reduce morbidity or even 
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· mortality from surgical resection. Another treatment modality, like chemoembolisation has also 
: shown comparable treatment results with surgical resection for small HCC though not in a 
randomised trial setting ( 126) . 
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, Hepatic Arterial Occlusion 
Hepatic arterial occlusion or de-arterialization is another form of palliative treatment for 
inoperable HCC. It has been investigated as the sole therapeutic manoeuver and in conjunction 
, with intra-arterial chemotherapy (chemoembolisation). Hepatic arterial occlusion can be 
permanent and this is done by surgical ligation at laparotomy or by embolizing the feeding 
hepatic artery of the HCC with inert particles through hepatic angiography percutaneously. The 
principle of arterial occlusion is to induce ischaemia and necrosis of the HCC. Since the liver has 
a dual blood supply from",the hepatic artery and portal venous system, occluding the hepatic 
artery, which is the major supply of blood to the tumour, does not render the whole liver 
ischaemic. However, it is relatively contra-indicated if the portal system is blocked due to tumour 
invasion or thrombus. 
Surgical hepatic artery ligation or transection of smaller feeder vessels has been used by 
surgeons for HCCs. Four trials of surgical arterialligation are listed in Table 1.12. The treatment 
results were dismal and peri-operative mortality was high as well. This was due to poor selection 
of patients, since most had advanced disease, either complicated with tumour rupture or pain. 
Patients with an occluded portal vein seemed particularly at risk for rapid, fatal, postoperative 
liver failure(127, 128). 
Table 1.12 Results of Surgical Hepatic De':'arterialisation in HCC 
Investigators No. of Response (%) A verage Survival Perioperative 
patients (>=10% shrinkage) (months) Complications 
Lai et al(65) 33 37 1 11 deaths 
Almersjo et al(126) 5 <1 3 deaths 
Balasegaram et al(128) 24 8 deaths 
Olwenx et al(129) 15 27 6 deaths 
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Lack of long-term clinical efficacy from this approach is probably due to the rapid 
development of collateral vessels. The study by Plengvanit et al shows that neovascularization 
: can occur within one week of hepatic artery ligation(130). Collaterals could originate from any of 
the nearby arteries including the splenic hilar, inferior phrenic, gastric or gastroduodenal arteries. 
There was one prospective randomized study done in Hong Kong by Lai et al comparing surgical 
. hepatic de-arterialization and a control group receiving no treatment. Despite treatment-related 
mortality, especially in the de-arterialization group, no survival advantage could be demonstrated 
when compared to the contrpls, with median survivals both less than three months(131). 
Hepatic arterial embolisation can be done percutaneously through hepatic angiography 
which is a safer procedure and has less morbidity than surgical de-arterialization. Several types of 
foreign materials are used to occlude tumour vessels in HCC. Steel coils, Ivalon (250-590J..Lm) 
particles and gelatin sponge particles (Gelfoam, 3mm cubes) are used to occlude larger vessels 
more centrally located. Ivalon and steel coils can produce permanent occlusion of the hepatic 
artery while the other materials (Gelfoam, degradable starch micro spheres) only produce 
temporary occlusion. A temporary occlusion can allow subsequent intra-arterial treatment after 
the vessel opens up again. This is widely practis~d in conjunction with cytotoxic chemotherapy in 
chemoembolisation (to be discussed later in the respective section). 
The side-effects after percutaneous hepatic arterial embolisation are usually pain, fever 
and nausea. There may be a transient increase in liver enzymes(132) which is due to enzymes 
released by the dead malignant cells. Despite good symptomatic control for most well-selected 
cases for embolisation, the treatment has failed to improve survival as a whole. It remains as one 
of the choices of palliative treatment for pai~ or tumour rupture(133). 
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· Prognosis 
Although there are differences in incidence and frequency of co-existing cirrhosis among 
. different ethnic groups, the prognosis is in general very poor regardless of race and place. There 
is not much difference in prognosis among different histological variants of HCC except the 
fibrolamellar type which has already been discussed in the section on pathology. 
Aneuploidy, which was detected in 50% of HCC patients, correlated significantly with 
tumour size, the presence of vascular invasion or intra-hepatic metastasis, and poorer overall 
"., I~ 
survival. By multivariate analysis, nuclear DNA content, vascular invasion, and intrahepatic 
metastasis were found to be independent prognostic factors(134). Other poor prognosticators are 
poor Karnofsky Performance Score of less than 80, ascites, bilirubin greater than 1.5mg/dl, serum 
glutamic-oxaloacetic transaminase greater than 35 lUlL, alkaline phosphatase greater than 95 
lUlL and raised AFP levels(135). 
The TNM staging system for liver tumours that was used by the Union Internationale 
Contra le Cancer (UICC) and American Joint Committee on Cancer is outlined in Table 1.13. 
Stage I HCC are mostly operable cases except when they have very poor liver function, and can 
be expected to have approximately 50% 3-year' survival rate. Many of the stage I patients are 
asymptomatic and belong to the group of small HCC and therefore have favourable prognosis. 
Stage 11 disease, especially in those with vascular invasion has a poor prognosis even if resectable 
and is expected to have a post-resection survival rate of 25% at 3 years. Stage III disease is 
composed of a mixture of operable and inoperable disease. Those patients with multiple tumours 
involving both lobes of the liver, vascular invasion or extra-hepatic disease are probably 
inoperable and deemed to have a poor prognosis. The reported survival rates of this group of 
patients are ranged from 10% to 50% at 3 years according to whether there is presence of 
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cirrhosis or the disease is operable or not. Stage IV A and B diseases are commonly inoperable 
with disseminated disease having a grave prognosis. 
Table 1.13 TNM Staging System for Liver Tumours(136) 
Primary Tumour (T) 
TX Primary tumour cannot be assessed 
TO .. ~ No evidence of primary tumour 
TI Solitary tumour 2 cm or less in greatest dimension without vascular invasion 
T2 Solitary tumour 2 cm or less in greatest dimension with vascular invasion, or 
Multiple tumours'limited to one lobe, none more than 2 cm in greatest dimension without 
vascular invasion, or 
A solitary tumour more than 2 cm in greatest dimension without vascular invasion 
T3 Solitary tumour more than 2 cm in greatest dimension with vascular invasion, or 
Multiple tumours limited to one lobe, none more than 2 cm in greatest dimension with 
vascular invasion, or 
Multiple tumours limited to one lobe, any more than 2 cm in greatest dimension, with or 
without vascular invasion 
T4 Multiple tumours in more than one lobe or tumour(s) involve(s) a major branch of portal 
or hepatic vein(s) 
Lymph Node (N) 
NX Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
NI Regional lymph node metastasis 
Distant Metastasis (M) 
MX Presence of distant metastasis cannot be' assessed 
MO No distant metastasis 
































Since surgical resection is still the only treatment that can potentially produce a cure and 
alter the course of disease, whether the disease is operable or not very much affects the prognosis. 
, In the VI CC classification, there is a lot of mixing of inoperable and operable cases among 
respective stages so that the stage does not accurately reflect the prognosis of individual patients. 
The main drawback of the VICC system is that it does not include liver function parameters in 
staging HCC patients and poor liver function is commonly the deciding factor that makes the 
disease inoperable. Furthermore, the VICC classification appears to be complicated and not easy 
to use. In 1985, a more -simple and practical staging classification was proposed by Okuda et a1 
after reviewing 850 Japanese patients with HCC(97) (Table 1.14). It is a working staging system 
based entirely on clinical grounds which also takes into account the liver function of the patient. 
All of the patients were treated in the late '70s and early '80s. Surgical treatment was carried out 
in 18.5% of patients. There were 27% patients who did not receive any treatment and the rest 
received various forms of non-surgical treatment. The median survival of 229 patients who 
received no specific treatment was 1.6 months, 0.7 months for stage III patients, 2 months for · 
stage 11, and 8.3 months for stage I. The Okuda classification considered 3 parameters of liver 
function: presence of ascites, serum albumin and bilirubin levels. It correlates better with 
prognosis than the VICC classification and also has implications as to the operability of the 
patients. 
Table 1.14 Okuda Staging Classification for HCC 
Tumour Siz~ As~it~s Albumin Bilirubin 
>50% <50% <3g/dl >3g/dl >3mg/dl <3mg/dl 
Stage (+) (-) (+) (-) (+) (-) (+) (-) 
I (-) (-) (-) (-) 
, 11 1 or 2 (+) 
III 3 or 4 (+) 
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CHAPTER 2 
Clinical Study of 1119 cases of HCC inP.W.H. (1985-1993) 
In order to improve patient management and coordinate research in the treatment of HCC, 
the Joint Hepatoma Clinic (JHC) was set up in the Prince of Wales Hospital (PWH) in 1985. The 
clinic sees all cases of HCC, or suspected HCC, as referrals from private doctors and other 
departments within the hospital, organises investigations, enters patients into appropriate 
treatment protocols and follows up all patients on trial protocols. The team of doctors in JHC 
..... :. 
comes from various specialties: surgical oncology, interventional radiology, hepatology, 
pathology and clinical oncology. All patients have baseline biochemistry, haematology, virology 
and radiology studies (CXR, usa of liver and abdomen) on the day fIrst seen in JHC. 
, This retrospective study was done to review all cases seen in JHC over the past 9 years 
(from 1985 to 1993) who had been diagnosed to have HCC. The purpose is to show the present 
status of conventional treatments in HCC (systemic chemotherapy, regional intra-arterial 
chemotherapy, embolisation or supportive care alone). Outcome of various treatments, mainly 
survival duration, can serve as the baseline when comparing with other new treatments. This 
review will discuss clinical features, laboratory findings, prognostic factors, treatment outcome in 
terms of survival. 
' . 
Patients 
One thousand one hundred and nineteen patients who were diagnosed to have HCC in the 
Joint Hepatoma Clinic over the past 10 years (1984-1993) were studied. The diagnosis was 
established either histologically or by a serum AFP concentration of more than 500J..lg/L with 
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compatible radiological findings (either by USG, CT or HAG). Patients with bile duct cancer or 
secondary liver tumours were excluded. 
Methods 
A list of indexed patients with ICD code 155 (HCC) seen in the Department of Clinical 
Oncology, P.W.H., fro~ 1985 to 1993 was retrieved from the computer record. All the new cases 
-:{4 " 
seen in the Joint Hepatoma Clinic during the same time were also gathered from the attendance 
record. Both list supplemented each other and were combined to make a complete list. The 
patients' clinical notes were retrieved according to the list and reviewed if it satisfied the 
diagnostic criteria of HCC as listed above. The following information were recorded: 
1. General demographic data including ethnic group, sex, age, date first seen In our 
department, 
2. Haematological parameters at presentation: Haemoglobin level, total WBC count, platelet 
count, PT, APTT, 
3. Biochemical parameters at presentation: serum total bilirubin, albumin, alkaline 
phosphatase, alanine transaminase, AFP levels, 
4. Hepatitis B surface antigen status, 
5. Type of treatment received: surgery, systemic chemotherapy, intra-arterial chemotherapy, 
embolisation, supportive care and other treatments, 
6. Date of last event (either last follow up date if alive or default, death). 
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Statistical methods 
Analysis was performed using the Statistical Package for the Social Sciences (SPSS)(l). 
I Survival curves were calculated from the date first seen in the Joint Hepatoma Clinic to date of 
death or last event (default or alive) u&ing the Kaplan-Meier method. Comparison of curves was 
performed by the log-rank test. Multivariate analysis was performed to examine the independent 
I significant prognostic factors identified by the univariate analysis. The proportional hazards 
regression model of Cox was used(2). Results in univariate analysis were considered significant if 
the probability of occurrence by chance was 5% or less (p ::; 0.05). 
Results 
There was a total of 1771 patients seen in the mc between January 1985 and December 
1993. After merging with the list from the department patient registration computer record and 
scrutinising the diagnosis, 1119 patients records were reviewed. Most of the excluded patients 
were having one or more than one of the following reasons in order of importance: unavailable 
record at the time of review, uncertain diagnosis of HCC, only seen once in the mc and 
defaulted. 
The demographic data are shown in Table 2.1. The age distribution is shown in Figure 
2.1. Laboratory findings are shown in Table 2.2. Distribution of various forms of treatment is 
shown in Figure 2.2. There were 43% patients who were not suitable for any form of treatment 
except supportive care, considered to be terminally ill at presentation. Only 10% of all patients 
had surgical resection. The remaining 47% patients were entered into various trials for systemic 
or regional intra-arterial treatments. 
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Table 2.1 Patient Characteristics of 1119 Patients With HCC 
No. of patients 1119 
Chinese in origin 1119 
Sex: Male 989 
Female 130 
Male/female ratio 7.61:1 
Age: Median 56 
Range 13 - 87 
Table 2.2 Laboratory Findings for 1119 HCCPatients 
No. of Median Range Reference Range 
patients 
Haemoglobin (g/dL) 1041 12.8 3.8 - 20.0 13.2 - 16.7 (male) 
11.5 - 14.3 (female) 
PT (sec) 896 13.2 9.2 - 32.3 9 - 12 
APTT (sec) 886 36.3 7.4 - 71.0 22 - 37 
Albumin (gm/l) 1062 35 17 - 51 36 - 48 
Total bilirubin (J..Lmolll) 1071 18 1 - 898 0-15 
Alkaline phosphatase (lUll) ,1062 187 16 - 1938 30 -90 
Alanine transaminase (lUll) 1053 61 1 - 971 <58 
AFP (J..Lg/l) 1066 16821 (1 - 3,300,000) < 10 
Positive Negative 












































































































































































































Two hundred and ninety-seven patients were only seen once and then defaulted. Eight 
hundred and twenty-two patients were evaluable for survival analysis. Among these 822 patients, 
there were 35 patients still alive and 787 patients were dead. The survival data are listed in Table 
2.3 and the overall survival curve in Figure 2.3. The overall median survival including all patients 
was 2.23 months (range 0.03 - 92.37) calculated from the date of presentation to last event (death 
or alive). All the long term survivors (surviving more than 1 year) had surgical resection done . 
... .,: . .. 
The survival curves of various palliative treatments are shown in Figure 2.4. There is no 
statistical significance among all forms of non-surgical treatment. However, the treated group has 
a slightly better prognosis than the supportive care group (p < 0.005). This is expected because of 
case selection. 
Table 2.3 Survival status of 967 HCC patients 
Alive 
Death 
Lost to follow up 
Total: 



























































































































































































































































































































































































i, Prognostic factors 
All the parameters were tested with multiple regression and univariate analysis and the 
significant prognosticators for survival are shown in Table 2.4. Low serum albumin level (below 
36 g/l) is associated with a worse prognosis (Fig 2.5). Higher than normal total bilirubin level 
(more than 15 Jlg/l, Fig 2.6), high alkaline phosphatase level (more than 160 lU/l, Fig 2.7), high 
alanine transaminase activities (more than 58 lUll, Fig 2.8), high AFP level (more than 1,000 
Jlg/l, Fig 2.9) are associated with a worse prognosis. Anaemia at presentation is associated with a 
' ..,.,1 
.,. 
worse prognosis (Fig 2.10) but abnormal prothrombin time is not (Fig 2.11). Age (stratified by 
age = 56), sex and hepatitis status were not found to be significant in prognosis. Multivariate 
analysis was performed using the proportional hazard modeling and the results were unchanged 
except alanine transaminase level which became insignificant (Table 2.5). Treatment is not in the 
model. 
Table 2.4 Significant Prognostic Factors 
(P<0.05) For Survival 
(Monovariate Analysis) 
Variables cut-off p - value 
value* 
AFP 1000Jlg/l 0.0001 
Haemoglobin 13.2g/dl 0.0063 
Albumin 36g/l 0.0001 
Total bilirubin 
. 15Jlmol/l 0.0001 
Alkaline phosphatase 1601U/l 0.0001 
Alanine transaminase 581U/l 0.0001 
* Cut-off values are chosen to separate the studied 
population into 2 groups with comparable number 
o/patients 
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Table 2.5 Significant Factors After 
Multivariate Analxsis 
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The first clinical study of 340 cases of HCC from the Joint Hepatoma Clinic was 
published in 1990(3). In that study, the median survival of all patients was 8 weeks. An earlier 
study which was published in 1981 by Lai et al of 211 Chinese HCC patients in Hong Kong also 
found similar survival duration(4). The present study found a median survival of 2.23 months 
which is no different than previous study. The outlook of HCC patients has not changed much 
over the past decade. A lot of patients present still present late and often have unresectable 
disease. Various non-surgical treatments were offered to about half of the patients but did not 
succeed in prolongation of survival significantly. The marginal benefit is probably due to case 
selection. 
Our results in terms of survival seem to be worse than reported series outside Hong Kong. 
The study of 850 cases of HCC in Japan by Okuda et al reported an overall median survival of 4.1 
months(5). Another study by University of Texas M.D. Anderson Hospital of 163 patients 
showed an overall median survival of 7.1 months( 6). The surgical resection rate (16%) was 
higher with the latter series. The difference in survival may be due to racial difference, in the 
natural history of the disease or earlier presentation. Delay in treatment and diagnosis does not 
appear to be a cause of the difference because the JHC normally see the patient within 1 week of 
diagnosis and treatment can usually be commenced within 2 weeks if indicated. 
Karnofsky performance score, total bilirubin, albumin, alanine transaminase levels at 
presentation were found to be significant prognostic factors in Shiu's study(3). From the present 
study, we also found that AFP, haemoglobin, alkaline phosphatase, . at presentation are 
prognostically significant when more patients were studied. The status of hepatitis B surface 
antigen is not prognostically significant in both studies. 
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It was also noted in the present study that about 50% (Fig 2.2) of the patients who had 
inoperable HCC but not terminal, had satisfactory performance, score and liver function, were put 
on different forms of non-surgical treatment. Although the impact on survival is small, the overall 
outlook of HCC patients may be improved significantly if the form of non-surgical treatment can 
be improved. 
The analysis of initial symptoms was not repeated in the present study. Early report by 
Shiu(3) of 340 Chinese HCC patients has already given an account of the clinical features on 
presentation and is showii"in Table 2.6. The majority of patients presented with abdominal pain, 
mainly in the epigastrium or right upper quadrant, as reported in most of other series. Delay in 
diagnosis is commonly seen because the symptoms were attributed to other benign conditions. 
Table 2.6 Predominant Symptoms at Presentation 
Symptom/sign No. of patients Percentage (%) 
Abdominal distension/discomfort 259 76 
Malaise/anaemia/weight loss 15 4.4 
Haematemesi s/malean a 15 4.4 
Acute abdomen 10 2.9 
Abdominal mass/hepatomegaly 9 2.6 
Jaundice 9 2.6 
Asymptomatic 6 1.8 
Ankle oedema 4 1.2 
Bone pain 4 1.2 
Chest pain 4 1.2 
Haemoptysis 1 0.3 
Fever 1 0.3 
Dyspnoea 1 0.3 
Convulsion 1 0.3 
Diarrhoea 1 0.3 
Conclusion to Part I 
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HCC is a major clinical problem especially in Oriental populations. The prognosis of 
;. inoperable HCC is extremely poor. The expected median surv~val duration is about 8-10 weeks. 
I Even for patients selected for various forms of non-surgical treatment, the expected survival is 
only slightly longer than this. There are many patients who have inoperable disease at 
presentation but who are not in a terminal condition, ' and also are suitable for entering into 
various treatment protocols. An effective treatment for these patients may improve the overall 
outlook significantly. Since the current treatment for inoperable HCC does not prolong survival, 






Conventional Treatment for Hepatocellular Carcinoma 
, CHAPTER 3 
Chemotherapy for Hepatocellular Carcinoma 
Review of the Literature in systemic chemotherapy 
As early as the 19QPs, Brennan et al used 5-Fluorouracil (5-FU) in palliating patients with 
HCC although the response rate was only a 10%(1). Subsequent studies using intravenous or oral 
, 5-FU also · gave poor results with response rates of less than 10% and no impact on survival. As 
new drugs became available, these drugs were extensively tested for activity in HCC, mostly 
phase II settings (Table 3.1). Most chemotherapy trials were uncontrolled trials and they used 
different response criteria making interpretation and comparison of results difficult. The objective 
response rates reported were invariably below 25%. Quite often, that same degree of response 
could not be repeated by another observer using the same drug. Since complete response rate is 
lower than 10%, the effect of systemic chemotherapy on survival is minimal. Combination 
chemotherapy has not been proved to give a better response rate or to improve survival over 
single agent. Furthermore, many of these cytotoxic agents have a lot of side-effects. Considering 
the relatively short survival of patients with inoperable HCC, it is not justified to give all patients 
chemotherapy because of poor response and marked toxicity. The reported response rates of HCC 
to selected cytotoxic drugs given systemically are listed in Table 3.1. 
The group of anthracyclines and anthraquinones have so far been the group to show the 
most consistent response rate in HCC. Doxorubicin, one of the anthracyclines, is most often used 
in treatment of HCC. The initial trial by Olweny et al in 1975 showed an 80% objective response 
rate with a median survival of 8 months(2). However, further studies with larger number of 
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patients failed to show the same degree of response. The overall response rate from 13 published 
Doxorubicin trials is about 19% (3). The results from various trials using Doxorubicin are shown 
in table 3.2. The main toxicity from Doxorubicin treatment are cardiac toxicity and bone marrow 
suppression and both are dose-limiting. Survival duration after Doxorubicin treatment is difficult 
to determine because many reports excluded early deaths but the weighted average median 
survival from 13 studies was only four months(3). New analogues of anthracyclines and 
anthraquinones were also tested but did not improve the overall response rate although there was . 
a reduction of toxicity (Taple 3.3). 
Table 3.1 Single Agent Activity in HCC 
Investigators Drug No. of ~atients Resl!onse (% ) 
Brennan et aI, 1964(1) 5-FU 19 10 
Plengvanit et aI, 1964(4) Mechlorethamine 23 9 
Damrongak et aI, 1973(5) Vinblastine 25 8 
Falkson et ai, 1980(6) Neocarzinostatin 30 23 
Falkson et ai, 1981 (7) Amsacrine 35 3 
Cavalli et ai, 1981 (8) VP-16 25 12 
Melia et aI, 1981 (9) Cisplatinum 13 1 
Melia et aI, 1983(10) VP-16 24 13 
Falkson et aI, 1984(11) Neocar'zinostatin 28 7 
Falkson et aI, 1987(12) Cisplatinum 35 17 
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" Table 3.2 Doxorubicin Single Agent Activity in HCC 
Investigators Dose {mg/m:2 g3w2 No. of eatients ResEonse (%2 
OIweny et ai, 1975(2) 75 14 79 
Ihde et ai, 1977(13) 60-75 13 15 
- Vogel et aI, 1977(14) 20-75 41 11 
Falkson et aI, 1978(15) 40-60 57 16 
lohnson et aI, 1978(16) 60 44 32 
Olweny et aI, 1980(17) 
""'" 
75 74 30 
Williams et aI, 1980(18) 60 63 35 
Melia et aI, 1983(10) 60 31 26 
Barbate et aI, 1984(19) 30-50 12 0 
Chlebowski et aI, 1984(20) 75 52 12 
Choi et aI, 1984(21) 70 45 24 
Falkson et aI, 1984(22) 40-60 89 8 
Sciarrino et aI, 1985(23) 60 109 1 
In view of the poor results from single agent treatment, combination regimens were 
investigated. These trials employed various drugs with Doxorubicin or 5-FU. Most were, again, 
uncontrolled and involved small number of p~tients. These attempts again failed to improve 
tumour response rate or overall survival when compared to single agent therapy. However, 
treatment-related toxicity were markedly elevated with multiple drug therapy. Selected trials of 
combination chemotherapy in HCC are shown in Table 3.4. 
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: Table 3.3 Anthracyclines and Anthraquinones Activity in HCC ( excluding 
Doxorubicin) 
Investigators Drug No. of ~atients Res~onse (% ) 
Falkson et aI, 1984(24) Mitoxantrone 19 11 
. Van Echo et aI, 1984(25) Mitoxantrone 24 8 
Dunk et aI, 1985(26) Mitoxantrone 22 27 
Cheng et aI, 1985(27) Idarubicin 15 0 
Hochster et aI, 1985(28) Epidoxorubicin 18 17 
Shiu et aI, 1986(29) 
- '1 ' , Epidoxorubicin 17 0 
Table 3.4 Combination Chemotherapy in HCC 
Investigators Drug No. of patients Response 
(%) 
Baker et aI, 1977{30j Doxorubicin 38 13 
5-FU 
Bezwoda et aI, 1.982(31) Doxorubicin,5-FU 36 44 
VM26 
AI-Idrissi et aI, 1982(32) Doxorubicin, 5-FU 40 13 
Mitomycin C 
Falkson et aI, 1984(22) Doxorubicin,5-FU 38 21 
MeCCNU 
Ravry et aI, 1984(33) Doxorubicin, Bleomycin 60 16 
Gailani et aI, 1972(34) 5-FU, Ara-C 22 5 
Falkson et aI, 1984(22) 5-FU, Streptozotocin 55 13 
Falkson et aI, 1984(22) 5-FU, MeCCNU 49 8 
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HCC occurs in males more than females as noted in Chapter 1. This, together with the 
. detection of oestrogen(35) and androgen(36) receptors in HCC tissues, suggested hormonal 
, manipulation may be worthy of therapeutic evaluation. There is also clinical and experimental 
, evidence indicating that oestrogens are involved in the control of hepatocyte proliferation both in 
normal and in neoplastic conditions. Tamoxifen which is an anti-oestrogen showed no significant 
anti-tumour activity in one trial(37). Ho~ever, from a prospective controlled trial by Farinati et al 
on 32 cirrhotic patients with inoperable HCC receiving tamoxifen (30mg/day) or no treatment, 
there was statistically significant prolongation of survival in the tamoxifen-treated arm over the 
control arm with 35% as opposed to 0% survival at 12 months(38). Another prospective 
controlled study by Melia et al randomised 59 patients with inoperable HCC to receive either 
single agent Doxorubicin or tamoxifen with Doxorubicin (39). There was no difference in 
response rates or survival duration between the two arms. One patient from this trial had a 
complete remission for 30 months after combined treatment and maintained on tamoxifen alone 
for 18 months suggesting that tamoxifen may have a role in maintenance of Doxorubicin-induced 
remissions. Whether tamoxifen has a definite role in treatment of HCC has to be determined by a 
larger randomised study. Anti-androgen therapy has been used by Forbes et al using cyproterone 
acetate and reported 5 out of 23 male HCC patients having an objective response lasting for 8 
weeks(40). 
Besides cytotoxic agents, biological response-modifiers were used in the treatment of 
HCC. The recombinant alpha-interferons have been frequently tested for activity in HCC and 
produced comparable response rate and median survival duration with cytotoxic 
chemotherapy(41). The dose of interferon is between 5-15 million units which is a higher than 
normal dose and leads to marked toxicity( 42). It was concluded, in The Gastrointestinal Tumour 
Study Group, that alpha-2b-interferon has no significant anti-tumour activity in HCC( 43). 
However, a more recent, randomised, study of 71 Chinese HCC patients by Lai et al reported 
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prolonged survival and more tumour regression with high dose alpha-interferon (50 million 
. units/m2, 3 times per week) than no treatment( 44). Toxicity was considerable in this study as 
about 1/3 patients required dose-reduction because of persistent fatigue after interferon therapy. It 
seems that a high dose is required to produce optimal response rate and toxicity is proportionally 
more severe. The survival duration reported in Lai's study is still short (median survival 14.5 
weeks). Recombinant gamma-interferon was also tested in two trials and both concluded that 




: Phase 11 trials of Systemic Chemotherapy for Inoperable Hepatocellular 
Carcinoma in PWH 
Most of the above-mentioned trials tested various drugs among mostly non-Oriental HCC 
. patients. In Hong Kong, the prevalence of HCC is such that a large number of patients can be 
recruited for phase 11 studies over a short period of time. Consequently, the author has been able 
to complete five phase 11 systemic chemotherapy trials with various agents since 1985. The 
results are summarised in Table 3.5. 
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2 4' -Epidoxorubicin (29) 1985-1986 17 0 17 
3 4' -Epidoxorubicin(48) 1986-1987 33 9 10 
4 5-FU + HDFA(49) 1988-1989 25 0 15 
5 Ifosfamide(50) 1990-1991 17 0 13 
Patients and Methods 
All the patients that entered into various studies were from the Joint Hepatoma Clinic of 
Prince of Wales Hospital. The diagnosis of HCC was by histology or raised AFP of more than 
500J.lg/L with compatible features on USG/CT scan or HAG. They were considered to be 
inoperable by the surgeon because of locally extensive disease, poor liver function or 
performance score, major vascular involvement or extrahepatic disease. They were entered into 
various studies if they satisfied the following criteria: 
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1. Age ~ 75 
2. Satisfactory liver function tests (total bilirubin < 60Jlmol/l) 
3. Satisfactory bone marrow function (WBC count of > 3x109/l, platelet count> 
4. No serious medical illness. 
5. Clinically or radiologically evaluable disease 
6. Patient consent 
Trials 1-3 with VP16-213 or 4' -Epidoxorubicin were all out-patient treatment, whilst 
trials 4 and 5 required admission for continuous infusions. The detail dose schedule will be 
presented in the respective section. Response criteria was according to W.H.O. criteria 
(appendix). Trials 1-3 used clinical measurement of liver span and trials 4-5 used radiological 
means as response criteria. Toxicity criterias were according to the W.H.O. recommendations 
(appendix). The end-points were tumour response, toxicity profile and survival. 
Trial 1: Phase 11 Study of High Dose Etoposide (VP16-213) in Hepatocellular 
Carcinoma (47) 
Etoposide, or VP16-213, is a semi-synthetic derivative of podophyllotoxin, a naturally 
occurring compound extracted from the roots an,d rhizomes of the plants Podophyllum peltatum. 
This drug has both parenteral and oral form. It has been proved to have activity in a wide range of 
solid tumours, mainly non-small and small cell lung cancer, haematological malignancies, germ 
cell tumour and ovarian carcinoma. However, the activity of Etoposide in gastrointestinal 
malignancies is low. Cavalli et al in 1981 (8) and Melia et al in 1983(10) had published phase 11 
studies of Etoposide in HCC. Both reported about 12% objective response rate. 
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The activity of Etoposide is tested in this phase 11 trial. Eighteen Chinese patients were 
.. ' entered and evaluable for response, survival and toxicity. The dose given was Etoposide at 
t 
'. 200mg/m2 intravenous in a short infusion, given daily for 3 days once every 3 weeks. There was 
. no observable tumour response but the treatment was well tolerated. The overall median survival 
was 74 days. The conclusion from this trial was no appreciable activity of Etoposide at this dose 
level. The dose of Etoposide was comparable to that reported by Cavalli et al (120mg/m2 D1-5, 3 
weekly)(8) and Melia et al (180mg/m2 D1-3, 3 weekly)(10) but the response rate was inferior. 
This study used clinical assessment of liver span as response criteria which was not as 
accurate as radiological assessment. However, there was no response documented because most 
disease showed progression during treatment even on clinical ground. 
Trial 2: Phase 11 Trial of Epirubicin in Hepatoma (29) 
Epirubicin (4' -Epidoxorubicin) is a second generation anthracycline and was selected for 
clinical trials based on its pre-clinical anti-tumour activity and lower cardiac and gastrointestinal 
toxicity compared to its parent compound Doxorubicin. It is active in a wide range of solid 
tumours including sarcoma, breast cancer, ovarian cancer and lymphoid malignancies . 
. Doxorubicin has been proved to be active in HCC and produced an objective response rate of 
16%(16). This trial was conducted from 1985 to 1986 and tried to delineate the activity of 
Epirubicin in Chinese HCC patients. 
Seventeen patients were entered into the study. Nine of 14 patients had prior surgical 
treatment which had relapsed locally and become inoperable. The treatment consisted of 
Epirubicin 75mg/m2 by intravenous bolus injection on day 1 once every 3 weeks for a maximum 
of 8 courses. The dose was reduced to 40mg/m2 if the total bilirubin was higher than 20J.lmol/L. 
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, The median age of all patients was 47.5 (range 36-70). The patient characteristics are listed in 
Table 3.6 below. 
Table 3.6 Patient characteristics 
Number of patients 17 
............................................................................................................................................................................................... 
Median age (range) 47.5 (36-70) 
Sex (male/female) 15/2 
Median pre-treatment bil~ubin (Jlmol/L) 15 (4-35) 
(range) '," " 
Median Karnofsky performance score 70 (50-90) 
(range) 
Median AFP (Jlg/L) (range) 4797 (10.9-235,200) 
A total of 59 courses of epirubicin were administered and there was no response seen in 
any of the 14 patients. The treatment was well tolerated; only 2 patients (14%) developed grade 1 
haematological toxicity according to the W.H.O. criteria, with a mild to moderate degree of 
nausea, vomiting and alopecia. The median survival of all patients was 17 weeks. This trial 
concluded lack of activity of Epirubicin in HCC at this dose level. The study by Hochster et al 
using Epirubicin at a median dose of 90mg/m2 showed partial response of 17%(28). Therefore, 
further trial should be aiming at a dose of 90mg/m2 or above. 
Trial 3: The Efficacy of High Dose 4'-Epidoxorubicin in Hepatocellular 
Carcinoma(48) 
Based on results from previous trial, the dose of Epirubicin was escalated to 90mg/m2 in 
this study. The entry criteria of patient were the same as previous trial. Thirty-five patients were 
entered into the trial. Patients' characteristics are listed in Table 3.7 below. 
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Table 3.7 Patients' Clinical Characteristics 
Number of patients 
Median age (range) 
Sex (male/female) 
Median Karnofsky performance score 
(range) 
Median pre-treatment bilirubin (Jlmol/l) 
(range) 
Median pre-treatment PT (sec) (range) 
Median AFP (Jlg/L) (range) 








The patients received a median number of 2 courses (ranged from 1 to 8) of intravenous 
4' -Epidoxorubicin at a dose of 90mg/m2, 3 weekly for maximum of 8 courses. Thirty-five 
patients were entered and 33 were evaluable for response and survival. Three out of the 33 (9%) 
patients showed objective tumour response. The tumour response rates are listed in Table 3.8. The 
treatment was relatively well tolerated with a moderate degree of haematological toxicity and 
alopecia, and a mild degree of nausea and vomiting. Pre- and post- treatment cardiac ejection 
fraction by multi-gated imaging method were performed in 5 patients and there was no significant 
drop (>10%) in their ejection fractions. Toxicity of the Treatment is listed in Table 3.9. The 
overall median survival was 72 days (ranged from 31 to 393) counting from the first day of 
treatment. 
Table 3.8 Tumour Response Rate 
Complete Response 1/33 (3%) 
Partial Response 2/33 (6%) 
Static Disease 5/33 (15%) 
Progressive Disease 25/33 (76%) 
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Toxicity of High Dose Epirubicin ,Treatment in HCC 
(n=33) 
W.H.O. grade 
1 2- 3 4 
5 5 1 0 
0 2 2 0 
1 0 0 0 
12 16 4 0 
Nausea/vomiting 12 5 1 0 
" · 1' 
With this dose, there was a low response rate of 9% in total. The overall median survival 
was short which was not much difference than no treatment. There was only one patient who 
survived more than one year and who had a complete response to the treatment. Compared with 
the earlier study, Trial 2, the response rate had been slightly improved suggesting that response 
may be dose-dependent. This is in keeping with the data on Adriamycin therapy(15). However, 
further increase in dose will increase toxicity at the same time. There were a few patients, not 
reported in the trial who were treated with higher dose at 120mg/m2. There were severe mucositis 
and bone marrow suppression at this dose level. 
Trial 4: A Phase 11 Study of 5-FluorouraciI and High Dose Folinic Acid in 
Inoperable Hepatocellular Carcinoma(49) 
5-FU has mild activity in HCC. Brennan et al reported a 10% response rate as a single 
agent(l). There are in-vitro studies and clinical evidence that high dose folinic acid can enhance 
activity of 5-FU by biochemical modulation(49a). The mechanism of action is stabilisation of the 
thymidylate synthetase and 5-FU metabolites complex by high concentration of folate cofactor. 
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This study was performed to evaluate this new combination In terms of tumour response, 
survival and toxicity. 
Twenty-five patients with untreated inoperable hepatocellular carcinoma diagnosed by the 
usual criteria were entered into the trial. The initial dosage of 5-FU was 500mg/m2/day 
administered as 22 hour intravenous infusion for 5 days. The cycle was repeated every 3 weeks. 
This was escalated to 19m!m2/day if tolerated by the patient. Folinic acid was given 
200mg/m2/day as 2-hour infusion after each 5-FU. The patient characteristics are listed in Table 
3.10 below. 
Table 3.10 Patient Characteristics 
Number of patients 
Median age (range) 
Sex (male/female) 
Median Karnofsky performance score 
(range) 
Median tumour size (cm) (range) 





9.8 (5 to 18) 
3263 (18-1990,000) 
Twenty-five patients were recruited between October 1988 and October 1989. Eighteen 
patients had AFP level more than 500J.lg/l (range 18-1,990,000J.lg/l). Nine patients received an 
escalated dose to 19m!m2/day of 5-FU. However, severe stomatitis was seen at this dose level. 
There were no response documented in all patients by radiological measurements. Twelve 
patients had stable disease while the remaining patients had progressive disease. Side-effects are 
listed in Table 3.11. The median survival was 15 weeks (range 6-71) calculated from the first date 
of treatmen t. 
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Myelosuppression was mild. Other toxicity included nausea and vomiting, mucositis and 
diarrhoea. There was no treatment related mortality. The median survival time of 25 deceased 
patients was 15 weeks. It was concluded that 5-Fluorouracil and high dose folinic acid at this dose 
have no activity in hepatocellular carcinoma and do not prolong survival. 
) 
Table 3.11 Toxicity of Patients Treated With 5-FU 
and High Dose Folinic Acid (n=25) 
- "' {' Grade 
0 1 2 3 4 
Alopecia 18 5 2 0 0 
Anaemia 16 6 3 0 0 
Chest pain 25 0 0 0 0 
Diarrhoea 19 3 1 2 0 
Mucositis 13 1 2 9 1 
Neutropenia 23 1 1 0 0 
Nausea/vomiting 18 4 2 1 0 
Neuromotor 24 1 0 0 0 
Phlebitis 13 12 0 0 0 
Thrombocytopenia 23 0 2 0 0 
It was concluded in this trial that 5-FU and high dose folinic acid have no activity in HCC. 
Although potentiation of 5-FU activity was documented in colonic carcinoma, it does not occur in 
HCC. The response is even worse than 4' -Epidoxorubicin. Severe mucositis was the main dose 
limiting toxicity which prevented further dose escalation above 500mg/m2 of 5-FU. 
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TrialS: Phase 11 Study of High-Dose Ifosfamide in Hepatocellular Carcinoma 
, Ifosfamide is a new alkylating agent of the oxazaphosphorine group which has clinical 
efficacy against several malignant tumours such as sarcoma, lymphoid malignancies, ovarian 
cancer, breast cancer and germ cell tumours. This drug is tested for activity in this phase 11 trial. 
Ifosfamide was given as a continuous infusion at a dose of 2.5gm/m2 daily for 5 days. Mesna 
rescue was given as a continuous infusion at a daily dose of 2,000mg/m2 for 6 days. The 
treatment was repeated once every 3 weeks for a maximum of 6 courses. 
Seventeen patients were entered including 15 males and 2 females with median age of 50 
(range 28 - 67). The patient characteristics are listed in Table 3.12 below. 
Table 3.12 Patient Characteristics 
Number of patients 
Median age (range) 
Sex (male/female) 
Median Karnofsky performance score 
(range) 
Median pre-treatment bilirubin (Jlmol/l) 
(range) 
Median pre-treatment albumin (g/l) 
(range). 








The patients received a median number of 2 courses (ranged from 1 to 4). All except 2 
patients were evaluable for tumour response. There was no complete or partial responder. Eight 
out of 17 patients (47%) had static disease and 7/17 (41.2%) progressive disease. The response 
rates are listed in Table 3.13. The treatment was well tolerated. The most frequent toxicity was 
alopecia, which occurred in 11 patients, and 5 patients developed mild haematological toxicity. 
There was no evidence of liver or bladder toxicity. Overall, 14 patients were evaluable for 
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survival. The median survival was 92 days (range, 30-568 days). Toxicity profile is listed in 
Table 3.14. The treatment was generally well tolerated without evidence of encephalopathy, liver 
toxicity, cystitis or haematuria. Median survival of 15 evaluable patients was 92 days. 
Table 3.13 Response of Patients after High Dose Ifosfamide 
Complete or partial response 0/17 
Static disease 8/17 (47%) 
Progressive disease 7/17 (41.2%) 
Unknown 2/17 (11.8%) 
Table 3.14 Toxicity of patients Treated with High Dose Ifosfamide 
(n=17) 
W.H.O. Grade 
1 2 3 4 
Haematological 4 1 0 0 
Liver 0 0 0 0 
Alopecia 2 4 5 0 
Nausea/vomiting 0 6 0 0 
The results are generally disappointing and concluded lack of activity of Ifosfamide in 
HCC. The study by Thongprasert et al(51) reported a response rate of 23% and cannot be 
repeated by us. However, Ifosfamide at this dose level was relatively well tolerated. 
123 
\ 
Conclusion From Various Phase IT Trials 
The results are very poor. The bestresponse rate was still below 15%. This is inferior to 
the reported response rates fro~ various phase 11 studies that were done elsewhere. The median 
survival is no different from most patients receiving no treatment as discussed in Chapter 2. 
Although the patients were all selected patients, the response to treatment is inferior to those 
described in the literature. This may represent a difference between Oriental and non-Oriental 
patients. The patients also tend to present late which may be due to aggressiveness of the disease. 
Side-effects from different treatments are variable depending on the dose and drug. A dose of 4'-
Epidoxorubicin above 90mg/m2 is too toxic to patients. Bone marrow suppression was most 
marked with high dose 4' -Epidoxorubicin therapy. Other common side-effects include alopecia, 
nausea and vomiting, malaise and anorexia. Since the duration of chemotherapy can be up to 18 
weeks and median survival is approximately the same, the value of systemic chemotherapy has to 
be reappraised. 
There are many reasons why HCC is so resistant to chemotherapy. The expression of p-
glycoprotein(52) which is a marker for multi-drug resistance has been documented in HCC. Other 
reasons include heterogeneity of the tumour cells and prolonged tumour doubling-time. The 
centre of HCC is very often necrotic and has poor blood supply. Therefore, there may be many 
hypoxic cells which are resistant to chemotherapy. It seems that conventional systemic 
chemotherapy has reached its limit in HCC treatment. The choice of drug is limited and toxicity 
is marked. With all these constraints, a new route of administration of drugs or a new modality of 
treatment have to be discovered before the outlook of HCC patients can be improved. 
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Review of the Literature in Intra-Arterial Chemotherapy for HCC 
Owing to the fact that HCC responds poorly to systemic cytotoxic treatment and more 
active agents are not available, attempts have been made to give the drug through a different route 
and try to improve efficacy with available agents. The liver is known to have a dual blood supply, 
both from the portal venous and systemic arterial systems. It is also known that large liver 
tumours derive their blood supply mainly from the hepatic artery(53,54). During hepatic 
angiography when radio-opaque contrast is injected into the hepatic artery, the HCC usually 
shows up as a hypervascular tumour. Therefore, infusion of cytotoxic drugs into the feeding 
hepatic artery has the theoretical advantage of increasing total drug exposure to hepatic tumours 
and may improve tumour cell-kill. This treatment is called .regional, or intra-arterial, 
chemotherapy. 
The aim of regional chemotherapy is to obtain higher concentration of cytotoxic drugs 
within the tumour relative to the systemic circulation. This is related to the blood supply of the 
tumour and also extraction of drug by the liver. However, not all drugs have high liver extraction 
rate. Those with high liver extraction rates are usually selected for regional chemotherapy. 
Furthermore, those drugs with short plasma half-life and are even better because systemic toxicity 
can be reduced. The liver extraction rates and half-life of selected drugs are listed in Table 3.15. 































These drugs are commonly employed in regional intra-arterial treatment in both primary 
and secondary hepatic tumours. The fluoropyrimidines (5-FU and 5-FUDR) are perhaps the best 
agents for intrahepatic use. They have a high rate of systemic clearance and increased hepatic 
drug exposure when given intra-arterially compared to intravenous treatment. They are given 
either during hepatic angiography or via an implantable arterial port such as the Port-A-Cath® or 
Infusaid ® device. The latter approach requires a laparotomy to place the catheter. 
Regional intra-arterial chemotherapy was first tested with single agents such as 
Doxorubicin, Mechloethamine, Mitomycin C, Cisplatinum, 5-FU and FUDR. Doxorubicin 
appeared to be more active than other agents (Table 3.16). 
Table 3.16 Regional Chemotherapy with Single Agents 
Investigators Drug No. of Response Survival 
Patients (%) (Months) 
Olweny et al Cl7) Doxorubicin 10 60 
Urist et al(56) Doxorubicin 13 47 20 
Cherani et al(57) Mechloethamine 60 33 
Kinami et al(58) Mitomycin C 14 50 7 
Cheng et al(59) Cisplatinum 16 19 
Ansfield et al (60) 5-FU 11 27 
Watkins et al(61) FUDR 6 33 22 
Wellwood et al(62) FUDR 28 54 7 
Single agent Doxorubicin was used because this drug is relatively active in HCC. Side-
effects like myelosuppression, cardiotoxicity and gastrointestinal toxicity were all noted (17,56) . 
Chearani et al treated 60 patients with Mechloethamine but response criteria and survival 
information were not available(57). Intra-arterial Cisplatinum was given by Cheng et al(59) but 
marked toxicity was reported. However, another study by Campbell et al(63) showed only a small 
relative pharmacokinetic advantage in humans for administering intra-arterial Cisplatinum 
compared with intravenous administration. The study by Watkins et al(61) reported a 33% (2 out 
126 
of 6) response rate with 22 months average survival. However, this study used clinical and 
subjective response criteria and also calculated survival from the onset of symptoms so that 
survival duration was artificially prolonged. The response rates reported from various small 
single-arm studies are highly variable from 19% to 60%. However, the survival is still far from 
satisfactory and the impact from treatment is small. 
Combination chemotherapy was then tested by 3 different groups uSIng mainly a 
Doxorubicin containing cocktail. The results from these 3 trials are listed in Table 3.17. 
Table 3.17 Regional Chemotherapy with Combinations 
Investigators Drug No. of Response Survival 
Patients (%) (Months) 
Patt et al (04) FUDR, Doxorubicin 30 70 8 
Shildt et al(65) 
Mitomycin C 
FUDR, Doxorubicin 30 10 
Carr et al (66) 
Streptozotocin 
Doxorubicin 25 50 12 
Cisplatinum, (X-Interferon 
The response and survival rates did not appear to be better than the single agent except for 
the study by Patt et al (64). This study has the largest and best documented response rate to a 
combination of FUDR, Doxorubicin and Mitomycin. Median survival was about 8 months. 
However, severe toxicity like cholangitis and -bone marrow suppression are reported in this trial. 
The treatment also required an operation to insert an injection device for prolonged infusion of 
drugs. The study by Carr et al (66), using combination Doxorubicin, Cisplatinum and (X-
interferon, showed an impressive response rate of 50% and median survival of 12 months. Nine 
patients of this series received liver transplant. More patients have to be studied before we can 




The modality of chemoembolisation has become popular as a form of treatment of HCC in 
the Far East. It is the procedure involving occlusion of the tumour vascular bed coupled with 
cytotoxic drug administration, either temporarily or permanently. The theoretical advantage is a 
gre~ter cytotoxic drug concentration in the tumour as the arterial blood flow is slowed down or 
even stopped. Temporary blockade of the arterial system can be done with degradable starch 
microspheres or gelatin sponge and has the advantage that it can be repeated. Nine trials are listed 
in Table 3.18 below. The response rates vary from 17% to 68% and they are all single-arm 
studies. 
Table 3.18 Intrahepatic Artery Chemoembolisation 
Investigators 
Sasaki et al (67) 
Ohnishi et al(68) 
Lin et al(69) 
Fujumoto et al(70) 
Audisio et al (71) 
Pelletier et al(72) 
Venook et al (73) 
Ohnishi et al (7 4) 
Ohnishi et al (7 4) 
Drugs 
Cisplatinum + Gelfoam 
Mitomycin C + microcapsules 
5-FU + Ivalon 
5-FU/Mitomycin C + starch 
Mitomycin C + microcapsules 
Doxorubicin + Gelfoam 
Doxorubicin/Cisplatinum/ 
Mitomycin C + Gelfoam 
. Mitomycin C + microcapsules 
Mitomycin C + Gelfoam, + 
microcapsules 




















Another approach used the tumour ~argeting substance, Lipiodol. Lipiodol is an oily 
contrast X-ray medium which was found to be retained selectively in HCC for many weeks after 
intra-arterial administration(75,76). Hence, Lipiodol can act as a carrier which prolongs retention 
of high concentrations of anti-cancer drugs. A preliminary study in Japan using lipophilic 
cytotoxic drugs such as styrene maleic acid neocarzinostatin (SMANCS) solubilised in Lipiodol 
and then administered intra-arterially to HCC patients yielded some encouraging results(77). 
Hydrophilic drugs such as Doxorubicin(78) and Cisplatinum(79) may also be admixed with 
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Lipiodol in an emulsion and given intra-arterially. The treatment can be combined with the 
technique of chemoembolisation which is very popular in Japan and other parts of Asia. The 
response rates seem better than chemoembolisation without Lipiodol. Selected studies are listed in 
Table 3.19 
Table 3.19 Intrahepatic Artery Chemoembolisation with Lipiodol 
Investigators 
Kasugai et al (80J 
Kobayashi et al(81) 
Kanematsu et al(82) 
Shibata et al (83) 
Konno et al (84) 
Beppu et al (85) 
Drugs 
Cisplatinum + ethiodised oil * 
'Doxorubicin + ethiodised oil 
Doxorubicin + ethiodised oil 
Cisplatinum + ethiodised oil 
SMANCS + ethiodised oil 
Cisplatinum + ethiodised oil + 
aclarubicin micro spheres 
* Ethiodised oil is same as Lipiodol 














From these single-arm studies, the objective response rates were improved with regional 
chemotherapy. However, the use of embolisation in addition to chemotherapy increased side-
effects such as fever, abdominal pain and transient elevation of transaminases. Cystic artery 
spasm and cholecystitis were not uncommon. , Despite promising results from single-arm studies 
on regional chemotherapy, there is no randomised trial to compare results with systemic 
chemotherapy. Kalayci et al compared intra-arterial Adriamycin and Lipiodol with intravenous 
adriamycin at the same dosage and could not find any difference in response and survival (86) . 
There are also a few reports on pharmacokinetics to support its use and potential benefit over 
systemic chemotherapy. The pharmacokinetic study of Kalayci' s patients was reported by 
Johnson ·et al who showed that there was no difference in plasma drug levels in terms of area 
under the· curve, between intra-arterial Doxorubicin with or without Lipiodol or intravenous 
Doxorubicin (87) . The pharmacokinetic parameters and systemic toxicity were the same for 
intravenous Doxorubicin, intra-arterial Doxorubicin and intra-arterial Doxorubicin with Lipiodol. 
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Our own study in PWH showed that the mean serum concentration-time profile of 4'-
Epidoxorubicin in eight HCC patients who were given intra-arterial Lipiodol-Epidoxorubicin was 
lower than intra-arterial Epidoxorubicin only(88). There were 3 patients in this study that were 
given both intravenous Epidoxorubicin and intra-arterial Lipiodol-Epidoxorubicin. It was found 
that the bioavailability of Epidoxorubicin in the systeinic circulation after intra-arterial Lipiodol-
Epidoxorubicin was actually lower than after intravenous injection. This suggests some form of 




Intra-Arterial Chemotherapy Trial Performed in PWH 
In order to test the activity of intra-arterial chemotherapy in HCC, the first prospective 
intra-arterial chemotherapy protocol was initiated by the author in 1987. The first study is an 
early phase 11 study using an escalating dose of 4' -Epidoxorubicin (from 50mg/m2 to 90mg/m2). 
The second study is a formal phase 11 study using an uniform dose of 4' -Epidoxorubicin at 
90mg/m2. The latter trial was compared with a matched group receiving the same dose of 
intravenous 4' -Epidoxorubicin in terms of response, toxicity and survival. 
I. An Early Phase IT Trial on Treatment of Inoperable Hepatocellular Carcinoma by 
Intra-Arterial Lipiodol and 4'-Epidoxorubicin(89). 
Background 
Treatment of inoperable HCC with systemic chemotherapy is not satisfactory. 
Doxorubicin is currently the most active agent in HCC and has produced an average response rate 
of 19% from 19 studies(3). Intra-arterial Doxorubicin has been investigated for activity in HCC 
as a single agent. The number of patients studied was small · and the average response rate from 
two studies was about 50%(17,56). Side-effects such as myelosuppression and cardiac toxicity 
were found in these studies. 4' -Epidoxorubi~in is an anthracycline analogue of Doxorubicin 
which has also been shown to be active and less toxic than Doxorubicin(90). This drug is mainly 
eliminated by hepatic metabolism and biliary excretion. Therefore, systemic toxicity may be 
reduced by giving the drug intra-arterially. ~arlier study using intravenous 4' -Epidoxorubicin at 
90mg/m2 had produced a response rate of 9%(48). Intra-arterial 4' -Epidoxorubicin has not been 
studied before. Therefore, this study intends to find out whether the response rate can be 
improved and toxicity lower, compared to intra-arterial Doxorubicin therapy. 
131 
\ 
It was also mentioned above that Lipiodol has the property of being retained within HCC 
tissue(7 5,91). Therefore, mixing of Lipiodol with drugs given intra-arterially may theoretically 
increase drug exposure by the tumour. Intra-arterial chemotherapy with Lipiodol was studied with 
drugs like Doxorubicin(81,82), Cisplatinum(80,83,85) and Mitomycin(92). The response rate was 
about 40%. This study was designed to find out the effects of a 4' -Epidoxorubicin and Lipiodol 
mixture after injection into the hepatic artery in terms of tumour response, survival duration and 
toxicity. 
Patients and methods 
Patients aged 70 years or less with either histologically proven HCC or serum AFP greater 
than 500J..lg/l with a compatible angiographic pattern were eligible for study. Only patients with 
inoperable HCC were entered. Inoperability was determined by presence of bi-Iobar or extensive 
disease or major vascular invasion on USG. Patients with extrahepatic metastasis, inadequate 
bone marrow function (WBC < 3xl09/l or platelet < 100xl09/l), poor liver function (total 
bilirubin> 50J..lmol/L, prothrombin time> 18 sec), previous chemotherapy, serious concomitant 
medical illness, or a Karnofsky Performance Score of less than 70 were excluded. Patients with 
post-operative recurrence would still be eligible. Ascites or oedema did not preclude patients 
from entering into the trial. Other pre-treatmept investigations included USG of liver, serum AFP 
level, HBsAg status, chest X-ray. eT scan was optional. Patients who failed angiography because 
of arterial anomaly were excluded from the study. 
The chemotherapy mixture consisted of 5m1 Lipiodol (Lipiodol ultra fluide, Lab. Guerbet, 
France) and 4'-Epidoxorubicin at a dose ranging from 50 to 90mg/m2. This was prepared by 
dissolving 4'-Epidoxorubicin in 3m1 of sterile water and then mixing with Lipiodol by a vortex 
machine for 3 minutes. The preparation was injected slowly over 3 to 5 ~nutes into an arterial 
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catheter which was placed through femoral arterial puncture and selective hepatic artery 
cannulation under fluoroscopic control. The catheter was .removed after the procedure. The 
treatment was given once every 4 weeks. The dose of 4'-Epidoxorubicin started at 50mg/m2 and 
escalated to 70mg/m2 and 90mg/m2 in subsequent cycles if there was no undue toxicity or 
disease progression. Complete blood picture, clotting profile, liver function test and 
electrocardiogram were performed before each course of treatment. In the event of bone marrow 
suppression, treatment was delayed weekly until the leucocyte count returned to 3xl09/l and the 
platelet count returned.,to 100xl09/l. A maximum of 6 cycles were to be given if there was 
observable tumour response after 2 cycles. Toxicity of treatment was scored after each course 
according to World Health Organisation (W.H.O.) recommendations of acute and subacute 
toxicity of cancer treatment. In addition, any complication from angiography was also recorded. 
Response of treatment was assessed by liver CT scan, hepatic angiography and serum AFP 
level after 2· courses or cessation of treatment. Complete remission was defined as total 
disappearance of disease on clinical examination, CT scan of liver, hepatic angiography and a 
normalised serum AFP level «20J.Lg/l). Partial response was defined as a 50% or more reduction 
in the product of 2 greatest perpendicular diameters of the largest tumour nodule measured 
radiologically by CT scan or angiography. Stable disease was defined as no change or less than 
partial response. The remaining was classified as having progressive disease. Survival duration 
was calculated from the day of initiation of_treatment to the time of death or last event. 
Results 
Sixteen patients were entered into the study. Fifteen patients had no previous treatment 
and one patient had local relapse of the disease 16 months after partial hepatectomy. Their 
characteristics are listed in Table 3.20. 
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Table 3.20 Patient Characteristics For Intra~Arterial Lipiodol 
and 4'-Epidoxorubicin Trial 
Total number of patients 




Number of biopsy proven cases 
Patients with AFP > 500Jlgll 
HBsAg positive 
Median bilirubin level (mg/dl) 
Median prothrombin time (s) 
Median SGPT (lUll) 













Three patients were inevaluable for response and survival because of default to follow-up 
after one or two courses of treatment. Two of them preferred alternative treatment by traditional 
herbal medicine after one course of treatment. One patient had an operation done in another 
hospital when he felt better after two courses of treatment. The median number of courses of 
chemotherapy was 2 per patient (range from 1 to 3). All the patients have died at the time of ' 
writing. 
The response rates are shown in Table 3.21. There were no complete responses, two 
partial responses (15.4%), three with stable disease (23.1 %) and eight with progressive disease 
(61.5%). Median survival calculated from date of first treatment to death for 13 evaluable patients 
was 10 weeks (range 5-43). Five patients with a partial response or static disease survived a 





Table 3.21 Treatment Results For Intra-Arterial Lipiodol 
and 4'-Epidoxorubicin Trial 
Total no. of courses 









3/13 (23~ 1 %) 
8/13 (61.5%) 
Thirteen patients were evaluable for toxicity. The treatment toxicity according to W.H.O. 
gradings are tabulated in Table 3.22. One patient had grade 2 thrombocytopenia after the third 
course of treatment with 90mg/m2 4'-Epidoxorubicin. Otherwise bone marrow toxicity was not 
detected. Nausea and vomiting were observed in three patients (grade 1 to 2) after higher doses of 
treatment. Alopecia was universal for patients who received 70mg/m2 or more 4'-Epidoxorubicin. 
There was no cardiac toxicity documented by clinical and electrocardiographic methods. There 
was no complication related to angiography or arterial puncture and the procedure was well-
tolerated. 
Table 3.22 Treatment Toxicity For Intra-Arterial Lipiodol 
and 4'-Epidoxorubicin Trial 
Toxicity W.H.O. grade 
0 1 2 3 4 
Haemoglobin 13* 0 0 0 0 
Leucocyte 13 0 0 0 " 0 
Platelet 12 0 1 0 0 
Alopecia 5 5 2 1 0 
Nausea/vomiting 9 3 1 0 0 
Cardiac 13 0 0 0 0 




From this study, escalating doses of 4'-Epidoxorubicin and Lipiodol was used and a 
response rat~ of 15.4% was obs.erved. The treatment was well tolerated and no serious treatment-
related complications were observed. It was decided not to perform more sophisticated 
investigations to document cardiac toxicity because in the earlier study, using the same dosage of 
intravenous 4' -Epidoxorubicin, there was no cardiac toxicity detected(29,48). Tumour response 
was judged by angiography and CT scan in this study which only showed 2 partial responses. 
This is far from satisfa-ctory. The duration of response was also short, and rapid progression of 
disease rendered patients unable to receive more than three cycles of treatment. Survival was 
short and was not better than no treatment (referred to Chapter 2 ab~ve). Both partial responders 
showed a response after 70mg/m2 of 4' -Epidoxorubicin. Therefore, further studies should start at 
least at this dose level and a higher response might be seen .. Furthermore, combining the treatment 
with embolisation, using Gelfoam or other particles may further increase the response rate. The 
uniformity of the Lipiodol and 4' -Epidoxorubicin emulsion may not be ideal because the latter 
drug is not soluble in Lipiodol. The mixing may be improved by using a special solvent which 
can make both substances more miscible. Whether the drug can actually carried by the Lipiodol is 
not known. Pharmacokinetics of intra-arterial chemotherapy with and without Lipiodol need to be 
studied before such approach is beneficial. 
It was concluded that intra-arterial 'Lipiodol and 4'-Epidoxorubicin chemotherapy at the 
present dosage has minimal activity in hepatocellular carcinoma and no major impact on survival. 
However, at the present dose level, the treatment was well-tolerated . . A higher dose of 4'-
Epidoxorubicin at 90mg/m2 for further phase 11 trial should be contemplated in the future. 
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IT. Phase IT trial of Treatment of Inoperable Hepatocellular Carcinoma by Intra-
Arterial Lipiodol and High Dose 4'-Epidoxorubicin, a Comparison with Intravenous 
4' -Epidoxorubicin(93) 
Background 
The background of this study is similar to the previous study. After the above pilot study 
conducted in 1987(89), it was concluded that intra-arterial Lipiodol and 4' -Epidoxorubicin was 
active in HCC and the treatment was well tolerated with an escalating dose of 4' -Epidoxorubicin 
from 50mg/m2 to 90mg/m2. Response was seen at a dose above 70mg/m2 and that study also 
suggested further phase II trial at a uniform dosage of 90mg/m2. However, due to a small number 
of patients studied in the previous trial and the 4' -Epidoxorubicin . dose of 90mg/m2 was not 
adequately tested, it was decided to go for another phase II study with high dose 4'-
Epidoxorubicin at 90mg/m2 with Lipiodol instead of a ph~se III randomised trial. 
Therefore, a second intra-arterial chemotherapy trial was started in 1989 using Lipiodol 
and 4' -Epidoxorubicin at the recommended dose level. During the gap between the last one and 
the new trial, the standard treatment of inoperable HCC was intravenous 4' -Epidoxorubicin at 
90mg/m2, once every 3 weeks. This is the same as the dose of 4'-Epidoxorubicin in the new 
phase II study of Lipiodol and 4' -Epidoxorubicin. Patients treated during this interim period 
between two intra-arterial treatment protocols were selected for comparison as historical control 
for tumour response, treatment toxicity and . survival. Particle embolisation was not added because 
too many compounding factors will make the results difficult to interpret. 
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Patients and Methods 
Patients aged 75 years or less with inoperable HCC proven either by histology or serum 
AFP level greater than 500J..lg/l with compatible angiographic features were entered into the trial. 
Patients with extrahepatic disease, inadequate bone marrow function (WBC <3x109/l or platelet 
<100x109/l), poor liver function (total bilirubin> 50pmol/l, prothrombin time> 18 sec), previous 
chemotherapy or surgery, serious concomitant medical illness, or a Karnofsky Performance Score 
of less than 70 were excluded. Patients who failed angiography because of anatomical or 
technical reasons were aiso excluded from the study. Other pre-treatment investigations included 
measurement of serum AFP, HBsAg status, electrocardiogram, chest radiography and tumour size 
measurement by USG and CT scan. 
Suitable patients with informed consent were subjected to selective hepatic artery 
cannulation under fIuoroscopic control using the Seldinger technique. A mixture of 5ml Lipiodol 
and 90mg/m2 4'-Epidoxorubicin (dissolved in 3ml water and mixed with Lipiodol using a vortex 
machine) was injected slowly over 10 minutes into the arterial catheter. The catheter was 
removed after the procedure. Patients were observed for 2 days in the ward and discharged 
afterwards if there were no acute side-effects~ The treatment was repeated itself once every 4 
weeks if there was no undue toxicity. Assessment of response by USG, CT scan and serum AFP 
were done after 2 courses of treatment. The maximum number of treatments is 8 which was given 
to those with a favourable response after 2 -cycles and without serious toxicity. Complete blood 
picture, clotting profile, liver function tests and electrocardiogram were performed before each 
course of treatment. In case of bone marrow suppression, treatment was delayed weekly until the 
leucocyte count returned to 3x109/l and platelet count to 100x109/l. Side-effects were 
documented according to W.H.O. criteria. Complications from angiography were also recorded. 
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, Response of treatment was assessed by'1iver USG, CT scan, HAG and serum AFP after 2 
courses. Complete remission was defined as total disappearance of disease on clinical 
examination, CT scan, angiography and a normalised AFP level « 20Jlg/l). Partial response was 
defined as a 50% or more reduction in the product of 2 greatest perpendicular diameters of the 
largest tumour nodule measured radiologically by eT scan, USG or angiography. Stable disease 
was defined as no change or less than partial response. The remaining was classified as 
progressive disease. Survival duration was calculated from the day of first course of treatment to 
the time of death or lastevent. 
A matched group of· patients treated between the interim period and immediately before 
the present trial was chosen as the control group. The control group composed of consecutive 
patients with the same entry criteria as the present intra-arterial treatment who had inoperable 
HCC, no previous treatment, no extra-hepatic disease and were treated with intravenous 4'-
Epidoxorubicin 90mg/m2. Assessment of response for the historical control group was similar to 
the intra-arterial treatment group but without the HAG criteria. Definition of response was the 
same for both group except no HAG ~riteria for the historical control group. Both groups were 
compared for response rate, toxicity and surviv~l. Actuarial survival curves were plotted using the 
Kaplan-Meier method and compared using log rank tests. 
Results 
Thirty eligible patients were entered into the trial. Twenty-eight patients were male while 
2 were female. The median age was 52 (range 27 - 75). The median Karnofsky Performance 
Score was 90 (range 70 - 100). Twenty-eight patients who were treated by intravenous 4'-
Epidoxorubicin 90mg/m2 were selected as control arm. Comparison of patient characteristics 
between present trial and intravenous control arm are shown in Table 3.23. 
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Table 3.23 Comparison of Patients Characteristics Between Intra-Arterial 




Median age (range) 
Median KPS (range) 




Median albumin g/l 
Median total bilirubin J..Lmol/l 
Median ALT (IU/l) "" 

























A total of 89 courses of treatment were given with a median of 3 courses per patient 
(range 1 to 8). Twenty-seven patients were evaluable for response while 3 patients died early in 
the study and were considered to have progressive disease. There were no complete responses, 2 
partial responses (6.7%), 6 had static disease (20%) and 22 progressive disease (73.3%). Only 3 
out of 19 patients who had a raised AFP initially (>500J..Lg/l) had more than 50% decrease of AFP. 
However, they did not have even a partial response. Comparison of response rates with those of 
the intravenous control arm are shown in Table 3.24. 
Table 3.24 Comparison of Response Rates.,Between Intra-Arterial 
and Intravenous Treatment -
Treatment eR PR SD PD 
n (%) n (%) n (%) n (%) 
Intra-arterial 0(0%) 2 (6.7%) 6 (20%) 22 (73.3%) 
Intravenous 2 (7.1 %) 2 (7.1 %) 5 (17.9%) 19 (67.9%) 
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Side-effects were mainly mild anaeniia and alopecia. Vomiting and leucopenia were 
uncommon. There was no life threatening complication due to chemotherapy or angiography. 
After the procedure, two patients had mild right upper quadrant pain which was transient and well 
controlled by simple analgesics. Tr~nsient low grade pyrexia was also common and usually 
started on day 1 and lasted for 2 to 3 days. Hospital stay per patient was less than 72 hours. There 
was otherwise no immediate complication. Also, there was no cardiac toxicity documented on 
clinical ground and no patient required delay of treatment because of bone marrow suppression. 
When compared with ,the intravenous control arm, bone marrow toxicity, gastrointestinal 
sympt~ms and alopecia were similar (Table 3.25). 
All patients had died of progressive disease at the time of ~iting. The median survival 
was only 18.9 weeks (range 4.1 to 87.3 weeks). For the historical control arm, the median 
survival was 14 weeks (range 4.3 to 97.3 weeks). Actuarial survival curves of both groups of 
patients are shown in Figure 3.1. There is no difference in survival between the two groups of 
patients (p=O.7). 
Discussion 
The response rate of intra-arterial treatment from this trial was only 6.7% which seems 
worse than the previous trial despite a higher dose of 4' -Epidoxorubicin. This is probably due to 
small number of cases studied in the previou's trial. The response criteria for the intra-arterial 
group is stricter than the intravenous group because HAG which is more sensitive than USG or 
eT scan is used. There was no difference in terms of survival compared with a historical control 
group treated with same dosage of 4' -Epidoxorubicin. The findings are in keeping with similar 
I. study by Kalayci et al (86) who used Doxorubicin instead. Side-effects were comparable . except 
that nausea and vomiting appeared to be less in the intra-arterial group. 
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The results are in general disappointing. The high response rate reported from other 
studies me!ltioned earlier are not reproduced by us despite a selection of patients. This is in 
keeping with a relatively low response rate in patients of this study treated with intravenous 
treatment. Therefore, . tumour cell resistance to chemotherapeutic agent seems to be the most 
important reason for failure. This cannot be overcome by varying the route of administration of 
cytotoxic drugs. It can be argued that particle embolisation was not added in this study. However, 
from earlier experience in hepatic arterial embolisation, collaterals to supply the tumour can occur 
rapidly after embolising,.the hepatic artery. Furthermore, shunting of the blood and cytotoxics to 
the systemic circulation through arteriovenous shunts occurs rather rapidly after injection of the 
cytotoxics. There is still substantial systemic toxicity after intra-arterial treatment. This is in 
keeping with the study by J ohnson et al (87) that the drug level in the peripheral blood is no 
different between intravenous and intra-arterial treatments with or without Lipiodol. 
Since the present study is not a phase III study, firm conclusions cannot be drawn as to 
whether intra-arterial treatment is better or not. The next step should be a randomised study 
comparing intravenous and intra-arterial treatment with Lipiodol. Such a randomised trial is 
currently underway. 
Conclusion to Part 11 . 
Cytotoxic chemotherapy is the first attempt to improve outlook of patients with inoperable 
HCC. Both systemic and regional intraarterial treatments are tested and the results from literature 
and the author's studies are presented. The treatment results are in general disappointing. Tumour 
response rate from various form of treatment are not more than 20% and median survival not 
more than 3 months despite case selection. New treatments should be tested and compared with 
the present treatment results in terms of tumour response rates and median survival. 
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Table 3.25 Comparison of Toxicity Between Intra-Arterial 
and Intravenous Treatment 
W.H.O. Grade Intra-Arterial 


























































































































































































Novel Treatment for Hepatocellular Carcinoma 
CHAPTER 4 
Selective Internal Radiation Treatment for 
Hepatocellular Carcinoma 
Review of the Literature on Radiotherapy for Liver Tumours 
External beam irradiation 
External beam irradiation is seldom used for liver tumours because. the liver is a radio-
sensitive organ. Normal liver tolerance to radiation is a critical factor to be considered. Indeed, as 
early as 1940 it was recognised that normal liver cells are as radiosensitive as are the malignant 
ones(I). Maximum tolerance of normal liver to radiation is generally accepted to be between 
2,500 and 3,000 cOy(2,3) to the whole liver and it was estimated that t~e risk rises rapidly when 
doses above 3,500 cOy (200 cOy fractions) are used(3,4). In Austin-Seymour's review of 11 
patients who received whole liver irradiation and boost treatment of 5,300 cOy to 7,000 cOy 
equivalent, it was recommended that no more than 30% of the liver should be irradiated in excess 
of 3,000 cOy to 3,500 cOy (200 cOy fractions) in order to avoid radiation hepatitis(5). 
The biliary ducts appear to have a greater tolerance to radiation than the liver parenchyma. 
In the treatment of cholangiocarcinoma, intra-cavitary brachytherapy boosts have been 
administered to a dose as high as 10,600 cOy to a depth of 0.5 cm in combination with 
fractionated external beam irradiation (6) . 
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Clinically, radiation hepatitis may vary in severity from mild abnormalities of liver 
function tests to progressive liver failure. Ingold et al described 13 cases of radiation hepatitis in a 
series of 40 patients who received whole liver irradiation (1,300-5,100 cOy over 18-40 days)(3). 
Clinical presentation was with progressive hepatomegaly, ascites and deteriorating liver function 
tests(3,7). In Ingold's review, the risk app~ared to be related to dose as mentioned above; no 
damage was seen in the five patients treated with a total dose of 3,000 cOy, while 12 cases and 3 
fatalities were seen in 27 patients receiving doses larger than 3,500 cOy. 
Histologically, the acute phase of hepatic injury due to radiation is characterised by 
congestion in the central veins and central lobular sinusoids. This is followed by proliferation of 
epithelial cells in the central lobular zone, liver cell atrophy and degeneration(3,8). Laboratory 
findings in acute radiation hepatitis include elevated serum alkaline phosphatase, glutamic-
oxaloacetic transaminase, glutamic-pyruvic transaminase and decreased bromsulphthalein 
clearance rate(3). Late changes in the liver are characterised by central lobular and peri-portal 
fibrosis with cirrhosis. Clinically, liver failure may occur acutely (within weeks) or chronically 
(up to two years after treatment), but the ensuing mortality is high. Schacter et al(9) reviewed 32 
cases from the literature and reported a mortality of nearly 50 per cent. However, if there is 
another element of liver damage occurring at the same time such as malignancy, it is very 
difficult to differentiate whether the deterioration is due to radiation hepatitis or not. 
Despite all these constraints, external beam irradiation to liver tumour is still used in 
) 
certain, conditions. It is mainly used with a palliative intent to treat symptomatic patients with 
liver metastases. The indications are pain and discomfort due to a rapidly expanding lesion in the 
liver. The dose of radiation is kept between 2,500 and 3,000 cOy in conventional fractionation 
though this is insufficient to obtain durable tumour control. Irradiation of the surrounding organs 
including transverse colon and kidneys is also a problem. 
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External beam irradiation in the treatment of HCC has received little attention. As noted. 
in Chapter 1, most HCC patients have cirrhosis which makes the non-tumourous liver more 
-'. 
susceptible to radiation damage. . Phillips and Murikami (10) reviewed 26 years experience at 
Memorial Sloan Kettering Cancer Centre of 26 HCC patients treated with external beam 
irradiation and reported partial remission in 14 patients (Table 4.1). This was an unusual series 
concerning HCC because half were women and the symptom duration prior to radiation was 12 
months on average which implies a somewhat indolent course. Of interest is that no response was 
seen with radiation doses of less than 2,000 cOy. This series was updated by EI-Domeiri and 
reported deaths in 70% of patients less than six months after therapy(ll) (Table 4.1). Combined 
chemotherapy with external beam irradiation may have a better treatment result than radiotherapy 
alone and was tested in a randomised trial by Cochran et al(12). In this trial, patients with 
inoperable HCC were randomised to receive quadruple chemotherapy (5-FU, Cyclophosphamide, 
Methotrexate, .Vincristine) or whole liver irradiation plus the same chemotherapy after a break 
from radiotherapy. There were 10 patients who received chemotherapy alone and 8 received 
radiotherapy (200 cOy per day for 15 fractions over 21 days) and chemotherapy. There were only 
2 patients from the latter arm who survived long enough to receive chemotherapy . None of the 18 
patients had any objective response. The survival in the radiotherapy arm was significantly 
worse(12). Compared with other modalities, external beam irradiation failed to improve survival. 
Other manipulations to increase the effectiveness of external beam irradiation such as 
concomitant intravenous or intra-arterial chemotherapy with radiotherapy and the use of radio-
sensitizers have been evaluated but none were proved to be beneficial. 
\ 
Table 4.1 External Beam Irradiation Treatment For HCC 
. Investigators Radiation dose to No. of patients Response Survival 
tumour (cGy) (months) 
Phillips et al(IO) 700-4,500 26 14 5 
EI-Domeiri et al(ll) 1,000-3,600 · 31 <6 
Cochrane et al(12) 3,000 8 0 3 
More recently, in an attempt to improve the therapeutic ratio, several new approaches 
have been developed. The aim is to increase tumour radiation dose while sparing normal liver. 
These include using external irradiation with conformal radiotherapy and radio-sensitizers, and 
internal irradiation with radio-isotopes. 
Conformal radiotherapy can increase radiation dose to target tumour volume and at the 
same time allow adjacent normal tissue to be excluded from the treatment volume. It has been 
applied in treatment of other malignancies such as head and neck cancers, cerebral tumours and 
lung tumours. The application of conformal radiotherapy with intrahepatic arterial 5-FUDR as 
radio-sensitizer in treatment of hepatobiliary cancers was studied by the Ann Arbor group(13). 
Since normal liver is spared, a potentially tumouricidal dose of radiation higher than whole liver 
tolerance can be delivered safely. Hepatic tumours have received between 4,500 cOy and 6,000 
cOy without development of severe radiation . hepatitis. The dose is potentially tumouricidal and 
produced durable responses df up to eight months(13). In a subsequent study in which only 
primary hepatobiliary cancers were entered, the radiation dose to the tumour · was between 4,800 
and 7,260 cOy( 14). Objective responses were seen in all patients "Yith focal tumours. Median 
survival for localized HCC was 11 months. Only two patients had non-fatal radiation hepatitis. 
This suggests tumour regression with durable response is possible with ·an adequate dose of 
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radiation and sparing normal liver tissue during radiotherapy can reduce incidence of radiation 
hepatitis. 
In the search for abe~ter method which can deliver an even higher radiation dose 
selectively to a liver tumour, internal. irradiation using radio-isotopic sources seems an attractive 
approach. Internal irradiation treatment for hepatic tumours is mainly employed by administration 
of l:lnsealed radioactive sources. There are two methods of internal irradiation: by systemic radio-
labeled monoclonal antibodies or intra-arterial targeting therapy with radio-isotopes. Both 
methods require a carrier which specifically binds to the tumour or stays in the liver tumour for 
sufficient duration of time to deliver the planned radiation dose. 
Internal Irradiation with Radio-immunoglobulins 
With the development of monoclonal antibodies such as anti-ferritin and anti-AFP which 
are to some degree tumour-specific, HCC can be targeted after systemic administration of the 
appropriate antibodies. By labeling the antibodies with 131Iodine or 90Yttrium, a therapeutic 
dose of radiation can be delivered to the tumour specifically. A partial remission rate of 41 per 
cent and a complete remission rate of 7 per cent were achieved after 131 I -antiferritin 
treatment( 15). Median survival was up to five months for patients with raised AFP levels and ten 
months for AFP-negative patients. The treatf!lent was preceded by whole liver external beam 
irradiation, and radio-sensitizers (Doxorubicin and 5-FU) were added in latter phase of the trial. 
Hence, the radio-immunoglobulins served as a "boost" to the tumour, but it is difficult to be 
certain about the specific cytotoxic role of the radio-Iabeled antibodies. 
Taking into account the tumour-effective half-life and administered dose of radio-
immunoglobulins, the radiation dose to the tumour was calculated to be in the order of 1,000 to 
1,200 cOy. Since the treatment is given systemically, bone marrow toxicity is to be expected and 
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comprises mainly thrombocytopenia and leucopenia. The side-effects tend to be cumulative after 
repeated treatment. Host reaction to the antibody and the development of anti-antibodies were 
also recognised side-effects. The treatment was compared with systemic chemotherapy in a 
randomised trial which showed comparable response rates and survival duration. Those failing 
chemotherapy could still respond to 1311 -antiferritin° treatment( 16). Although the treatment is 
given systemically, its effect is mainly loco-regional by targeting to the tumour and the dose of 
1311-antiferritin is not sufficient to treat extrahepatic disease on its own. However, this approach 
does seem to be a more-effective method than external radiotherapy alone. 
Unsealed radioactive sources can also be given region ally into the feeding artery of the 
HCC. This has the advantage of reduction of systemic toxicity due to circulating radio-isotopes. 
Radio-Iabeled Lipiodol and inert microspheres (in glass, plastic or resin form) can be used in 
internal irradiation of HCC. These substances are also easier to prepare than radio-
immunoglobulins and have no problem with sensitisation. They can localise to the HCC and stay 
within the tumour longer than in normal liver. Therefore, such form of treatment is called 
"Selective Internal Radiation (SIR)". There are two radio-isotopes that are currently used for SIR, 
90Yttrium and 131 Iodine. 90Yttrium is usuaVy tagged to resin-based or glass microspheres and 




Selective Internal Radiation with 131Iodine-Lipiodol in HCC 
Background and review of the Literature 
131 Iodine, which is coriunonly used clinically in diagnosis, labeling of blood cells and 
imaging of diseases, has a physical half-life of 8.06 days. Lipiodol is a stable fatty-acid ethyl-
ester derived from poppyseed oil which contains 38% iodine by weight. Due to the high iodine 
content, it is radio-opaque. It was first used as an X-ray contrast medium in lymphangiography 
and hystero-salpingography( 17). There are 2 commercially available compounds, Ethiodol 
~ . (" 
(Savage Laboratory, Melville, NY 11747) and Lipiodol (Laboratoire Guerbet, France). They have 
similar properties. When Lipiodol is given into the feeding hepatic artery of an HCC, it is 
selectively retained in HCC for many weeks(18,19). Figure 4.1 is the plain X-ray of the abdomen 
of a patient suffering from HCC after intra-arterial injection of Lipiodol which shows intense 
uptake of Lipiodol within the tumour. It can stay up to month within HCC and clears away from 
non-tumourous liver within weeks. As this is fairly specific for · HCC, hepatic intra~arterial 
Lipiodol combined with CT scan may be used for the diagnosis of HCC(20-22). Earlier study was 
done on liver biopsies from HCC tissue that contained Lipiodol with lipid staining and X-ray 
micro analysis. It was shown that the lipid dioplets of Lipiodol in the cancer tissue contained 
highly concentrated iodine(23). This property was first exploited in regional intra-arterial 
chemotherapy in the treatment ofHCC (Chapter 3). 
The targeting property} of Lipiodol can also be exploited in treatment of HCC through 
conversion of non-radioactive Lipiodol to radioactive Lipiodol. The rich iodine content in 
Lipiodol can be partially converted to radioactive 13110dine-Lipiodol (1311-L) by an atom - atom 
exchange reaction. The compound that produced was very stable and no dehalogenation was 




Fig 4.1 Plain X-ray Abdomen after Intra-Arterial Lipiodol 
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Madsen et al studied the bio-distribution and in-vivo kinetics of 131I-E in 4 patients with 
HCC(24). (Ethiodol was used rather than Lipiodol, therefore 131I-E). The dose of 131I_~ ranged 
from 0.2 to 24 mCi. The intra-arterial 131I-E was given with gamma camera imaging so that the 
activity over the liver and other organs could be traced. The study showed that 131I-E was 
localised in the tumour on the first pass through 'the liver. Approximately 80-90% of the 
administered activity localised within the liver and the remainder appeared to be in the lungs (10-
20%). The tumour to liver uptake ratio ranged from 8:1 to 12:1 suggesting good tumour targeting 
of 131I-E. There was also prolonged retention of 131I-E within the liver tumour. The effective 
(or biological) half-life ranged from 4.7 to 5.7 days, while in the liver it ranged from 3.5 to 4 
days. Serial peripheral blood samples were tested for radioactivity which was less than 0.9% of 
the administered dose of 131I-E. Approximately 1-3% of the radioactivity was cleared through 
the urine each day. Therefore, systemic toxicity is likely to be minimal. From this study, the 
absorbed dose to the tumour was calculated to be about 3,250 to 6,400 cGy which is already 
higher than external beam radiation or radio-immunoglobulin. 
Similar results were obtained by another group of Japanese researchers using 131Iodine-
Lipiodol(25). The in-vivo kinetics of 131I-L showed that there were two decreasing components 
for washout of 131I-L, the rapid initial decrease and the slow decrease afterwards. The rapid 
initial fall was due to arteriovenous shunting of 131I-L to the lungs. Therefore,. the lungs can 
potentially be jeopardised if the shunting percentage is high. Furthermore, the degree of targeting 
which is reflected by the tumour to non-tumour uptake ratio of 131I-L is also important in 
predicting radiation hazard to adjacent liver tissue. Those cases with high lung-shunting and poor 
targeting are not suitable for this treatment. 




Physical aspects of 131Iodine-Lipiodol 
131Iodine-Lipiodol (131I-L) emits gamma radiation with an energy of 364 KeV and has a 
physical .half-life of 8.04 days .. The mean half-life is 11.6 days. Its ~ radiation is weak with a 
maximum energy of 600 KeV (mean 187 KeV). The penetration power of the ~ emission has a 
maximum range in tissue of about 2 mm and the mean penetration in softtissue is 0.4 mm which 
is "about 16 to 160 cell diameters. One of the advantages of 131I-L is that its gamma radiation can 
easily be detected by a gamma camera so that dosimetric values can be obtained easily. Based on 
~ '" t · 
the work by Madsen et al (24), the dose to tumour from 1311_ L treatment can be calculated as 
follows: 
Dose (cOy) = Ao 73.8 x E x Te x - . 
M 
16 radiation 1 
E = average ~ energy = 0.197 MeV 
. Ao 
+ 0.0346 x Te x T x g x -
M 
Iy radiation 1 
Te = effective (biological) half-life (days) 
. cOycm2 
T = specIfic gamma ray constant = 2.18 x . 
mCIhr 
g = geometric factor = 3nR (R <10) for spherical subject with radius = R 
Ao = initial activity (mCi) 
M = mass of tumour (gm) 
For instance, a 4 cm diameter tumour ~as treated with 1 mCi of 131I-L: 
I 
4 Te = 6 days, volume of tumor = - x nr3 = 33.5m1 
3 
density of tissue = 1.03, mass = 34.5 gm 
Dose = 73.8 x 0.187 x 6 x 1000 uCi + 0.0346 x 6 x 2.18 x 19 x 1000 uCi = 12,612 cOy I 
35 gm 35 gm . . 
154 
\ 
The calculation is based on total accumulation of 1311_ L within the tumour. When 1311_ L 
is given intra-arterially, it is also taken up partially by non-tumourous liver. However, due to the 
property of Lipiodol, most of the 1311_ L is taken up by the tumour and the rest cleared away by 
non-tumourous liver relatively fast. Therefore, there is a therapeutic advantage over the tumour 
and a possible therapeutic dose of radiation can be given to the tumour without jeopardising non-
tumourous liver. Based on Madsen's study, to increase the dose of 1311-E to 50 mCi to treat a 35 
gm tumour (about 4 cm in diameter) would deliver more than 11,000 cOy to the tumour, only 
1,500 cOy to the non-tumourous liver, 1,100 cOy to the lungs and less than 100 cOy to the whole 
body. Therefore the radiation burden to the non-tumourous liver and other systemic organs is 
quite acceptable. This is the first time in the treatment of HCC that a potentially tumouricidal 
dose of radiation can be safely delivered by a single radiotherapeutic modality. 
The radioactive iodine may be taken up by systemic organs after degradation of 1311-L in 
the liver. Therefore, it is essential to block the thyroid with non-radioactive iodide solution before 
treatment. Radiation protection should be no different from that commonly employed in the 




Selective Internal Radiation Treatment forHCC with 131I-L in PWH 
, The first clinical study of 131I-L was started by the author in 1989. The project aimed to 
study the effect of 131I-L after intra-arterial injection. Full dosimetric study was done in one 
patient who has an intra-arterial port in situ and will be reported below as the first part of the 
study. The second part of the study is a clinical study of tumour response, survival duration and 
treatment toxicity after 131 I -L treatment. 
Bio-distribution of 131I-L in one HCC Patient 
Background 
Similar in-vivo kinetic study of 131I-L to Madsen et al(24) and Nakajo et al(25) was 
repeated in 1 patient. This was done to confirm the findings of other studies. I was only able to 
perform full in-vivo kinetic study in 1 patient because of limitation in gamma camera time. It is 
also not possible to put in an arterial port for all patients because a laparotomy is not justified for 
such purpose. 
Preparation 0/1311-L 
Preparation of 131I-L was done in the radio-isotope laboratory by an atom-atom exchange 
reaction based on the work of Madsen et al(24). The labeling procedure began by boiling 131I in 
O.lM NaOH to dryness in the presence of 0.5mg Potassium Iodide. The residue was refluxed in 
25ml of acetone for 20·minutes and then 1-2ml of Lipiodol was added. The solution was refluxed 
for an additional. 30 minutes. The acetone was then removed using a rotary evaporator with a 
water bath at 70oC. The product was cooled and drawn into a sterile vial and was autoclaved in a 
boiling butanol bath. The labelling efficiency was verified by chromatography and had been 
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found to be more than 99%. Handling of all radioactive materials and patients receiving radio-
isotope treatment conformed with local rules and the code of practice on radiation safety in Hong 
Kong Government Hospitals(26). Figure 4.2 shows making of 1311-Lwith a rotary evaporator 
behind a thick lead shield. 1311-L is stored in a plastic syringe protected by a lead cylinder (Fig 
4.3). 
Patients and Methods (Fig 4.4) 
The distribution and kinetics of 131I-L was studied in a patient who was a 36 year old 
man with residual HCC after cytoreductive surgery. He had a 4.2 cm tumour in the right lobe of 
the liver (Fig 4.5). Further resection was not possible because of limited liver reserve. An arterial 
port (Port-A-Cath, Pharmacia Deltec Inc., St. Paul, MN 55112, USA) was inserted into the 
gastroduodenal artery and planned for further treatment with 1311-L. After he had recovered from 
the surgery, he was given Lugol's solution (aqueous iodine solution) 2 drops tds for 1 week 
before the 1311-L dose and to be continued for 2 months after the injection. A diagnostic 
angiogram was performed through the port to make sure correct positioning and patency of the 
port. A tin colloid liver scan (99mTc, 2 mCi) was also done to show the anatomical appearance of 
the liver and tumour for comparison with the 1 mCi 131I-L diagnostic scan later. 
Prior to the administration of the 1311:,L, transmission images through the lungs and liver 
regions were acquired on the gamma camera and stored on a computer. Approximately 1 mCi of 
131 I in solution was mixed into a flood field phantom and · scintigraphic images were acquired 
both with and without the patient interposed between the phantom and the gamma camera. The 
1311 transmission factor was then determined from the transmission images. This served as 




Fig 4.2 Making of 131I·L with a Rotary Evaporator 
behind a Thick Lead Shield 
.'8 
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Fig 4.3 131I-L inside a Lead Guarded Syringe 
Then the patient was given a small dose of 1mCi 131I-L through the port. Whole body 
and respective organ (liver, spleen and lungs) gamma scans were done serially for 4 days (Fig 
4.4). This served to find the biological half-life of 131I-L so that subsequent fractionated dose 
schedule of 131I-L could be determined. 
Approximately 1 week after the test dose of 131I-L, the planned therapeutic dose of 1311_ 
L was given through the Port-A-Cath. The treatment was done in the gamma camera suite. 
Gamma counting of liver, spleen and lung bases was done during the injection and for at least 
half an hour. Repeat gamma-scanning of various organ (lungs, thyroid, liver, spleen, kidneys and 
colon) was done 1 hr, 2 hr, 4 hr, 6 hr, 24 hr, 48 hr, 72 hr, 96 hr after injection (from 
commencement of injection). The clearance of 131I-L from selected organ~ was determined from 

































































































































































































































































































































































































































































































































Serial blood samples (5ml heparinised blood) were taken at time 0 min, 5 min, 15 min, 30 
min, 1 hr, 2 hr, 4 hr, 6 hr, 24 hr, 48 hr, 72 hr, 96 hr after commencement of injection. These were 
saved for gamma counting by a scintillation counter to document radioactivity in the blood. All 
urine and faeces were collected daily for 3 days and sent to the isotope laboratory for 
radioactivity measurement. 
Fig 4.Scr Scan before l~_lI-L Treatment 
Results 
The dynamic scan after 131I-L dose as detected by gamma camera is shown in Figure 4.6. 
This patient was given 50 mCi of 131I-L through an implantable Port-A-Catheter in 3 fractions as 
the scheme in Figure 4.7. He had experienced no side-effect from the treatment. The activity 
detected by the gamma camera over selective organs after a single dose of 1311_ L is shown in 
\ 
Figure 4.8. The tumour had a' higher activity than non-tumourous liver and lungs. This confirms 
the selectivity of 131I-L over HCC. The gamma scan picture/ after the first dose of therapeutic 
131I-L is shown in Figure 4.9. The high intensity area corresponds to the tumour. The activity 
slowly decayed according to the biolo~ical half-life of 131I-L which was about 4 days. Peripheral 
blood and excretory products were collected for measUrement of radioactivity and the results are 
listed in Table 4.2 and 4.3. Trace radioactivity was detected in the peripheral blood and urine but 
nil in the faeces. 
According to the"bio-distribution data, the estimated tumour dose was 11,950 cOy over 
about 16 days. The estimated lung and liver doses were 1,100 cOy and 1,550 cOy respectively 
over about 16 days. This suggests a therapeutic advantage of, intra-arterial 131I-L and 
demonstrated that a tumouricidal dose of radiation (more than 10,000 cOy) could be delivered to 
the tumour. This patient had CT scan of the liver 2 months after the therapeutic treatment which 
showed a partial remission (Fig 4.10). 
Table 4.2 Percentaye of 1311 Activity in 
Peripheral Blood After 31I-L Treatment 











Table 4.3 Percentage of 1311 Activity 

















Fig 4.6 Dynamic Gamma Scan During 131I-L Injection 

































































































































































































































































































































































































































































































Fig 4.9 Gamma Scan Picture after 131I-L Treatment 




In-vivo kinetic studies of intra-arterial 1311-E and 1311-L in HCC had been done by 2 
groups of researchers(24,25). T~e number of patients studied in each of these two studies was 
only 4. Madsen's study(24) had 2 patients not evaluable because there was no selective tumour 
localisation due to infiltrative tumour and hepato-portal shunting. Therefore, patients with 
suspected arteriovenous or arterio-portal shunting should not be selected for this treatment. 
Nakajo's study(25) again showed accumulation of 1311-L mainly within the HCC and not in 
other extrahepatic organ's. There was a rapid and slow decreasing components in the decay of 
131I-L. The rapid component of decay may be due to arteriovenous shunts existing within the 
tumour. 
The study was repeated here in one of the HCC patients. There was good localisation of 
tumour after 1311-L. There was no 1311 activity detected outside the liver. The biological half-
life of 131I-L was about 4 days and the calculated tumour dose was more than 10,000 cOy which 
is potentially tumouricidal for a 4 cm tumour. This was confirmed by dramatic regression of the 
tumour after treatment. As all three studies showed the biological half-life is from 4 to 6 days, 
this can be confidently used for dose calculation in subsequent clinical trial and a full dosimetric 
study is not required. The trace amount of radioactivity recovered in the peripheral blood and 
excretory products imply minimal systemic effect of the treatment. 
Although it is only possible to report one case here for in-vivo kinetics of 1311-L, the 
results are similar to other studies. It was then decided to go ahead with a full clinical study and 
this is reported below. 
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Clinical Study on the Use of 131I-Lipiodol in the Treatment of Inoperable HCC 
Background 
The treatment of inoperable HCC has been disappointing with either systemic or regional 
chemotherapy as mentioned in Chapter 3. Cure of inoperable HCC seems an illusion before we 
have an effective systemic cytotoxic drug. An effective loco-regional treatment which is non-
toxic may prolong good"quality of life for these patients though it may not be a cure. From the 
background studies and the in-vivo kinetic study, selective internal radiation with 1311_ L should 
be more effective than external beam irradiation or radio-immunoglobulin treatment because of a 
higher dose of radiation. The relatively low dose of radiation to non-tumourous liver and 
extrahepatic tissues makes it a safe procedure with minimal systemic toxicity. Treatment is 
adequate for tumours less than 5 cm and can be free from all the toxicity related to systemic 
chemotherapy. The conversion of Lipiodol to radioactive 131 1-L was also found to be successful 
in the laboratory. Labeling efficiency was usually above 99%. It was decided not to use the 
commercially available 131I-L because the dose per unit volume was too low with the 
commercial preparation. The clinical study on the use of 1311 -L to treat inoperable HCC was 
started in 1990. 
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Patients and Method 
There were 2 different protocols used for patients with tumours larger or smaller than 5 
cm. Patients with tumour size less than 5 cm were given single 1311-L treatment during HAG and 
patient with tumour more than 5 cm were given fractionated 1311-L treatment through an arterial 
port that was inserted during operation. The diagnosis of HCC was either by histology or raised 
AFP (> 500J!g/L) with compatible findings of HCC on CTIUSG. In all cases, the tumour was 
inoperable because of either extensive disease or severe cirrhosis. Previous treatment such as 
surgery, chemotherapy or 'chemoembolisation did not exclude patients from entering into the trial. 
Other selection criteria are listed below: Age::; 75, Karnofsky Performance Score ~ 70, total 
bilirubin ::; 5 OJ!mol/L , platelet count ~ 100xl09/L, no concurrent serious medical illness, no 
thyroid disease, no prior chemotherapy within 4 weeks before entering into the trial, no 
extrahepatic disease, single hepatic artery without anomaly on HAG, no major vascular 
involvement by the tumour including the main portal vein, main hepatic artery, hepatic veins or 
inferior vena cava on HAG. There had to be a measurable lesion on CT scan or USG. Patient's 
consent had to be obtained before entering into the trial. The following routine investigations 
were performed for eligible patients: CBP, RLFT, PT APTT, serum AFP, HBsAg status, USG 
and CT scan of liver, CXR and a diagnostic HAG. 
Suitable patients were given Lugol's sqlution (aqueous iodine solution) 2 drops tds for 1 
, week before treatment and to ) be continued for 2 months after 1311_ L injection. Those with 
inoperable disease diagnosed on laparotomy had cytoreduction surgery, cholecystectomy and 
insertion of an implantable Port-A-Catheter (Pharmacia Deltec Inc., St. Paul, MN 55112, USA) 
into the gastroduodenal artery done. Others did not require surgery. 
For those patients who had an arterial port inserted, a diagnostic angIogram was 
performed through the port to make sure correct positioning and patency of the port. A test dose 
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of 1mCi 131I-L was given afterwards to determined the effective half-life through repeated 
gamma scan as mentioned in the bio-distribution study. 
The intended absorbed dose to the HCC was no less than 10,000 cGy. The recommended 
upper dose limits for the non-tumour9us liver and lungs were 3,000 and 2,500 cGy respectively. 
Preparation of 1311_ L was done in the laboratory with the same method mentioned in previous 
bio-distribution study. The dose of 131I-L was delivered either during hepatic angiography with 
single fraction treatment or through a Port -A -Catheter for fractionated treatment. If the diameter 
of the · tumour was nor-greater than 5 cm, the proposed dose scheme by Park et al (27) was 
followed (Table 4.4). For tumours larger than 5 cm, the dose of 131I-L is too large for single 
injection and the volume of Lipiodol is too large for the HCC to hold. In this circumstance, the 
dose of 131I-L was fractionated to 3 doses and given through the Port-A-Catheter. The second 
and third doses were given at 1 and 2 effective half lives respectively which was determined 
earlier by the test dose. The dose of second and third injections is half of the first dose (Fig 4.7). 
For those who did not have a Port-A-Catheter, the dose of 131I-L was given during HAG. 
















For patients having an arterial port, 131I-L was injected into the port manually in the 
gamma camera suite. Gamma counting of liver, spleen and lung bases was done during the 
injection and for at least half an 40ur. Other patients received the treatment during HAG. All 
patients were nursed in an isolation ward after the treatment and discharged home when the 
activity of the radio-isotope was below 0.37 GBq (10 °mCi) which was about 2 to 3 weeks after 
treatment and longer for fractionated treatment. 
Patients with raised pre-treatment AFP had blood taken for an AFP level on the day 
before treatment, on alternate days until discharge, and weekly thereafter. A CT scan was used to 
document response 2 months after treatment. For monitoring of toxicity, blood counts and liver 
functions tests were performed at the same time as blood samples taken for AFP measurement. 
Other symptoms were also recorded daily in the hospital and on each follow-up which was done 2 
to 4 weekly after discharge. Grading of toxicity was according to the W.H.O. classification 
(appendix). Definition of response is also listed in the appendix section. Survival duration was 
calculated from the first day of 1311_ L treatment. Actuarial survival curve was plotted 0 by the 
Kaplan-Meier method. 
Treatment Results 
From August 1990 to June 1993, 26 p~tients with inoperable HCC were entered into the 
trial. There were 22 males and 4 females aged from 29 to 72 (median age 53.5). The median 
Karnofsky Score was 90% (range, 80% to 100%). Ten patients had definitive surgical resection as 
, the first treatment where later recurred locally before treatment with 131I-L. Six patients had 
cytoreductive surgery and the residual disease treated with 1311_ L. Eight patients had inoperable 
HCC with no previous treatment. Two patients had inoperable HCC which failed treatme~t with 
intra-arterial oily chemoembolisation. 
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Nine patients had a Port-A-Catheter inserted during laparotomy and subsequent 131I-L 
gIven through the port. These patients were originally intended either for resection or 
cytoreduction. Twenty-two patients had evaluable disease radiologically. Twenty-six patients had 
multinodular tumours. Considering the largest measurable lesion, median tumour size was 4.1 cm 
in diameter (range, 2 to 9 cm). According to Okuda's staging classification, there were 12 stage I, 
14 stage 11 and no stage III patients. Four patients with evaluable lesions only on laparotomy, 
either because of diffuse disease or resection margin involvement, were evaluated for toxicity and 
survival. Fifteen patients had raised AFP levels with a median level 5,465J.lg/L (range, 79 to 
131,450J.lg/L). The patient characteristics are listed in Table 4.5. 
Tumour response, toxicity and survival 
Four patients who had relatively large tumours (9 to 9.5 cm) were given fractionated 1311_ 
L doses ranging from 1.85 to 4.44 GBq. The rest of the patients received single fraction treatment 
of median dose 1.85 GBq (ranging from 1.11 to 2.22 GBq). Four patients had repeated treatment 
because of recurrent disease or a rising AFP level. They received a total dose of more than 3.75 
GBq. The maximum total dose of 131I-L given was 7.4 GBq in one patient which was delivered 
in two doses 4 months apart. 
All except one patient were evaluated for response either radiologically and/or by change 
in AFP levels. There were 2 complete responses (8%), 11 partial responses (44%), 5 static 
diseases (20%) and 7 progressive diseases (28%). The overall response rate was 52%. The first 
CR patient was a 71 year old lady with cytoreduction surgery done leaving behind residual 
disease. This patient is still alive without any evidence of disease for more than 16 months. The 
second CR patient was a 62 year old man with 2 previous resections. 131I-L was given after the 
second local relapse. The lesion regressed completely after · treatment. Of 15 patients who had 
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raised AFP levels, 10 and 8 patients had more than 50% and 90% reduction in AFP levels 
respectively. Two patients had reducti~n of AFP less than 50%. Only 3 patients had no response 







Table 4.5 Patient Characteristics for 1311_ L Trial 
No. Sex Age Disease status Previous Size of ' Initial 
on entry treatment tumour AFPlevel 
(cm) (~g/L) 
1 Male 36 Residual 'disease Cytoreductive surgery 4.2 6,820 
after s~gery 
2 Female 65 InoperableHCC Nil 9 18,771 
3 Male 60 Inoperable HCC Nil 9 1,215 
4 Male 35 Recurrence after Surgery, chemotherapy, 9.5 81,300 
surgery chemoembolisation 
5 Male 55 Residual disease Cytoreductive surgery 2.3 
after surgery 
6 Female 71 Residual disease Cytoreductive surgery margIn 
":,(, 
after surgery 
7 Male 50 Recurrence after Surgery 3.5 79 
surgery 
8 Male 57 Recurrence after Surgery 9 
surgery 
9 Male 41 Residual disease Cytoreductive surgery, 6 
after surgery 
10 Male 50 Recurrence after Surgery, 5.4 665 
surgery chemoembolisation 
11 Female 48 Residual disease Cytoreductive surgery margIn 
after surgery 
12 Male 54 Inoperable HCC Nil 6 
13 Male 45 Residual disease Cytoreductive surgery 2 1,941 
after surgery 
14 Female 52 Recurrence after Surgery 3 
surgery 
15 Male 29 Residual disease Cytoreductive surgery 5.4 559 
after surgery 
16 Male 67 Recurrence after Surgery 3 9,171 
surgery 
17 Male 44 Recurrence after Surgery 6 ' 682 
surgery 
18 Male 60 Inoperable HCC Nil 4.5 380 
19 Male 60 Residual disease ' Cytoreductive surgery 3 
after surgery 
20 Male 53 Recurrence after Surgery 2.3 
surgery 
21 Male 32 Residual disease Cytoreductive surgery 2.5 
after surgery 
22 Male 58 Inoperable HCC Nil 4 5,465 
23 Male 70 Recurrence after Surgery margIn 131,450 
surgery 
24 Male 72 Inoperable HCC Nil diffuse 2,913 
25 Male 62 Recurrence after Surgery 2 
surgery 
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Twenty-two patients had evaluable disease radiologically. One CR and 3 PR were 
documented by CT scan. Twelve patients had stable disease and the remainder progressive 
. ; 
disease. CT scan both before and after treatment of one patient who achieved PR after 1.85 GBq 
(50 mCi) 131I-L is shown in Figures 4.5 and 4.10 respectively. Although the majority of patients 
had stable disease as assessed radiologically, the AFP level decreased gradually 'after treatment as 
. shown above. 
The treatment was well tolerated in general. There was no complication relating to 
angiography. All patients'were completely ambulatory after the treatment and the average stay in 
hospital was 2 weeks for single fraction treatment. Liver enzyme levels showed no significant 
change after the treatment. Deterioration of liver function usually occurred during the terminal 
phase of the disease and was attributed to recurrent disease rather than radiation hepatitis. 
However, · there was one patient who received a total of 4.81GBq of 131I-L, had a very protracted 
course of deteriorating liver function over 5 months with controlled local disease. The patient 
remained in good general condition despite deep jaundice and high liver enzyme levels. This 
might be due to radiation hepatitis. There was no bone marrow toxicity documented. 
Nineteen patients had died and 7 remained alive at the time of analysis giving a minimum 
median survival of 6 months (range, 1.2 to 16.6 months). The 7 surviving patients had median 
follow up of 10 months (range, 2.3 to 16.6 months). Overall response and survival is shown in 
Table 4.6. The Kaplan-Meier actuarial survival curve of all patients is plotted in Fig 4.12. There 
, ) 
was a 50% survival at 7 months after treatment. 
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Table 4.6 Overall Response and Survival for 131I-L Trial 
No. . Sex/Age Dose of 13II_L Change in AFP Overall Survival 
(GBq) (%) Response (months) 
.................................................................................................................................................................................................................................................... 
1 M/36 1.85 +2.96# -94.1 PR . 10.97 
2 F/65 3.7 + 3.7# -97 PR 6.27 
3 M/60 2.22 + 2.22# -39.4 PR 3.4 
4 M/35 4.44 -6.7 PD 2.3 
5 M/55 1.48 SD 12.9 
6 F/71 1.11 CR 16.57+ 
7 M/50 ,·,·1.48 -79.8 PR 13.53 
8 M/57 1.85 + 1.21# PD 1.97 
9 M/41 1.85 SD 4.07 
10 M/50 1.85 -100 PR 13.97+ 
11 F/48 1.85 . inevaluable 7.13 
12 M/54 1.85 PR 5.4 
13 M/45 1.85 -56.5 PR 11.03 
14 F/52 1.85 PD 7.3 
15 M/29 1.85 rIsIng PD 2.07 
16 M/67 1.85 -98.6 SD 8.57 
17 M/44 1.85 rIsIng PD 2.53 
18 M/60 1.85 -.?5.7 PR 12.17+ 
19 M/60 1.85 PD 1.2 
20 M/53 1.85 SD 10+ 
21 M/32 1.85 SD 9.3+ 
22 M/58 1.85 
--
-99.7 PR 3.6 
23 MnO 1.85 rIsIng PD 4 
24 Mn2 1.85 -95.5 PR 2.3+ 
25 M/62 1.85 CR 4.2+ 
26 M/52 1.85 -100 PR 3.47 












































































































The use of 1311-L or 1311-E to treat HCC has been reported by other groups. Bretagne et 
al(28) treated 15 HCC patients ~ith 1311-L and documented an average reduction in tumour size 
of 50% in 9 cases. Eleven out of 12 patients with initial elevated AFP levels had a median drop of 
55% after treatment. The dose of 1311-L ranged from 900 MBq to 2,400 MBq (24.3 mCi to 64.9 
mCi). Tolerance was in general good; transient pain and fever were documented but there was no 
evidence of progressive liver dysfunction. Another study on Chinese HCC patients was done by 
Lui et al in Taiwan(29). "Ten patients with inoperable HCC was given 1311-L at an average dose 
of 23.1 mCi. Selective targeting by 1311-L was documented with a tumour to non-tumourous 
uptake ratio of up to 25:1. The response rate was 70% and overall median survival was 9 months. 
There was no major complication from the treatment. 
This treatment was used as a single modality in the treatment of 24 HCC patients in one 
Korean study which reported a tumour reduction in 89% for patients with a small tumour « 4cm 
in diameter) and 65% for patients with a tumour size between 4 and 6 cm. All the responsive 
cases were accompanied by reduction of serum AFP level. The prescribed dose of 1311-L ranged 
from 555 to 2,220 MBq (15 to 60 mCi)(30). ·An European multi-centre trial using radioactive 
Lipiodol to treat 63 HCC patients produced an objective response in 40% of patients with 
minimal toxicity while keeping the radiati_on dose to normal liver below 2,000 cGy(31). All the 
trials used single treatment of 13,11-L and the-total dose was at most 60 mCi. 
From earlier clinical study of 26 patients treated by intra-arterial 1311-L, the dose of 1311_ 
L was escalated to over 100 mCi and there was no increase in toxicity. This is possible through an 
arterial port and by fractionating the dose. This can allow large tumours to receive higher dose of 
radiation and also fractionation the dose can allow time for the non-tumourous liver to recover. 
The objective tumour response rate was 52% which appears to be better than conventional 
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treatments. Many patients were heavily pre-treated with cytotoxic chemotherapy or had surgery. 
Normally, such patients respond poorly to other treatments. In the past, these patients were 
offered systemic chemotherapy, chemoembolisation or percutaneous ethanol injection. The results 
are not satisfactory as seen in Chapte~ 1 and 3. The expected median survival is around 3 months 
after diagnosis. 
Through selective internal radiation with 131I-L, radiation dose to the tumour can be 
escalated and at the same time keeping normal tissue within the limit of radiation tolerance. In the 
present study, there was an overall response rate of 52% and radiation-induced toxicity was 
minimal. The dose of 131I-L was further increased to 3.7 GBq (100 mCi) by 3 fractions in 4 
patients (patients 2,3,4,8 in Table 4.3) who had tumours larger than 6 cm. Radiation hepatitis was 
not encountered and three out of 4 shown partial response. This can be an alternative method that 
can be used to treat larger tumours. The tumour can also receive a more uniform dose over an 
extended period of time than with single treatment. This is justified only if an arterial port is 
available for repeated injection. Repeat treatment was done in 4 patients and their total dose of 
131I-L was more than 3.7 GBq. Tolerance was good and there was no significant toxicity 
documented. 
The present approach has its own limitations. The energy of 1311_ L may not be high 
enough to treat tumours larger than 5 cm with a single fraction (24). The activity required will be 
too large and radiation hazard is a potential problem to operating personnel. It is possible to 
fractionate the dose but this is only possible if an arterial injection port is implanted which 
requires a laparotomy. This may not be justified if the treatment is of palliative intent. To 
improve the efficacy further, a more powerful radio-isotope in terms of energy and penetration 
power may be used to treat large tumours. Nevertheless, 1311_ L treatment still has a place in 
treating tumours less than 5 cm which are not suitable for resection. It may also be indicated as 
post-operative adjuvant treatment to eradicate microscopic disease after surgery. A randomised 
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trial of post operative intra-arterial 131I-L is currently ongoing in our centre and expected to 
produce results in 1 to 2 years. 
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Selective Internal Radiation with 90Yttrium-Microspheres in HCC 
Background and review of the Literature 
The use of 1311-L is limited by the energy of 1311-L. Tumours larger than 5 cm require a 
large dose of 1311 and are difficult 'to be treated. Use of larger doses of 1311 is not practical 
because of difficulty in radiation protection and the volume of 1311-L required may be too large 
for the tumour to hold. Fractionation of the 1311-L dose is possible to overcome this problem but 
this requires an operation to place the injection port or the patient has to undergo repeated HAG. 
90Yttrium (90y) is commonly used as an unsealed source in internal radiation treatment. 
Theoretically, 90y is more suitable for large tumours (more than 5 cm) because of its higher 
energy which provides a deeper penetration and higher tumour dose·rate(32). It is also safer in 
terms of radiation protection because of its pure ~ emission. The half-life of 90y is short (64.2 
hours) which makes the stay in hospital shorter than 1311_ L treatment. The treatment can be given 
either systemically or regionally. 90y labeled tumour specific monoclonal antibodies are given 
intravenously to treat ovarian cancer(33,34), Hodgkin's lymphoma(35) and Non-Hodgkin's 
lymphoma(36). Systemic administration commonly causes bone marrow suppression due to 
irradiation and the antibodies can induce sensitisation by the host as well. 
Since liver tumours are supplied almost exclusively by the hepatic artery, as opposed to 
the portal vein(37), regional treatment with intra-arterial 90y labeled microspheres can deliver a 
tumouricidal dose of radiation to hepatic tumours. Regional administration can reduce systemic 
side-effects of the isotope if the micro spheres does not leak to the systemic circulation. 
Regional 90y treatment is done by giving 90Y-microspheres intra-arterially. 90y_ 
micro spheres are made by tagging 90y onto carriers such as ceramic, glass, plastic or resin 




when given into the hepatic artery, they stay in the vascular bed of the tumour indefinitely. These 
radio-Iabeled substances are stable and inert both chemically and antigenically. 
The concept of using intrahepatic arterial radioactive micro spheres treatment for liver 
tumours was first described by Prinzmetal et al in 1948(38). In the late 1960s, 90Y-microspheres 
was first used by Ariel et al to treat 37 patients with inoperable liver cancer(39). Objective 
response was observed in 32% of the patients. The treatment was done by giving ceramic 90y_ 
micro spheres into the coeliac axis. The dose to the tumour was estimated as between 10,000 to 
20,000 cGy assuming 'uniform distribution of the isotopes within the liver. However, it was 
commented that exact dosage calculation is difficult because of the pure ~ radiation and several 
assumptions had to be made. Furthermore, injection of 90Y-microspheres into the coeliac axis 
can cause morbidity due to leakage of microspheres into the circulation of the gut. 
Subsequent trials were published using 90Y-microspheres for non-HCC liver tumours by 
Grady et al in 1979(40), Mal1travadi et al in 1982(41) and Ariel et al in 1982(42). However, these 
results were achieved with two major side-effects; leaching of 90y from the resin or ceramic 
matrix with accumulation of the isotope in bone leading to bone marrow suppression, and 
shunting of the infusing microspheres to the lungs and other organs. The latter effect ' led to 
pulmonary fibrosis and gastrointestinal bleeding( 43). In fact, 3 out of 25 for Grady's series died 
from complications of the treatment(40). With the improvement in radio-Iabeling techniques, 
much more stable 90y -micro spheres became available. The leach percentage has decreased 
substantially and the product became more stable. Erbe et al had tested the physical stability of 
90Y-glass-microspheres and found a 0.02-0.13% leached rate in non-ionized water or saline at 
370 C(44). There have also been improvements in radiological techniques and selection of patients 
for internal radiation treatment so that the technique has become safer today. 
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Glass 90Y-microspheres were used by Herba et al to treat 15 patients with liver tumours 
(12 metastatic, one carcinoid, one islet cell tumour and one hepatoma)(45). Most patients had 
stable disease after treatment and the estimated dose to the liver was up to 10,000 cGy. Houle et 
al treated 7 patients with inoperable HCC with glass 90Y-microspheres in a pilot study(46). The 
treatment was given during HAG. The absorbed dose to the liver was estimated to be between 
5,000 and 10,000 cGy, and up to 32,000 cGy to the tumour. There was no significant toxicity 
documented. In this study, the radiation dosage to the liver was not directly measured. The 
administered amount of,,90y -micro spheres was based on the volume of the patient's liver and the 
desired total radiation absorbed dose to the liver assuming a uniform distribution of the 
micro spheres within the hepatic parenchyma. Extrahepatic shunting was mentioned in this study 
as the main limitation to the treatment. Houle's group studied further 10 patients with HCC using 
glass 90Y-microspheres. Eight of the 10 patients had significant .concentration of 90Y in the 
tumour with tumour-to-liver perfusion ratios ranged from 1.0:1 to 10.0:1 (47). The radiation dose 
that was given ranged from 5,000 cGy to 10,000 cGy. All patients were reported to have stable 
disease. There was no significant side-effects except for one patient who developed radiation-
induced duodenal ulcer. 
Another study by Blanchard et al used plastic 90y -micro spheres to treat 15 patients with 
liver metastases and one patient with hepatoma. Five partial responses (more than 50% decrease 
in tumour volume) and 2 minor responses were documented(48). Six patients developed gastritis 
or gastric ulceration from this study which was probably due to leakage of micro spheres to the 
circulation of the gastrointestinal tract. A more recent study was done in China which involved 18 
Chinese patients with HCC treated with glass 90Y-microspheres. A 33% survival rate at 1 year 




Resin 90Y-microspheres were used by the group in Western Australia by Gray et al(50). 
Most of the patients treated had metastatic liver tumours. Treatment was given intra-operatively 
through an arterial catheter inserted into the gastroduodenal artery. The overall mean fall in CEA 
levels was 70% of pre-treatment level and tumour volume reduction of more than 50% was 
documented in 10 out of 22 treated patients. 
These studies show that it is now possible to deliver even higher doses of radiation than 
external beam radiation, 131I-L or radio-immunoglobulins safely to hepatic tumours. With the 
more powerful isotope, 1arger tumours can now be treated. However, most of the studies involved 
metastatic liver tumours. Only the Canadian(47) and Shanghai(49) studies involved HCC patients 
but they only had small number of cases. The experience in treating metastatic hepatic tumours 
cannot be extrapolated to HCCs because cirrhosis is commonly present which makes non-
tumourous liver more susceptible to radiation. Furthermore, arteriovenous shunting which is 
common inHCC can shunt radioactive microspheres to the lungs and cause radiation 
pneumonitis. 
Measurement of dose is crucial to the study of a new form of radiation treatment. 
However, most early studies were done percutaneously during HAG and accurate measurement of 
dose was not possible because of the pure ~ radiation. The radiation dose to liver and tumour was 
only an extrapolation assuming uniform distribution of micro spheres in the liver and tumour. 
However, the concentration of microspheres within the tumour is expected to be higher because 
of higher blood flow. The only study which accurately measured tumour and liver absorbed doses 
was done by Gray and his associates who gave the treatment through a Port-A-Catheter placed 
during laparotomy so that a ~ probe can be applied onto the liver surface to measure dose. 
Multiple liver biopsies for liquid scintillation counting were also done to verify doses to each part 
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of the liver(51). By such means accurate dosimetry can be which was not possible with 
percutaneous injection during HAG. 
With such a background, the first clinical study of intra-arterial resin 90Y-microspheres in 
the treatment of inoperable HCC was initiated in 1990 in P.W.H. This was designed to test the 
hypothesis that selective internal radiation treatment with intra-arterial 90y -micro spheres IS 
feasible, safe and effective in treatment of the disease. The objectives are the following: 
1. To document tumour response and survival after intra-arterial 90Y-microspheres 
treatment 
2. To document toxicity after 90y -micro spheres treatment 
3. To measure the dose distribution after 90y -micro spheres treatment 
4. To correlate dose of 90Y-microspheres with response and survival 
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Physical aspects of 90Y-microspheres 
90y has a physical half-life of 64.2 hours and mean half-life of 3.86 days. The emitting 
radiation by 90y is mainly electron (~ radiation) with a maximum energy of 2,270 Ke V and 
mean energy of 936.7 KeV. The penetration distance in tissue is better than 131Iodine (Table 
4.7). It is also easier for radiation protection because of pure electron radiation and the short half-
life. The comparison between 131I-L and 90Yttrium micro spheres is shown in Table 4.7. 
The disadvantage of 90y is difficulty in verifying dosimetry because of its pure ~ 
emission. One has to use a ~ probe placed in proximity to the source before the radiation can be 
detected. Therefore, when 90Y-microspheres are used to treat HCC, a laparotomy has to be 
performed before accurate dosimetry can be obtained. 
The 90Y-microspheres used in the studies are resin based micro spheres prepared by The 
Australian Nuclear Science and Technology Organisation (ANSTO). A photomicrograph of 90y_ 
micro spheres in suspension is shown in Figure 4.13. They are about 29-35 Jlm in diameter which 
is the size of the arterioles in tumour tissue. It is stable in non-ionised water at 370 C and leaching 
of radio-isotopes from the microspheres is negligible. The microspheres are biologically and 
chemically inert and non-degradable. When the microspheres are given into the feeding hepatic 
artery of the HCC, they will follow the blood flow and lodge in the vascular bed of the tumour, 
thus irradiate the tumour internally. Figure 4.14 shows the histological appearance of a 
micro sphere sitting inside an arteriole within HCC tissue. Under normal circumstances, the 
micro spheres will stay within the tumour indefinitely. However, when there are large 
arteriovenous shunts, some of the microspheres may go to the lungs. Since the pulmonary 
arterioles are smaller than the microspheres, the microspheres will lodge within the lungs rather 
than circulating systemically. 
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Table 4.7 . Comparison between 131I-L and 90Yttrium-Microspheres 
131I_L 90Yttrium (microspheres) 
Physical half-life 8.04 days 64.2 hours 
Mean life (~) 11.6 days 3.86 days 
Radiation emitted: 
a. ~ - radiation 
1. Maximum range in tissue 
. ;, 
(cytotoxic range) 2mm Ilmm 
2. Mean penetration in tissue 
(soft tissue density = 1.03) 0.4 mm 2.5 mm 
3. Maximum energy 600 KeV 2270 KeV 
4. Mean energy 187 KeV 936.7 KeV 
b. 'Y - radiation 364 KeV nil 
A, = decay constant 
The absorbed dose by tissue in general after internal radiation with 90y can be obtained 
by standard published value which is 47.2 cOy per day per gm of tissue per IJlCi of 90y. Since 
the mean life of 90y is 3.86 days (Table 4.7), the dose from IJlCi of 90y per gm of tissue (D) 
over complete decay of 90y is as follows: D = 47.2 x 3.86 = 182.2 cOy. Therefore the total dose 
of radiation to the tissue is: 
D ( G) 182.2 x Activity(uCi) 
ose c y = -m-a-ss-of-ti-ss-u-e=--("';"'g-m-)"';"" (equation 1) 
This was verified by Fox et al(51) who re-calculated the dose from liver tissue treated 
with 90y -microspheres. The dose at a particular point within the tissue (either tumour or non-
tumour) is calculated by computing the distance from that point to each micro sphere in the 
neighbourhood of the point. Microspheres 11 mm (or slightly less than that) away from the dose 
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point did not need to be included because of the finite range of the ~ radiation (cytotoxic range = 
11 mm, Table 4.7). The depth dose relation published by Russell et al(52) is used to estimate the 
,~ 
dose contribution from each micro sphere. The total dose was obtained by summing the 
contributions to the dose from all microspheres. Hence the dose at a selected point is given by: 
(equation 2) 
where D is the dose in Gray (over complete decay), Qi is the activity of the ith micro sphere in 
MBq and ri is the distap.ce to the ith micro sphere in mm. The effective range of electrons, L, is 
taken as 8 mm. The microspheres were assumed to represent point sources of activity so that no 
lower limit was placed on the value of ri except that ri = 0 was excluded from consideration. The 
value of ri is most unlikely to be zero, thus this does not affect the 'calculation(51). In order to 
work out the ri values, Fox et al took liver tissue samples after internal radiation with 90y_ 
micro spheres and cut 16 mm sides sliced at 500J.lm intervals and located every micro spheres in 
the section. Therefore, the dose to the tissue can be calculated reasonably accurately_ The 
following formula was obtained with Fox's study: 
-2 
D = 4.97 x 10 A/W Gray (equation 3) 
where D is the radiation dose to tissue over complete decay in Gray, A is the total activity (MBq) 
of 90y -micro spheres in a mass of liver of W kg. After converting the units, the equation is as 
follows: 
D (cGy) = 4.97 x 37 A(JlCi)/W(gm) 
_ 183.9 x Activity(uCi) 
mass of tissue (gm) (equation 4) 
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Equation 4 is almost the same as equation 3. Therefore, the calculated dose was verified with in-
vivo studies. Equation 1 will be used from now on as the standard equation to calculate dose of 
radiation for 90y -micro spheres treatment. 
Using equation 1, the prescribed activity of 90Y-microspheres can be calculated if the 
doses to tumour and non-tumourous liver are determined. In order to give an adequate 
tumouricidal dose to the liver tumour, the dose of 90Y-microspheres is prescribed so that 
"maximum" non-tumourous liver tolerance is reached. This would secure maximum dosage to the 
tumour without the complication of radiation hepatitis. From the experience with internal 
radiation with 1311-L, and the literature, the non-tumourous liver, which commonly has cirrhosis 
at the same time, can tolerate up to 5000 cOy (internal radiation) without radiation hepatitis. For 
non-cirrhotic liver, the tolerance can be up to 8000 cOy. Therefore, these are chosen as the ceiling 
doses of 90y -micro spheres that is to be prescribed. 
Since the 90y -micro spheres are not evenly distributed within the liver after intra-arterial 
injection, it is important to predict the distribution of the micro spheres before the therapeutic 
dose. This can be done by doing a pre-treatment Technetium-99m-macroaggregated albumin scan 
(Tc-MAA). This is further discussed in the section on "Selection of patients for internal 
radiation" and later in the Methods section. The result of this scan gives a tumour to n011-
tumourous uptake ratio (TIN ratio) of Tc-MAA which is a simulation of the subsequent 90y_ 
micro spheres treatment. This ratio must be larger than 2 and the larger the better in terms of 
preferential uptake of the isotope by the tumour. 
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In a typical situation of an inoperable HCC 10 cm in diameter, in a cirrhotic background, 
and with a TIN ratio of 3 (calculated from the from pre-treatment Tc-MAA scan), the dose of 
90y -micro spheres required can be calculated as follows: 
volume of tumour = 524 m1 mass of tumour = 524 gm 
assuming total liver mass = 1500 gm 
=:> mass of non-tumourous liver = 1500gm - 524gm = 976 gm 
assuming ceiling dose to normal liver is reached which is 5000 cOy 
Therefore dose to tumour = 5000 x TIN ratio = 15000 cOy 
A(N) = 5000 x 976 = 26.8 mCi = 0.990Bq 
182.2 
[A(N) = Activity of non-tumourous liver] 
A(T) = 524 x 15000 
182.2 
= 43.1 mCi = 1.60Bq 
. [A(T) = Activity of tumour] 
Total activity required = A(N) + A(T) = 2.59 GBq 
If the TIN ratio = 5 and dose to non-tumourous liver is kept at 5000 cOy 
A(T1) = 524 x 25000 = 71.9 mCi .= 2.66 GBq 
182.2 
Then, the total activity required = 2.66 + 0.99 = 3.65 GBq 
The absorbed dose by the tumour an~ the non-tumourous liver can be verified by two 
independent methods. Firstly, the doses over different regions of the liver can be measured by a 
calibrated ~-probe during laparotomy. Secondly, the radiation doses at a microscopic level can be 
estimated by liquid scintillation counting of dissolved biopsy samples taken from representative 
sites of the liver. This will be further discussed in the subsequent section. 
The first clinical study of 90y -micro spheres in the treatment of inoperable HCC was 
started in 1990. This project aimed to study the effect of 90y -microspheres after intra-arterial 
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injection and to investigate the dosimetry, tumour response, survival duration and treatment 
toxicity. The study is of 2 phases. The first phase study was an early phase 11 study with the 
treatment performed through laparotomy with full dosimetric study. The second study was a full 




Treatment of Inoperable Hepatocellular Carcinoma with Intrahepatic-Arterial 
90Yttrium Microspheres - An Early Phase 11 Study 
Treatment protocol 
I. Patient selection criteria 
Patients with inoperable HCC were entered. The diagnosis of HCC was either by 
histology or raised AFP > 500J..lg/L with CT /USG evidence of HCC. In all cases, the tumour was 
inoperable because of either extensive disease or severe cirrhosis. Previous treatment such as 
surgery, chemotherapy, chemoembolisation did not exclude patients from entering into the trial. 
Other selection criteria are listed below: 
1. Age "5: 75 
2. Kamofsky Performance Score ~ 70 
3. Total bilirubin "5: 50J..lmol/L, platelet count ~ 100xl09/L 
4. No concurrent serious medical illness that precludes a patient from laparotomy 
5. No chemotherapy within 4 weeks before entering into the trial 
6. No extrahepatic disease on pre-operative investigations 
7. No major vessel involvement by tumour including the main portal vein, main 
hepatic artery, hepatic veins or inferior vena cava on pre-operative investigations 
8. Measurable lesion on CT scan or usa 
9. Patient consent. 
IT. Pre-treatment investigations: 
1. CBP, RLFT, PT APTT 
2. AFP, ferritin, HBsAg 





5. HAG + Tc-MAA scan (The technique of this investigation will be discussed later 
in the respective section on selection of patient for selective internal radiation). 
The patients are considered suitable for 90Yttrium-microspheres treatment if they 
satisfy the following criterias: lung-shunting of Tc-MAA less than 15%, no 
significant shunting of activity to the gastrointestinal region, no multiple or 
complicated arterial blood supply to the liver on HAG and a TIN ratio of Tc-MAA 
of more than 2. 
Ill. Administration of 90Yttrium-microspheres 
Patients were subjected to laparotomy. Cholecystectomy and ligation of the right gastric 
artery was then performed followed by cannulation of the gastroduodenal artery with a Port-A-
Catheter (Pharmacia Deltec Inc., St. Paul, MN 55112, USA). Perfusion of both lobes of liver was 
checked by infusion of 10m! of 3% fluorescein (Fluorescite, Alcon Laboratories Inc.) and 
inspection of the liver with a Wood's lamp. The catheter was then connected to a 4-way valve 
fixed on an injection bracket made with 1cm thick perspex (Fig 4.15). Twenty f..Lg of angiotensin 
11 were first given into the Port-A-Catheter over a period of 10 sec. Thirty seconds later a pre-
determined fraction of 90Yttrium-microspheres (resin based microspheres, 29 to 35f..Lm in size, 
containing 90Yttrium at an activity of approximately 3x10-8 GBq per micro sphere, 3.3 x 107 
spheres per GBq, supplied by the Australian Nuclear Science and Technology Organisation, 
Sydney, Australia, Fig 4.13) was given. Allowing ten minutes for equilibrium, the radiation dose 
delivered to the non-tumourous liver and the tumours were measured by a calibrated solid state ~ 
probe (Radiation Monitoring Devices Inc., Fig 4.16) to obtain a mean count rate of ~ radiation 
emitting from the surface of the liver. It was decided to obtain as many readings over as wide an 
area as possible over both the normal and non-tumourous compartments (Fig 4.17). The mean 
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count rate was referred to a calibration curve from which the actual radiation dose for the tumour 
and non-tumour compartments could be calculated. Further injections of angiotensin 11 followed 
by 90Yttrium-microspheres were then made in order to increase the radiation dose to the desired 
level which was determined by the maximum tolerance of non-tumourous liver (5,000 cOy for 
cirrhotic liver and 8,000 cOy for non-cirrhotic liver, recommended by Fox et al(51». When the 
desired radiation level was reached, biopsy was then taken from the tumour and the non-tumour 
parts of the liver. These were used for histopathological study and for determination of the 
radiation levels in the ,tissue by liquid scintillation method (discussed below). The operation 
ended with connection of the catheter to a port which was buried subcutaneously in the left lower 
chest wall. After the operation, patients were nursed in an isolation ward and were discharged 




Fig 4.15 The Injection Apparatus for Y-90 Microspheres 
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Fig 4.17 Path of the Beta-Probe on the Liver Surface 
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IV. Monitoring of response and toxicity, calculation of survival 
Patients who had raised AFP had the blood taken for the tumour marker on the day before 
# 
surgery, daily for 7 days and then once every 3 days until discharged from hospital. During 
follow up, blood was taken once every 2 to 4 weeks. For patients who had low base-line (~ 
300ng/ml) AFP, serum ferritin level was used for monitoring response(53,54). At each of the 
follow-up visits, the Karnofsky score of the patient was recorded. 
Computerised tomogram (CT) was used to measure tumour volume and quantify 
regression of tumour. This was done routinely before, 2 months, 4 months, 6 months and 1 year 
after the procedure. All CT scans were submitted to an independent radiologist who manually 
traced areas of normal liver parenchyma and tumour involvement through the full thickness of the 
liver for all scan slices. These were then digitalised and the volumes of normal liver parenchyma 
and tumour were calculated by a computer. Interpretation of eT and follow up of the size of the 
tumour were assisted with usa which were done at 2 monthly intervals. A 99mTechnetium tin-
colloid liver scan was done at the end of the third month after therapy. The response criteria are 
the same as other studies in this thesis. 
For monitoring of toxicity, renal and liver functions tests were performed at the same time 
as each blood sample for AFP measurement. Symptoms such as pain, nausea and others were 
recorded daily and on each follow up visit. Repeat treatment of 90Yttrium-microspheres was 
given in patients with clear disease progression. 
The end points were maximum tumour response, the duration of time to progression and, 
ultimately, survival calculated from the time of diagnosis. The actuarial survival curve was 
plotted by the Kaplan-Meier method. 
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v. Measurement of TIN ratio by liquid scintillation count of biopsy specimens 
Incisional and trucut biopsies were taken from the tumourous and non-tumourous liver 
~ 
tissues. These were used for .histopathological study and for determination of radioactivity 
concentrations in the tissue by the liquid sci~tillation method. Liquid scintillation counts of the 
biopsy specimens were done in the following manner: the specimens were cut into small pieces of 
les~ than O.lgm each and weighed. Each sample was moistened with 50JlI of distilled water 
followed by digestion using Iml of tissue solubilizer (Protosol from DuPont). The mixture was 
- . " 
incubated at 590 C for 16 hours. Then, 500JlI of EDT A solution, 1 ml of distilled water, 50JlI of 
glacial acetic acid and 10ml of liquid scintillant were added. The solution was well shaken and 
was counted in a liquid scintillation counter (Beckman LS3801, Fig 4.18) with an Yttrium-
90/Strontium-90 standard (Amersham). The concentration of radioactivity of the tumourous and 
non-tumourous parts of the liver and hence the TIN ratio were computed. 





From November 1990 to May 1993, 18 patients were treated with inoperable HCC using 
90Yttrium micro spheres. There were' 17 males and 1 female. Age ranged from 18 to 74 years 
with a median of 52 years. All except 2 patients had had no previous treatment. One patient had a 
local recurrence after previous resection. Another patient had systemic chemotherapy and 
complete remission for 1 year before the disease locally recurred. The median tumour size was 13 
cm (range, 4 to 20 cm). Ten patients had raised AFP at presentation with a median level of 
80,145Jlg/L (range, 331 to 1,308,100Jlg/L). Details of these 18 patients are shown in Table 4.8. 
Table 4.8 Patient Characteristics for gOy -Micro sphere s Treatment 
No. Sex Age Disease status Previous Size of tumour Initial AFP 
on entry treatment (cm) level (J.1g/L) 
1 Male 55 Inoperable HCC Nil 6.5 331 
2 Male 60 Inoperable HCC Nil 12.5 
3 Male 50 Inoperable HCC Nil 16.7 586,900 
4 Male 52 Inoperable HCC Nil 20.0 1,157,600 
5 Male 18 Recurrent HCC Surgery 4.0 (multiple) 40,120 
6 Male 55 Inoperable HCC Nil 15.0 
7 Female 33 Inoperable HCC Nil 14.0 1,308,100 
8 Male 46 Inoperable HCC Nil 14.0 
9 Male 60 Inoperable HCC Nil 10.0 1,252 
10 Male 56 Inoperable HCC Nil 13.0 
11 Male 74 Inoperable HCC Nil 13.0 
12 Male 48 Recurrent HCC chemotherapy 8.0 10,476 
13 Male 43 Inoperable HCC Nil 16.3 
14 Male 49 Inoperable HCC Nil 12.0 120,170 
15 Male 50 Inoperable HCC Nil 13.7 
16 Male 37 Inoperable HCC Nil 14.0 202,950 
17 Male 60 InoperableHCC Nil 7.0 18,551 
18 Male 54 InoEerable HCC Nil 11.0 
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Two patients were found to have extrahepatic spread of the disease on intra-operative 
I ultrasound. One had a tumour thrombus in the right hepatic vein and another had a small 
peritoneal secondary. It is then decided to proceed with 90Yttrium-microspheres treatment. Both 
patients died of progressive disease, 2 months and 4 months after treatment respectively. The 
remainder underwent the full treatment and were available for disease and toxicity evaluations. 
The median prescribed dose of 90Yttrium-microspheres was 3 GBq (range, 2 to 7 GBq). 
From the ~ probe readings and liquid scintillation countings of biopsies, the average dose to 
tumours and non-tumouious liver were computed. The median dose to non-tumourous liver was 
6,448 cGy (range, 1,845 to 7,682 cGy). The median dose to tumour was 23,489 cGy (range, 
5,376 to 40,852 cGy). Some of the isolated nodules which had relatively poor TIN ratio and 
received less than optimal radiation were neglected. These patients survived poorly because of 
under-dosing. The radiation doses and response to treatment are listed in Table 4.9. 
ll. Response of serum tumour markers to 90Yttrium-microspheres 
All patients had more than 50% decrease in tumour marker for either ferritin or AFP after 
treatment. A drop of 80% or more in AFP level after treatment occurred in 8 of the 10 patients 
who had an AFP > 300J.lg/L and the level decreased by more than 50% in the other 2 patients (Fig 
4.19). The greatest drop of 99.8% in AFP occurred in a man aged 49 years with a 12cm tumour. 
For the 8 patients with low preoperative AFP, serum ferritin was assayed. The ferritin level 

















































































































































































































































































































































































































































































































































































































































































































Fig 4.19 Percentage Change of AFP levels after 90-Y SIR Treatment 
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HI. Response in terms of tumour volumes 
On the follow-up CT scans for the 16 patients without extrahepatic disease, no patient had 
~ 
a complete response. Figure 4.21 shows the pre- and post-treatment CT scan of a HCC patient 
who had a partial response after 3 OB,q 90y -micro spheres treatment. Partial response occurred in 
7 of the 8 patients who received> 12,000 cOy to all the tumours compared with 1 of 8 patients 
who received < 12,000 cOy to at least one of the tumour nodules. The difference is statistically 
significant (Fisher's test, p=5.05x10-3). Maximal tumour regression was commonly seen at 4 
months post treatment. -No case showed progression in size of tumour up to 4 months post 
treatment. 
IV. Determination of optimal tumour dose 
The response of tumours to radiation was dose related. Initially we started with < 3,000 
cOy to the non-tumourous part of the liver and gradually stepped up the radiation dose to the non-
tumourous part of the liver so that tumours could receive higher doses of irradiation. The dose 
that was delivered to the tumour was determined by the TIN ratio and the maximum dose to the 
non-tumourous part of the liver. With such an approach, it was found that a dose of more than 
12,000 cOy (Table 4.9) was associated with maximal reduction in tumour markers and volumes. 
Subsequent analysis showed better survival..if the dose was achieved. However, even with 
optimal dosage to the tumour, the non-tumourous part of the liver was able to tolerate up to 7,000 
cOy of radiation without evidence of radiation hepatitis. 
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Fig 4.21a er Scan Liver before Y-90 SIR 
Fig 4.21b er Scan Liver after Y-90 SIR 
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V. Toxicity of selective internal radiation therapy 
No operative mortality and major complication arose from 90Yttrium-microspheres 
~ 
treatment. The treatment was well tolerated in most patients. The median duration of stay in the 
hospital was 2 weeks post-operatively. Most of the patients had a transient rise of liver enzymes 
and bilirubin level after operation. Further deterioration of liver function occurred at the terminal 
phase of the disease when there was locally progressive disease at the same time. In one patient 
radiation gastritis was documented by gastroscopy, which responded to conservative treatment. 
There was no bone marrow suppression documented. No pulmonary complications were 
documented. Each patient had a sample of peripheral blood taken for measurement of 
radioactivity and none showed any activity. All patients returned to pre-treatment Karnofsky 
Performance Score within 3 weeks following treatment and some even went back to work. 
VI. Survival 
The median survival of all patients was 7.7 months. Excluding the 2 patients with 
extrahepatic disease who died 2 and 4 months respectively after treatment, the median survival. 
became 9 months (Fig 4.22). Those who had radiation doses greater than 12,000 cGy to all the 
tumours did better than those who had at least one of the tumour nodules receiving less than 
12,000 cGy. The median survival for the~~ two groups were 14 months and 6.S months 






















































































































































































































































































































































































































This pilot stl!dy has shown that HCC can respond to radiotherapy if the dose is large 
enough and that larger tumours can now be treated. At the same time, non-tumourous liver is free 
from radiation hepatitis even if the dose is up to 7,000 cGy. This is higher than the ceiling dose 
recommended for external beam irradiation (5) . The difference in maximal tolerating dose of non-
tumourous liver between internal radiation and external beam irradiation is because the former is 
delivered as a series of discrete point sources so that the measured doses are average doses only. 
There are many non-tumourous liver parenchymal cells receiving much less than that dose and 
are therefore spared. This is completely different from whole liver irra~iation using external 
beams in which all liver cells within the treatment field receive the same radiation dose and the 
upper limit of 3,000 to 4,000 cGy for external radiation cannot be exceeded(5). 
The direct measurement of the radiation dose during surgery enabled us to monitor 
accurately the radiation dose to the non-tumour part of the liver and to escalate the radiation dose 
to the tumour with safety. The only disadvantage of this treatment is that it requires a laparotomy. 
This can be avoided once dosimetry has been established. Actually for most subsequent studies, 
the treatment was given during HAG. It was felt that it was not safe and scientifically sound if the 
study started with percutaneous treatment because there was no dosimetric measurement possible 
with percutaneous approach. However, another study had-been carried out using pre-treatment 
Tc-MAA, scan which was used as a simulati~n of subsequent 90y -micro spheres treatment. This 
) 
will be discussed later in the section of selection of patient for SIR. In that study, the TIN ratio 
given by the Tc-MAA scan has good correlation with the TIN ratio obtained from intra-operative 
dosimetry. Therefore, it was felt that it was time to change the technique to percutaneous 
treatment during HAG and use the TIN ratio from Tc-MAA scan to predict doses. This may 
further cut down morbidities and duration of hospital stay. This leads on to the following section 
on percutaneous treatment of inoperable HCC by 90Y-microspheres during HAG. 
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Treatment of Inoperable Hepatocellular 'Carcinoma with Percutaneous Intra-Arterial 
90Yttrium Microspheres through Hepatic Angiography 
From the previous study, 90Y-microspheres was found to be effective in shrinkage of 
HCC and possibly prolonged survival of patient with inoperable HCC. However, the treatment 
needs to be given intra-operatively which is certainly' not ideal because it requires a laparotomy. 
The alternative is to give during HAG but as explained before, percutaneous treatment does not 
allow accurate dosimetry to be determined. 
During the same' period while the phase 1/11 study on 90y -micro sphere treatment protocol 
was undergoing, the possibility of using Tc-MAA scan as a simulation of 90y -micro sphere 
treatment to predict TIN ratio and percentage lung-shunting after SIR therapy was studied. The 
TIN ratios from Tc-MAA scan with those from intraoperative dosimetry and liquid scintillation 
counting of liver biopsies were verified. The results suggest good correlation which will be 
discussed in the subsequent section. 
Therefore, from October 1992, laparotomy for 90y -microsphere treatment has no longer 
been performed. Instead, treatment has been given during HAG and pre-treatment Tc-MAA scan 
was used to predict TIN ratio and percentage lung-shunting. 
Treatment protocol 
) 
I. Patient selection criteria 
Patients with inoperable HCC, as established on the basis of previously defined criteria 
were entered. In all cases, the tumour was inoperable because of either extensive disease or severe 
,cirrhosis. Previous treatment such as surgery, chemotherapy, chemoembolisation did not exclude 
patients from entering into the trial. The upper age limit of the present trial was relaxed to 85 
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years because no surgical operation is required and morbidity is expected to be small. However, 
the Karnofsky Performance Score is probably more important than age itself. 
Other selection criteria are listed below: 
1. Kamofsky Performance Score~ 70 
2. Total bilirubin ~ 50Jlmol/L, platelet count ~ 100xl09/L 
3. No concurrent serious medical illness 
4. No chemotherapy within 4 weeks before entering into the trial 
5. No extrahepatic disease on pre-operative investigations 
6. No major vessel involvement by tumour including the main portal vein, maIn 
hepatic artery, hepatic veins or inferior vena cava on pre treatment investigations 
7. Measurable lesion on CT scan or USG 
8. Patient consent 
IT. Pre-treatment investigations: 
1. CBP, RLFT, PT APTI' 
2. AFP, ferritin, HBsAg 
3. USG and CT scan of liver 
4. CXR 
5. HAG + Tc-MA-A scan (The patients are considered suitable for 90Yttrium-
microspheres treatment if they satisfy the following criterias: lung-shunting of Tc-
MAA less than 15%, no significant shunting of activity to the gastrointestinal 
region, no multiple and complicated arterial blood supply to the liver on HAG, 




DI. Administration of 90Yttrium-microspheres 
The preparation of 90Yttrium-microspheres was as before except that an equal volume of 
non-ionic radio-opaque contrast (omnipaque 300) was mixed with the micro sphere suspension to 
make it visible on HAG. Suitable patients were subjected to hepatic angiography through the 
Seldinger technique. The catheter tip was placed in the common hepatic artery or the feeding 
artery of the tumour. The position was the same as for the previous pre-treatment HAG + Tc-
MAA scan. The catheter was then connected to a 4-way valve fixed on an injection bracket made 
with 1cm thick perspex"(Fig 4.15). A pre-determined dose of 90Yttrium-microspheres which was 
based on the TIN ratio from pre-treatment Tc-MAA scan, was given into the angiographic 
catheter. The flow which was visible due to the radio-opaque contrast, was closely monitored by 
fluoroscopic control. The catheter was removed after treatment and haemostasis secured. The 
patient was then moved to the gamma camera suite for a Bremstahlung scan (Fig 4.24) to detect 
the secondary X-ray from the 90Yttrium-microspheres. This was to give a rough idea of the 
distribution of the microspheres and to exclude any leakage to other intra-abdominal organs or 
lungs. After the treatment, patients were nursed in an isolation ward for the purpose of radiation 
protection and were discharged home on day 5 post treatment when the radiation decayed to a 
safe level. The excretory products were collected whilst the patients were in hospital, for radiation 
detection. Patients were routinely given prophylactic antibiotics: intravenous ceftraxone 1 gm qd, 
metronidazole 500mg q8h, starting before the treatment which carried for 5 days. They were also 
give routine ranitidine for prophylaxis against gastritis. 
Repeat treatment was allowed if there was clear evidence of disease progression either in 
terms of AFP level or tumour size on eT or both provided the general condition, performance 
. score and liver function of the patient permitted. 
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Fig 4.24 Bremstahlung Scan after Y-90 SIR 
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IV. Monitoring of response and toxicity,'lcalculation of survival 
Patients who had raised AFP had the blood taken for the tumour 'marker on the day before 
surgery, then daily for 5 days" once every 2 weeks after discharged from hospital. For patients 
who had low base-lirie (:::; 300)lg/L) AFP, ' serum ferritin level was used for monitoring the 
response(53,54). At each of the follow up visits, the Karnofsky score of the patient was recorded. 
There was another prospective study looking into tumour volume changes after the 
treatment. This was done by comparing CT scan before treatment with scans at 2 months, 4 
months, 6 months and 1 year after treatment. All CT scans were submitted to an independent 
radiologist who manually traced areas of normal liver parenchyma and tumour involvement 
through the full thickness of the liver for all scan slices. These were then digitalised and the 
volumes of non-tumourous liver parenchyma and tumour were calculated by a computer. 
Maximal response was recorded according to the changes ,in tumour volume. The response 
criteria were the same as other studies in this thesis. 
For monitoring of toxicity, renal and liver functions tests were performed at the same time 
for each blood samples taken for AFP measurement. Repeat treatment with same approach of 
90Yttrium-microspheres was given in patients with definite proof of disease progression. 
The end points to be measured are degree of maximum tumour response, the duration of 
time to progression and ultimately survival calculated from the day of treatment. Actuarial 





From October 1992 till January 1994, 47 patients with inoperable HCC were entered into 
the study. There were 40 male and 7 female patients. Thirty-five patients were not previously 
treated and the remainder had recurrent HCC after surgery or chemoembolisation. Four patients 
had received previous SIR with 131I-L (50 mCi in three and 30 mCi in one) for recurrent disease 
before entering into the trial. The median age was 54 years (range, 24 to 84). The median 
Karnofsky Performance Score was 90% (range, 80 to 100). Thirty-five patients had raised serum 
AFP levels available for disease evaluation. The AFP negative patients were evaluated by the 
serum ferritin level. Many of the patients had more than one tumour and if the largest one was 
measured, the median size of tumour was 11.9cm (range, 6 to 22.6). The patient characteristics 
are shown in Table 4.10. 
Table 4.10 Patient Characteristics for Percutaneous 90y -Micro sphere s Treatment 
No. Sex Age Disease status Previous Size of tumour Initial AFP 
.............................................................................. ~~ .. ~~~~!. ....................... ~~~~~~~~.!. .......................... ~~~J. ....................... }~y.~~ ... (l:I:g,!.~J. ...... , 
1 Male 70 Inoperable HCC Nil 9 
2 Male 39 Inoperable HCC Nil 13.9 
3 Male 62 Inoperable HCC Nil 13 
4 Male 58 Inoperable HCC Nil 11.9 
5 Male 26 Inoperable HCC Nil 14 
6 Male 53 Inoperable HCC Nil 7 
7 Female 70 Inoperable HCC Nil 8 
8 Male 28 Inoperable HCC Nil 8.3 
9 Male 69 Inoperable HCC Nil 15 
10 Male 61 Inoperable HCC Nil 8.3 
11 Male 48 Inoperable HCC Nil 11.3 
12 Female 61 ' Inoperable HCC Nil 14.3 
13 Male 43 Inoperable HCC Nil 13.1 
14 Male 56 Inoperable HCC Nil 17.3 
15 Male 74 Inoperable HCC Nil 8.9 
16 Male 51 Inoperable HCC Nil 14.3 
17 Male 45 Inoperable HCC Nil 10.7 
18 Male 57 Inoperable HCC Nil 11.9 
19 Male 54 Inoperable HCC Nil 9.5 
20 Male 47 Inoperable HCC Nil 15.5 
21 Female 52 Inoperable HCC Nil 14.3 



















No. Sex Age Disease status Previous Size of tumour Initial AFP 
................................................. ; .......................... ?~ .. ~.~!~!. ........................ !.~.~~!.~.~.~! ....... ~ .................... J~.~} ........................ ~.~!~.~.J~.g!~) ..... .. 
23 Male 45 Inoperable HCC Nil 14.9 2,972 
24 Female 63 Inoperable HCC Nil 11.9 403,700 
25 Male 57 Inoperable HCC Nil 14.3 
26 Male 84 Inoperable, HCC Nil 11.9 
27 Male 54 Inoperable HCC Nil 14.3 11,848 
28 Female .. 68 Inoperable HCC Nil 12.5 11,418 
29 Male 41 Inoperable HCC Nil 14.3 2,030 
I, ' 30 Male 63 Inoperable HCC Nil 13.1 2,719 
,31 Female 43 Inoperable HCC Nil 11.9 2,038 
32 Male 59 Inoperable HCC Nil 14.3 
33 Male 64 Inoperable HCC Nil 19 3,405 
34 ' Male 48 '" Inoperable HCC Nil 9.5 6,548 
35 Male 63 Inoperable HCC Nil 20.2 
36 Male 64 Recurrent HCC Surgery 9.3 591 
37 Male 54 Recurrent HCC 131-I-L 6 
38 Male 42 Rec'urrent HCC Surgery 6.3 
39 Female 55 Recurrent HCC Surgery, 131-I-L ' 10.7 1,413 
40 Male 49 Recurrent HCC Surgery 8.3 
41 Male 52 Recurrent HCC Surgery 10.7 3,288 
42 Male 54 Recurrent HCC Surgery 7 15,102 
43 Male 32 Recurrent HCC Surgery, 7.1 
131-I-L, ETH 
44 Male 24 Recurrent HCC Surgery 16.7 8,027 
45 Male 61 Recurrent HCC Surgery, 131-I-L 8.3 825 
46 Male 62 Recurrent HCC Surgery, TOCE 22.6 271,040 
47 Male 62 Recurrent HCC Surgery, ETH 8.3 2,316 
TOCE = Trans arteria I oily chemoembolisation ETH = Ethanol Injection 
A total of 56 treatments were given. All were evaluable for response and toxicity. The 
median dose of 90Yttrium-microspheres was 4 GBq (range, 1.5 GBq to 5 GBq). All patients had 
a reduction in tumour marker levels. Forty-three patients had a more than 50% reduction of 
tumour marker levels. The fall in AFP levels and ferritin levels are shown in Figures 4.25 and 
4.26 respectively. Figure 4.27(a,b) show the pre- and post-treatment scans of a patient who 
received 5 GBq of 90Y-microspheres and achieved partial remission. The dose and response data 
are shown in Table 4.11. 
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Table 4.11 TIN ratio, Prescribed Dose and Tumour Marker Response Data Mter Percutaneous 
90y -micro spheres Treatment 
No. Tumour Size (cm) Dose (GBq) TIN ratio Decrease in tumour Survival (months) 
............. ~ ...................................................................................................................................... ~~r.~~.~~.(.%.>. .................................................................... 
1 9 3 5.9 62 17.3* 
2 13.9 5 5.9 99 16.2* 
3 13 4 5.9 60 2.8 
4 11.9 4 9.1 82 4.0 
5 14 ~ 4 3.8 95 8.3 
6 7 4 2.6 95 3.2 
7 8 3 5.1 96 1.8 
8 8.3 4 4.2 >99 7.5 
9 15 5 3.8 32 1.9 
10 8.3 4 8.8 91 2.9 
11 11.3 4 4.0 >99 3.5 
12 14.3 
.. ~ " 4 4.0 91 3.9 
13 13.1 4 9.6 95 4.5 
14 17.3 4 4.2 88 2.8 
15 8.9 3 6.9 72 4.1 
16 14.3 4 4.0 91 8.3* 
17 10.7 3 14.2 >99 8.3* 
18 11.9 4 5.9 99 7.9* 
19 9.5 3 6.2 68 2.8 
20 15.5 5 3.9 81 7.2* 
21 14.3 5 3.2 14 1.2 
22 15.5 4 3.4 54 2.4 
23 14.9 4 6.5 80 6.3* 
24 11.9 4 3.6 94 6.3* 
25 14.3 4 10.4 47 5.3* 
26 11.9 4 18.7 39 5.3* 
. 27 14.3 5 17.8 67 4.9* 
28 12.5 4 17.9 39 4.2* 
29 14.3 4 11.4 67 4.2* 
30 13.1 1.5 2.9 96 2.0 
31 11.9 4 4.4 98 2.4 
32 14.3 5 4.6 >99 2.3* 
33 19 5 3.4 80 2.1* 
34 9.5 1.5 8.1 99 1.6* 
35 20.2 5 3.8 1.6* 
36 9.3 3 4.1 88 6.2 
37 6 3 34 2.1 
38 6.3 3 ---- 67 3.3 
39 10.7 3 6.7 99 2.1 
40 8.3 4 3.5 53 3.2 
41 10.7 4 3.3 97 6.1 
42 7 2 4.2 23 7.9* 
43 7.1 3 5.9 99 7.2* 
44 16.7 5 3.8 77 6.9* 
45 8.3 1.5 2.2 95 2.3* 
46 22.6 5 3.2 34 1.2* 
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Fig 4.27a Pre 90Y-Microspheres Treatment 
Fig 4.27b Post 90Y-Microspberes Treatment 
224 
\ / 
Nine patients had progressive disease after responding to the first treatment and received 
the second treatment. Seven out of the 9 patients responded again to the treatment with a more 
than 40% reduction in the tumour marker levels. The results are listed below in Table 4.12. 
Table 4.12 Second Percutaneous 90y -Micro spheres Treatment for 9 Patients 
No. Tumour Size Dose Decrease in tumour Survival 
(cm) (GBq) markers (%) (months) 
1 9.5 1.5 42 17.3* 
" A " 
2 10.7 3 99 16.2* 
16 10 3 56 8.3* 
23 10.7 3 >99 6.3* 
24 11 3 6.3* 
25 11.9 4 44 5.3* 
36 10.7 3 93 6.2 
43 9.5 1.5 7.2* 
44 13.7 4 9 6.9* 
* Patients still alive 
The study on tumour volume responses is still in the process of analysis and the results are 
not ready for presentation here. The initial impression is that maximal tumour regression was 
commonly documented with the 4 months post-treatment eT scan. 
Twenty-three patients are alive at the time of writing giving a minimal median survival of 
6.05 months from the date of treatment. The actuarial survival curve is shown in Figure 4.28. 
Toxicity 
The treatment was in general well tolerated. The most common side-effect was right upper 





































































































































































































vascularity and , narrow hepatic artery. The Symptom usually responded very well to simple 
analgesics. This is likely due to the embolising effect of the micro spheres. Fever was also 
common which usually came on day 1 after treatment which might be due to tumour necrosis. 
There was one patient proved to de~eloped a liver abscess after the treatment. The AFP of this 
patient reduced ~y more than 99% of the pre-treatment value. Five patients who had epigastric 
pain and were subsequently diagnosed to have radiation gastritis by gastroscopy and biopsy were 
documented. They were all treated conservatively with anti-histamine-2 blockers. There was no 
bone marrow suppression documented. A slight transient rise in liver enzyme was commonly seen 
which usually had normalised at the first follow up after treatment. There was no evidence of 
radiation hepatitis clinically or biochemically in all patients including those who required 
repeated treatment. All the 3:ngiographic procedures were uneventful and no complications were 
encountered. The median duration of stay in hospital was about 1 week. The reason for a longer 
stay was commonly persistent fever. 
Discussion 
The degree of tumour response after percutaneous treatment as represented by the fall in 
tumour marker levels was remarkable. The procedure is very well tolerated which is important as 
a palliative treatment. Therefore, despite u~ing quite a high dose of internal radiation therapy 
when compared with other trials, there was no radiation hepatitis. The complication of radiation 
gastritis is well recognised with percutaneous treatment(47.48). 'This is due to reflux of 
micro spheres to the gastroduodenal artery if it is injected too fast or small tributaries arising from 
the hepatic arteries supplying the stomach. This can be prevented with appropriate embolisation 
of these arteries and inject the microspheres carefully. Radio-opague contrast was added into the 
micro sphere suspension so that the flow can be monitored by fluoroscopic control. This added 
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safety to the procedure. In conclusion, percutaneous intra-arterial 90y -micro spheres treatment is 
feasible, safe and effective. 
Conclusion for session 2 and 3 
From the bio-distribution study on 131Iodine-Lipiodol, it was shown that HCC can be 
selectively irradiated while keeping non-tumourous tissue under an acceptable limit of radiation 
tolerance. Therefore, a tumouricidal radiation dose can be delivered to treat HCC. From the 
clinical study on the use of 131Iodine-Lipiodol in the treatment of 26 patients with inoperable 
HCC, response in terms of tumour regression and reduction of AFP levels was documented. This 
showed that the treatment is feasible and effective. The lack of toxicity suggested that the 
treatment is also safe. 
Review of the physical aspects of 90y ttrium microspheres suggested that this may be an 
even more powerful agent to be used in the treatment of HCC. From the dosimetric study during 
intra-operative 90Yttrium micro spheres treatment, it was shown that 90Yttrium microspheres 
were preferentially taken up by HCC. Radiation to non-tumourous tissues can be controlled under 
an acceptable limit of tolerance. The early phase II study documented a high tumour response rate 
in terms of tumour regression and reduction of AFP levels, as well as lack of toxicity. Thus, it 
was shown that intra-arterial 90Yttrium microspheres treatment is feasible, safe and effective. In 
order to simplify treatment and reduce operative morbidities, a percutaneous approach for 
treatment was devised. This was made possible because pre-treatment Tc-MAA scan is a good 
predictor of TIN ratio and lung shunting percentages (to be discussed in the next session). The 
percutaneous approach documented again high tumour response rate and AFP reduction rate 
without undue toxicity. Therefore, selective internal radiation with 90y ttrium microspheres was 




Selection of Patients For 90Yttrium-Microspheres Treatment 
The previous chapter suggests that selective internal radiation is an effective palliative 
loco-regional treatment for inoperable HCC. However, it is limited by two factors. Firstly, it is 
not effective for extrahepatic disease~ Hence, it is important first to exclude extrahepatic disease 
before considering for SIR treatment. This can be done by pre-treatment radiological 
investigations: CXR, CT /USG of abdomen, bone scintigram if early bone secondaries are 
suspected. Secondly, SIR therapy with 90Y-rnicrospheres is not suitable for hypovascular 
tumours which have a poor tumour to non-tumour uptake ratio for the radio-isotopes because the 
tumour will not receive a sufficient dose and the non-tumourous liver mass be over-dosed with 
i\ radiation. 
Therefore, if 90y -microspheres SIR treatment is going to be given without intraoperative 
dosimetry, we need a reliable method to predict TIN ratios. The method should also be verified 
with intraoperative dosimetry and liquid scintillation counting of biopsies because they are the 
gold standard which reflect the true TIN ratio after a therapeutic dose of 90Y-microspheres. 
Furthermore, large arteriovenous shunts which are common in HCC may redirect the radio-
I ' isotopes to the lungs and cause radiation pneumonitis. Hence, it is also important to predict 
percentage lung-shunting before applying SIR therapy. 
The following section will discuss a new method using Technetium-99m macroaggregated 
albumin (Tc-MAA) scan to predict TIN ratio after SIR which has been verified by intraoperative 
r 
~" dosimetry and liquid scintillation counting of biopsies. Data on percentage lung-shunting 
predicted by Tc-MAA scan will also be presented. Tumour vascularity predicted by conventional 







Diagnostic Scintigraphy with Hepatic Intra-Arterial Technetium-99m 
Macroaggregated Albumin in the Determination of Tumour to Non-Tumour 
Uptake Ratio in Hepatocellular Carcinoma 
As mentioned in the previous section, the effectiveness and safety of SIR therapy with 
131I-L and 90Y-microspheres procedures depend on the vascularity of the tumour and the 
relative uptake of the radioactive agent by the tumour and the non-tumourous part of the liver 
(TIN ratio). In order to study the relative tumour to non-tumour uptake, one can use a test dose of 
the therapeutic radio-isotope to simulate the treatment. This is important not only to prove 
selectivity to tumour but also to predict radiation dosage to tumour and non-tumourous liver so 
that normal liver tolerance to radiation is not exceeded. In the 1311_ L situation, we can use a 
small dose of 131I-L and gamma camera to do accurate dosimetry. 'For 90Y-microspheres, it is 
not possible to use a test dose because the ~ emission cannot be directly detected externally. 
Therefore, we need a better method to simulate 90y -microspheres treatment which can give 
quantitative assessment of the TIN ratio externally without a laparotomy and which can be 
verified by intraoperative dosimetry, which is also safe and easy to perform. 
Technetium-99m labeled macroaggregated albumin (Tc-MAA) is prepared from a 
commercially available kit (Amersham Pulmonate 11). It is commonly used for lung perfusion 
scans. The diameter of Tc-MAA ranges from 10 to 60f.lm with an average of 30f.lm which is 
approximately the diameter of the micro spheres used in SIR therapy. It is bio-degradable so that it 
will not block the hepatic arterial system for long. This substance has been used in quantifying 
degree of lung-shunting in metastatic liver tumour(55). The aim of this study is to determine the 
TIN ratio by diagnostic scintigraphy with hepatic intra-arterial Tc-MAA in HCC patients and to 
~,', validate the results using intraoperative f3 dosimetry and liquid scintillation counts of the biopsied 
specimens in patients who received therapeutic 90y -micro sphere s treatment. 
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Patients and methods 
Patients from the Joint Hepatoma Clinic who were diagnosed to have HCC by the usual 
criteria were eligible to enter i~to this study. Routine laboratory and radiological investigations 
including full blood count, blood glucose, liver profile, liver enzymes, prothrombin time, partial 
prothrombin time, hepatitis B surface antigen, AFP, chest radiography and USG of the liver were 
pe!formed. Patients who were considered for surgical resection or regional chemotherapy or SIR 
therapy but required a diagnostic HAG as part of the pre-treatment investigations were considered 
eligible to enter into the"present study. 
Determination oJTIN ratio by diagnostic scintigraphy with Tc-MAA scan 
Selective hepatic angiography was performed with the Seldinger technique. The tip of the 
angiographic catheter was manipulated distal to the origin of the gastroduodenal artery and 20J..lg 
of Angiotension 11 (Ciba-Geigy) were given over a period of 10 seconds. This was followed by 
111 MBq (3 mCi) of Technetium-99m labeled macroaggregated albumin (Tc-MAA) (Amersham 
Pulmonate 11 with 80% of particles of size 10 to 60Jlm, average 30Jlm in size) 30 seconds later. 
The catheter was removed and the patient was then transported to the gamma camera suite. 
Scintigraphic images of the lungs, liver and gastroduodenal region from anterior, posterior and 
right lateral views were taken with an ana~og/digital camera (Philips). Liver scanning using 
99mTc tin-colloid (Amersham Hepatate 11) was performed routinely 2 days after the Tc-MAA 
scan. This serves as a negative scan because the HCC appears cold in the Tin-colloid image 
whereas the HCC is usually hot in Tc-MAA scan unless it is hypovascular (Fig 4.29). Hence, by 
using the gamma camera computer, the liver shape on the Tc-MAA scan could be outlined and 
the tumour(s) was localised with the aid of the HAG, CT and USG. The average count per cell of 




images taken from the three different views 'gave the TIN ratio. If more than one tumour was 
res~lved in the image, the mean uptake ratio was used. 
Measurement of TIN ratio by intraoperativeft-probe dosimetry 
Twelve patients were selected for SIR with 90Y-microspheres through laparotomy. The 
method for 90y -micro spheres treatment is discussed above and is not repeated here. After 
delivering the dose of 90y -microspheres, the radiation dose delivered to both the superficial parts 
,":- ":1' 
of the tumour and the non-tumourous liver were assessed by scanning the liver with a calibrated 
solid state f3 probe (Fig 4.16). This gave a mean count rate of (3-radiation emitting from the 
surface of the liver (intraoperative (3-probe dosimetry). This was referred to a calibration curve 
from which the actual radiation dose to infinity for the tumour and non-tumourolls liver 
compartments could be calculated. The calibration curve was established using a phantom 
containing standardised 90Yttrium-Silicate (Amersham) solution. Further injection of 
Angiotension 11 followed by 90y -micro spheres were then made in order to increase the radiation 
dose tO,the desired level. The therapeutic TIN ratio was measured with a ~ probe over as wide an 
area as possible on the surface of the tumour and parts of the liver at the end of the 90y_ 
micro spheres therapy. Usually more than 20 readings were taken over each of these areas and the 




Fig 4.29a Tc-MAA Scan of HCC 
Fig 4.29b Tm-colloid Scan of HCC 
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.. Measurement of TIN ratio by liquid scintillation count of biopsy specimens 
Incisional and trucut biopsies were taken from the tumourous and non-tumourous liver 
tissues. These were used for histopathological study and for determination of radioactivity 
concentrations in the tissue by liquid scintillation method. Liquid scintillation counts of the 
biopsy specimens were done in the following manner. The specimens were cut into small suitable 
pieces of less than 0.1 gm each and weighed. Each sample was moistened with 50Jll of distilled 
water followed by digestion using lmI of tissue solubilizer (Protosol from DuPont). The mixture 
was incubated at 590 C 'for 16 hours. Then, 500JlI of EDT A solution, 1 mI of distilled water, 50JlI 
of glacial acetic acid and 10mI of liquid scintillant were added. The solution was well shaken and 
was counted in a liquid scintillation counter (Beckman LS3801, Fig 4.18) with an Yttrium-
90/Strontium-90 standard (Amersham). The concentration of radioactivity of the tumourous and 
non-tumourous parts of the liver and hence the TIN ratio were computed. 
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Results 
Diagnostic scintigraphy with Tc-MAA was performed in 124 patients. There were 110 
, male and 14 female. Age ranged from 16 to 73 years with a median of 55 years. The size of major 
tumour of each patient was measured which ranged from 2 to 26.2cm with a median of 12.5cril. 
The TIN ratios for all the patient are tabulated in Table 4.13. Figures 4.30 and 4.31 shows 2 
typical cases of poor TIN ratio of 0.9 and good TIN ratio of 3.5 after Tc-MAA Scan respectively. 
The range of TIN ratio was 0.7 to 19.3 with a median of 3.8. 
Diagnostic Tc-MAA scan in the determination of the TIN ratio was validated in 12 
patients who subsequently underwent laparotomy for SIR therapy with 90Y-microspheres. The 
TIN ratios obtained by liquid scintillation counting of biopsies and intraoperative ~ probe 
counting was compared and showed good correlation (coefficient of linear regression r2=0.867, 
p=O.OOOl, Fig 4.32). The correlation between the TIN ratios determined from preoperative Tc-
MAA scan and intraoperative ~ probe dosimetry was good, with r2=0.805 and p=O.OOOl (Fig 
4.33). The correlation between TIN ratios as determined by Tc-MAA scan and by liquid 
scintillation count in 11 patients was also good (r2=0.957, p=O.OOOl, Fig 4.34). The data 
comparing TIN ratio by Tc-MAA with intnioperative dosimetry are listed in Table 4.14. The 
tumour biopsy obtained from patient number 12 turned out to be a necrotic tissue which was not 
suitable for liquid scintillation count. 
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Table 4.13 TIN Ratios for 124 Patients as Determined bv Tc-MAA Scan 
Number Sex Age Tumour size Vascularity score TIN ratio 
1 M 60 10 3 10.5 
2 M 20 ,4 3 3.4 
3 M 37 14 3 4.2 
4 M 64 15.5 0 0.9 
5 M 42 5.5 2 4.7 
6 M 71 7.7 3 2.6 
7 M 53 8 2 4.1 
,,' 8 M 41 10 0 1.1 t~ 
l 9 F -71 22 3 4.5 
10 M 57 3 2 8.3 
11 F 42 13.6 4 1.4 t 12 M 48 10.7 3 8 
13 F 65 9 2 3.6 
14 M 73 6 2 2.5 
15 F 73 6 3 3.2 
16 M 48 8 3 2.8 
17 M 67 7.1 3 3.2 
18 M 56 10 2 2.8 
19 F 54 3 2 2.3 
.\. 14.3 3 3.2 20 M 45 
21 M 69 7 3 3.6 
22 M 60 9 1 3.4 ~ 
. 23 M 33 5 2 4.5 
24 M 59 2 1 2.3 
25 M 60 26.2 1 1.8 
"'. 
" 26 M 16 9 3 3.6 
27 M 66 5 3 6.4 
~. 56 13 3 5.7 28 M 
29 M 33 7 2 2.8 
30 M 61 7.9 3 5.6 
31 M 64 15 4 2.8 
32 M 40 17 4 15 
i. 33 M 72 7 3 · 2.3 t 
" 34 M 64 9 2 9 
35 M 41 7 3 3.8 
36 M 37 9 3 5.5 
37 M 39 5.5 . 2 2.5 
38 M 54 11 3 13.6 
39 M 63 12.5 2 3.1 
40 M 53 8.3 0 6 
41 M 36 16.1 4 0.7 
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Number Sex Age Tumour size Vascularity score TIN ratio 
42 M 46 . 14 0 4.2 
43 F 67 6,5 3 4.7 . 
44 M 62 ,6 3 19.3 
45 F 57 9,5 3 5.7 
46 M . 56 13 3 3.1 
47 M 39 15.5 2 3.2 
_ 48 M 50 16.7 3 3 
49 M 49 12.5 1 2.3 
50 M 52 15.5 3 5.3 
51 M ·67 14.9 3 2.6 
52 F 61 16.7 3 9.5 
53 M 58 17.9 4 6.6 
54 M 64 16.1 2 2.4 
55 M 39 11.9 3 5.7 
56 F 34 14 4 3 
57 M 44 7.1 2 3 
58 M 55 16.7 0 8.4 
59 M 48 13.1 4 2.2 
60 M 54 13 4 2.7 
61 M 54 13.1 3 2.4 
62 M 71 10.7 3 4.3 
63 M 36 19 3 2.7 
64 M 61 13.1 4 1.3 
65 M 53 9.5 2 8 
66 M 50 13.7 3 6.4 
67 M 60 12.5 2 6.6 
68 M 59 17.9 2 5.2 
69 M 63 11.9 3 6.8 
70 F 62 13.1 3 8.2 
71 M 68 14.3 3' 5 
72 M 47 17.9 2 1.2 
73 M 55 15 2 4.7 
74 M 52 20 3 7.8 
75 M 70 23.8 4 · 3 
76 F 64 11.9 3 6.6 
77 M 56 13.7 3 11.1 
78 M 46 21.4 4 1.9 
79 M 43 19.6 . 4 7.3 
80 M 36 17.9 2 5.6 
81 F 70 13.1 3 2.8 
82 . M 42 15.5 4 4.5 
83 M 34 13.1 3 0.9 
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Number Sex Age Tumour size Vascularity score TIN ratio 
84 M 62 11.9 2 5.3 
85 M 45 9.5 2 10.3 
86 M 66 8.3 3 2.3 
87 M 59 13.7 2 1.9 
88 M 42 13.1 3 3 
89 M 64 9.3 1 4.1 
- 90 M 42 16.3 3 7.5 
91 M 60 6 2 3.9 
92 M 70 9 2 9.9 
93 M ':30 17.9 3 2.3 
94 M 46 17.8 1 3.5 
95 M 60 4 0 7.2 
L 96 F 66 16.1 3 2 
... 
i 97 M 32 13.1 3 3.1 t [" 98 M 64 17.8 3 2.9 ~r 
r 
! 99 M 46 5.3 1 5.1 
100 M 55 5 1 7.1 
101 M 39 13.9 0 5.9 
102 M 68 15.5 4 2.1 
: ~ 
103 M 73 10.7 4 5.7 
104 M 61 13 3 2.8 
105 M 59 15.5 2 3.5 
106 M 64 10.7 1 4.4 
107 M 44 6 2 5.8 
108 M 38 19 3 9 
109 M 52 17.9 4 . 7.7 
110 M 54 8.7 2 5.1 
111 M 43 14.9 4 3.7 
.' . 
112 M 40 13.1 3 4.4 
113 M 45 17.9 4 2.5 
114 M 32 7 0 3 
115 M 35 10.7 0 2.6 
116 M 48 16.7 3 3.3 
117 M 34 11.9 3 1.9 
118 M 48 8.3 1 3.5 
119 M 43 7 1 2 
120 M 55 16.7 2 7 
121 F 63 4.8 2 4.3 
122 M 62 11.9 2 5.9 
123 M 57 13.1 2 1.6 




Fig 4.30 Poor TIN ratio of 0.9 












































































































































































































































































































































































































































































































































































" Table 4.14 TIN Ratios Obtained By 3 Different Methods 
Patient No. TIN Ratio from Tc-
MAAScan 
TIN Ratio from Liquid 
Scintillation Counting 
TIN Ratio from p-
probe readings 
·····················i················································10··5································· ........................................................................................................................................  
. 10.5 13.7 
2 3.4 3.5 3.4 
3 4.2 6.2 5.4 
4 0.9 1.9 1.7 
5 5.5 5 4.6 
6 13.6 13.7 10.6 
... . !. 
7 4.2 5.2 5 
8 5.7 6 5.6 
9 3.1 4.7 3.9 
10 3 3.8 3.7 
11 3 3.2 3.6 
12 6.6 5.5 
Discussion 
In an attempt to improve on the results of loco-regional therapy of inoperable HCC, intra-
arterial 131I-L and 90Y-microspheres were used as reported above. The success of both 
treatments depends on a good TIN ratio. 
The three methods (Tc-MAA scan, intraoperative ~ probe dosimetry and liquid 
scintillation counting) that were used in the assessment of the TIN ratio differed considerably in 
the way the ratio was determined. While preoperative Tc-MAA scan measured the whole of the 
tumour and non-tumourous parts of the liver, intraoperative ~ probe only measured the superficial 
parts of the tumour and the non-tumourous liver, and liquid scintillation count measured only 
. very small biopsy specimens taken from the tumour and the non-tumourous'liver. Yet, correlation 
of the TIN ratios as determined by these procedures was gOdd. This has laid the foundation for the 
243 
percutaneous 90Y-microspheres treatment that pre-treatment Tc-MAA scan can reliably be used 
to predict tissue absorbed radiation dose. 
For the ~ probe dosimetry method, it is essential to take sufficient number of readings in 
order to allow for the heterogeneity 6f the tumour. For deep seated tumours covered by a rim of 
normal liver, part of the ~ radiation will be attenuated by the normal liver tissue and a lower 
tumour dose and hence TIN ratio might be recorded by the ~-probe. It is ideal to have multiple 
biopsy samples taken fF?m both the tumour and the normal liver for liquid scintillation counting 
to give more accurate dosimetric data. However this sometimes becomes unsafe in patients with 
cirrhosis and possible bleeding tendency. If a single tumour biopsy is taken from the necrotic part 
of the tumour, the dose obtained from the liquid scintillation will not be representative of the 
whole tumour. Tc-MAA scan, however, gives an overall preview of the dose distribution. Three 
dimensional scans by single photon emission computed tomography (SPECT) may further 
increase the accuracy of the prediction. 
Houle and his associate suggest the use of Tc-MAA scan to assess the degree of lung-
shunting · in patients with inoperable HCC to increase the safety of 90Yttrium-microspheres 
treatment( 46). The results suggest that diagnostic Tc-MAA . can be used to predict the TIN ratio 





Measuring Lung Shunting in Hepatocellular Carcinoma with Intrahepatic-Arterial 
Technetium-99m Macroaggregated Albumin 
As mentioned above, the TIN ratio will determine radiation dose to HCC and non-
tumourous liver which affects the effectiveness and safety of SIR treatment. The other factor 
which will affect safety is percentage lung-shunting. This is defined as the percentage of the 
prescribed intra-arterial radio-isotopes that leaks to the lungs due to arteriovenous shunts. 
Arteriovenous shunts is known to occur in metastatic liver tumour(56). Similar findings are likely 
to be present in HCCas well. Large arteriovenous shunting makes regional chemotherapy less 
effective and increases systemic toxicity. The relatively low radiation tolerance of lungs has 
aroused much caution in treating HCC with 90Yttrium- microspheres or 131I-L because high 
lung-shunting may induce radiation pneumonitis. In a few studies, Tc-MAA has been employed 
to assess the degree of shunting into the pulmonary circulation( 45-47). In the present study. Tc-
MAA was used to measure the percentage lung-shunting in HCC patients and tried to correlate 
with tumour vascularity and size. 
Patients and methods 
Patients with HCC (histology proven or with raised a-fetoprotein of over 500Jlg/L and 
USG evidence of liver tumour) who und.erwent HAG as an pre-treatment assessment for 
resectability or SIR therapy were eligible for the study. HAG was performed through the 
Seldinger technique. When the angiographic catheter was selectively placed in the hepatic artery, 
111 Mbq(3 mCi) of Tc-MAA (Amer~ham Pulmonate 11, with 80% of particles of size 10-60~m) 
were injected into the hepatic artery following 20pg angiotensin 11 (Ciba-Geigy). The catheter 
was then removed. 
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The patient was then transported to the gamma camera suite and scintigraphic images of 
the lungs, liver and gastroduodenal regions were taken with an analog/digital gamma camera 
(Philips). Total count rate was computed from the digitised image. Regions of interest were 
carefully drawn about the organs (liv,er and lungs) and the percentage of activity shunted into the 
pulmonary circulation was calculated as the ratio of the lung counts to the total counts. 
Tumour diameters were measured either by CT or USG. The vascularity of the tumours 
on HAG was independently assessed by an interventional radiologist who did not know the 
results of the vasculaiHy of the tumours determined by scintigraphic imaging. Vascularity on 
HAG was graded by a scale from 1 (hypovascular) to 4 (extremely hyp~rvascular). Presence of 
mild tumour staining without increase in number of vessels was . grade 1. Moderate tumour 
staining and increased number of vessels were grade 2. Intense tumour staining and markedly 
increased number of vessels which were also dilated and tortuous were grade 3. Tumours having 
all the grade 3 characteristics together with venous pooling were classified as grade 4. 
Representative HAG pictures from grade 1 to 4 vascularity are shown in Figures 4.35-38. The 
degree of lung-shunting was correlated with the size and vascularity of the biggest tumour. 
In 6 patients who had an implanted arterial Port-A-Catheters (Pharmacia, Deltec Inc., St. 
Paul, MN 55112, USA) in the gastroduodenal artery which led to the common ' hepatic artery, 
99mTc-MAA scans were repeated with and without angiotensin 11 by injection of the radio-
isotope through the subcutaneous ports to assess the degree of change of lung-shunting. For one 
patient who had liver resection for HCC and also placement of arterial Port-A-Catheter, Tc-MAA 
scan was repeated after surgery and the degree of lung-shunting was compared with that before 
the resection. Statistical analysis was by the Wilcoxon 2-sampletest and paired student t-test. 
\ 
[ ... 
Fig 4.35 Grade 1 Vascularity 
Fig 4.36 Gra.de 2 Vascularity 
\ 
! . ", 
Fig 4.37 Vascularity Grade 3 
Fig 4.38" Vascularity Grade 4 
\ 
Results 
From November, 1990 to March 1993, 124 patients with HCC and cirrhosis were entered 
into the study. The degree of lung-shunting was found to vary between patients and ranged from 
less than 1 % to 67.2%, with a median of 8.1 %. All the lung-shunting values, vascularity scores 
and tumour sizes are listed in Table 4.15. Figure 4.39 illustrates the sub-division of 124 patients 
according to the degree of lung-shunting. Two representative scintigrams are shown in Figure 
4.40 and 4.41 which has 1 % and 67.2% lung-shunting respectively. 
The size of major tumour of each patient was measured which ranged from 2 to 26.2cm 
with a median of 12.5cm. Plotting tumour sizes against lung-shunting showed no correlation (Fig 
4.42). 
The relationship between the percentage of lung-shunting and the tumour vascularity 
grading as assessed on HAG is illustrated in Figure 4.43. The lung-shunting percentage of 
patients having vascular score 1 and 2 are compared with those having score 3 and 4 using 
Wilcoxon 2-sample test, the p value is less than 0.0001. This suggests those with more vascular 
lesion are having larger lung-shunting. 
In 6 patients, lung-shunting percentages were estimated by injecting Tc-MAA through a 
Port-A-Catheters with and without angiotensin 11 pre-treatment. There was no difference in lung-
shunting for these patients (paired student t-test, p=0.16, Table 4.16). 
One of the patients had a 15cm right lobe tumour and vascular score of 3 on HAG had 
undergone right hepatic resection. The lung-shunting dropped from 28.5% (pre-operative) to less 




Table 4.15 Lun!! Shuntin!! % for 124 Patients as Determined bv Tc-MAA Scan 
Number Sex Age Tumour size Vascularity score Lung shunting % 
1 M 60 10 3 4.3 
2 M · 20 '4 3 9.8 
3 M 37 14 ' 3 7.5 
4 M 64 15.5 0 11.1 
5 M 42 5.5 2 3.5 
6 M 71 7.7 3 8.6 
7 M 53 8 2 4.5 
8 M 41 10 0 3.2 
9 F 71 22 3 9.9 
10 M 57 3 2 0 
11 F 42 13.6 4 44.5 
12 M 48 10.7 3 5.7 
13 F 65 9 2 8.2 
14 M 73 6 2 0 
15 F 73 6 3 7.6 
16 M 48 8 3 9.2 
17 M 67 7.1 3 0 
18 M 56 10 2 3.9 
19 F 54 3 2 0 
20 M 45 14.3 3 9.6 
21 M 69 7 3 36.4 
22 M 60 9 1 3.4 
23 M 33 5 2 9.3 
24 M 59 2 1 2.7 
25 M 60 26.2 1 36.7 
26 M 16 9 3 23.6 
27 M 66 5 3 4.3 
28 M 56 13 3 29 
29 M 33 7 2 4.8 
30 M 61 7.9 3 5.3 
31 M 64 15 4 17.4 
32 M 40 17 4 21 
33 M 72 7 3 14.6 
34 M 64 9 2 7.1 
35 M 41 7 3 9.3 
36 M 37 9 3 5.2 
37 M 39 5.5 2 5.2 
38 M 54 11 3 5.2 
39 M 63 12.5 2 4.9 
40 M 53 8.3 0 2.6 
41 M 36 16.1 4 5.2 
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Number Sex Age Tumour size Vascularity score TIN ratio 
42 M 46 14 0 16.6 
43 F 67 6,5 3 21 
44 M 62 6 3 61.1 
45 F 57 .9,5 3 5.6 
46 M 56 13 ' 3 5.6 
47 M 39 15.5 2 4.7 
48 M 50 16.7 3 18.8 
. 49 M 49 12.5 1 0 
50 M 52 15.5 3 6.1 
51 M 67 14.9 3 37.2 
52 F '61 16.7 3 13.5 
53 M 58 17.9 4 8.7 
54 M 64 16.1 2 7.9 
55 M 39 11.9 3 17.7 
56 F 34 14 4 6.7 
57 M 44 7.1 2 4.1 
58 M 55 16.7 0 4.5 
59 M 48 13.1 4 17.8 
60 M 54 13 4 67.2 
61 M 54 13.1 3 12.1 
62 M 71 10.7 3 11.7 
63 M 36 19 3 21.1 
64 M 61 13.1 4 26.7 
65 M 53 9.5 2 1.3 
66 M 50 13.7 3 6.6 
67 M 60 12.5 2 4.2 
68 M 59 17.9 2 26 
69 M 63 11.9 3 29.6 
70 F 62 13.1 3 12.8 
71 M 68 14.3 3 28 
72 M 47 17.9 2 18.9 
73 M 55 15 2 10.7 
74 M 52 20 3 11.4 
75 M 70 23.8 4 28.5 
76 F 64 11.9 3 11.6 
77 M 56 13.7 3 3.8 
78 M 46 2-1.4 4 5.2 
79 M 43 19.6 4 5 
80 M 36 17.9 2 3.5 
81 F 70 13.1 3 10.3 
82 M 42 15.5 4 50.1 
83 M 34 13.1 3 3.4 
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Number Sex Age Tumour size Vascularity score TIN ratio 
84 M 62 11.9 2 0 
85 M 45 9.5 2 4.4 
86 M 66 8.3 3 8.1 
87 M 59 13.7 2 13.4 
88 M 42 13.1 -3 11.1 
89 M 64 9.3 1 7.7 
90 M 42 16.3 3 11.8 
91 M 60 6 2 8.4 
92 M 70 9 2 4.9 
93 M 30 17.9 3 26.9 
94 M :46 17.8 1 23.9 
95 M 60 4 0 2.2 
96 F 66 16.1 3 3.5 
97 M 32 13.1 3 20.4 
98 M 64 17.8 3 8.9 
99 M 46 5.3 1 4.5 
100 M 55 5 1 2.2 
101 M 39 13.9 0 4 
102 M 68 15.5 4 27.2 
103 M 73 10.7 4 41.9 
104 M 61 13 3 32.7 
105 M 59 15.5 2 25.9 
106 M 64 10.7 1 3.4 
107 M 44 6 2 7.2 
108 M 38 19 3 1.8 
109 M 52 17.9 4 2.7 
110 M 54 8.7 2 4.8 
111 M 43 14.9 4 47.5 
112 M 40 13.1 3 18.1 
113 M 45 17.9 4 33.5 
114 M 32 7 0 4.2 
115 M 35 10.7 0 0 
116 M 48 16.7 3 27.1 
117 M 34 11.9 3 25.2 
118 M 48 8.3 1 2.2 
119 M 43 7 1 4.4 
120 M 55 16.7 2 10.4 
121 F 63 4.8 2 3.3 
122 M 62 11.9 2 7.6 
123 M 57 13.1 2 49.9 
124 M 57 9.5 3 6 

































































































































































·Fig-4AO ·Tc-MAA·Scan *ming:al% Lung Shunting 
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~CC is usually very vascular due to neovascularisation. Capillaries within the tumour are 
expected to be embolised by the Tc-MAA because of similar in size ' and few can leak through if 
there is no arteriovenous shunting. However, arteriovenous shunting is well known in HCC. 
Therefore the leaked Tc-MAA will go through these abnormal vascular channel and be detected 
in extrahepatic organs. The lungs, being a first pass organ and having similar capillary structure, 
will hold up the leaked Tc-MAA. Few MAA will leak to other organs because the capillary bed in 
the lungs is able to stop any further systemic leaking. Thus, measuring the degree of lung-
shunting can indirectly reflect the degree of arteriovenous shunting in the liver tumour. 
Other hepatic arterial perfusion scintigraphy using Tc-MAA had been employed to assess 
the leakage of regional chemotherapy for liv~r metastases into the pulmonary circulation(56,57). 
The percentage of lung-shunting was found to be between 6 and 26% (mean 12.3%) in a series of 
20 patients(56) and between 0.4 to 32% (mean 6.2%) in another series of 67 patients(57). A much 
wider range «1 % to 67.2%) of pulmonary shunting was observed in the 125 patients with 
primary liver cancer and cirrhosis. The degree of shunting appears to be higher in patients with 




, found 49% of patients with metastatic tumour had percentage equal to or greater than 5% whereas 
66% of the patients with HCC had a value equal to or greater ,than 5%. 
Our results also showed that the degree of arteriovenous shunting to the lungs was 
influenced by the vascularity of the' tumours but not by the tumour size. Thus, the pattern of 
blood flow through the tumour seems to be the determining factor of pulmonary shunting. This 
may be due to tumour which is vascular and rich in blood supply has more arteriovenous shunts 
with resultant increase in lung-shunting. The poor correlation between tumour size and lung-
shunting may be due :'to the fact that tumour size correlates poorly with vascularity. Some 
hypervascular tumours have minimal lung-shunting which do not agree with the trend in this 
study. One explanation is that the centre of the tumour may be necrotic and relatively 
hypovascular, yet on HAG is interpreted as hypervascular because the outer boundary of the 
tumour is hypervascular. This appears to be a pitfall in using HAG in assessment of vascularity 
because it is only a two-dimensional assessment and a hypovascular centre may be masked by a 
hypervascular shell of a tumour. This will be further discussed in the next study. 
Angiotensin 11 was suggested to induce vasoconstriction of normal blood vessels but not 
neoplastic ones(58). It had been used '·extensively in SIR therapy using 90Yttrium-
microspheres(59) and for targeting cytotoxic-loaded microspheres into liver tumours(60). 
Comparison of the percentage of lung-shunting with and without Angiotensin 11 in 6 patients 
showed no significant difference. This finding is in agreement with that of Goldberg et al(55) and 
these observations suggest that the vessels responsible for the shunting is neoplastic in nature. The 
dramatic decrease in the lung-shunting after resection for HCC in one patient concurred with 
Goldberg's finding but more patients should be studied to prove the point. 
In summary, arteriovenous shunting of Tc-MAA to the lungs after injection into the 
hepatic artery was found to have a wide !ange and it was high in a large proportion of patients 
'258 ' 
with HCC. The degree of shunting was related to tumour vascularity rather than tumour size. 
' .. 
Assessment of lung-shunting by Tc-MAA scan before any regional targeted treatment is useful in 
excluding patients who may have high risks of excessive pulmonary irradiation after SIR 




Correlation of Tumour Vascularity Grading by Selective Hepatic Angiography with 
TIN Ratio from Tc-MAA Scan in Hepatocellular Carcinoma 
From the previous 2 studies, Tc-MAA scan has been shown to be useful in predicting TIN 
ratio and lung-shunting percentages and both factors ar~ crucial to the success of SIR. It was also 
shown that tumour vascularity can influence TIN ratio and lung-shunting. The tumour vascularity 
also reflects the volume of the vascular space within the tumour. As mentioned before, a 
hypervascular tumour on HAG may not necessary mean the centre of the tumour is also vascular. 
A hypovascular tumour does not have enough vascular space to contain all the therapeutic drugs 
(either cytotoxics or radio-isotopes) introduced into the hepatic artery, and the excess will go to 
the non-tumourous part of the liver or into the systemic circulation. 
Tumour vascularity is conventionally assessed by HAG. The assessment is a subjective 
and qualitative estimation. Conventional HAG may give a false impression of a vascular tumour 
in these cases because it only gives a two-dimensional picture. The volume of the vascular spaces 
within these tumours can be quite small. 
Tc-MAA scan has been used to assess the vascularity of metastatic liver cancer and to 
predict the TIN ratio in SIR therapy(32,59,61-63). The present study attempts to correlate the 
vascularity gradings by conventional HAG with the TIN ratio as calculated by Tc-MAA scan in 
HCC. 
Patients and methods 
Fifty-one patients with HCC (diagnosed by the usual criteria) who were considered for 
surgical resection or regional chemotherapy or SIR therapy but required a diagnostic HAG as part 
of the pre-treatment investigations were considered eligible to enter into the present study. HAG 
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was performed by the Seldinger technique. A\diagnostic set of angiographic pictures was taken 
first. Tc-MAA scan was performed and the TIN ratio determined as described previously. 
The· radiologist who performed the HAG scored the tum0"!lr vascularity according to the 
scale from grade 1 (hypovascular) to ' 4 (extremely hypervascular). The presence of mild tumour 
staining without any increase in the number of vessels was grade 1. Moderate tumour staining and 
an increased number of vessels was grade 2. Intense tumour staining and a markedly increased 
number of vessels, which were also dilated and tortuous was grade 3. Tumours having all of the 
grade 3 characteristics"'and also showed venous pooling were classified as grade 4. Typical 
vascularity grading HAG pictures are shown in Figures 4.35-38. The HAG vascularity grading 
was then compared with the TIN ratio from the Tc-MAA scan by the Wilcoxon rank test. 
261 
Results 
. ~. The distribution of the different grades of vascularity were: 5 grade 1 cases, 13 grade 2 
cases, 24 grade 3 cases and 9 grade 4 cases. The median TIN ratio from the Tc-MAA scan was 
3.7 (range, 0.9 to 11.1). Table 4.'17 shows the vascularity grading and the mean TIN ratio, and 
Figure 4.44 shows the distribution of the TIN ratio in relation to the vascularity grading. The TIN 
ratio of grade 1 and 2 tumours (slight to moderate increase in vascularity) was compared with 
grade 3 and 4 tumours (severe to extreme increase in vascularity), but there was no statistically 
significant difference b~tween the two groups (Wilcoxon rank test: p=0.83). 

















Two patients are presented here to illustrate the discrepancy. First patient was diagnosed 
to have HCC by laparotomy and biopsy in another hospital. The surgical findings confirmed a 
relatively hypovascular tumour and the HAG 'assessed vascularity by our radiologist was grade 1 
(Fig 4.45). However, this case showed a good TIN ratio of 3.5 on the Tc-MAA scan (Fig 4.31). 
Conversely in the second patient, the HAG assessed vascularity of was grade 3 (Fig 4.46) whereas 







































































































































Fig 4.45 Grade 1 Vascu1arity on HAG 





. ,;" . 
Discussion 
, Regional intra-arterial chemotherapy, chemoembolisation and internal radiation therapy 
are increasingly used in the treatment of inoperable HCC. Vascular tumours that appear on HAG 
are commonly chosen for intra-arterial treatment because more blood flow can carry more of the 
therapeutic substances into the tumour. However, as explained before, a visually hypervascular 
tumour on HAG may have ,a poor TIN ratio so that drugs or radio-Iabeled targeting substances 
may not go inside the tumour. This is confirmed by the present study that vascularity gradings 
from HAG correlates p~'orly with TIN ratio by Tc-MAA scan. 
The findings in this study is not just relevant to internal radiation but to other intra-arterial 
treatment. However, this issue is seldom addressed in most intra-arterial treatment programmes. 
The introduction of Tc-MAA scan has provided an accurate method to predict the TIN ratio, and 
it is useful in the selection of cases suitable for intra-arterial treatment(61-62). The vascularity 
gradings that scored by conventional HAG correlates poorly with the TIN ratio from Tc-MAA 
scan. This suggests inaccuracy of conventional HAG in selecting patients for intra-arterial 
treatment. Therefore, Tc-MAA scan might be an essential investigation in selecting patients for 
intra-arterial treatment. In future intra-arterial chemotherapy or chemoembolisation trials, TIN 
ratio should be tested for correlation with tumour response and systemic toxicity. Furthermore, 
different TIN ratios might be related to different pharmacokinetics for drugs after intra-arterial 
administration. 
I 
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Pulmonary Complications from 90Yttrium-Microspheres Treatments 
Background 
Lung tissues are susceptible to radiation damage. From an animal study on rats after 
whole body irradiation, the capillary' endothelial and .type I cells (epithelial lining cells) in the 
lungs appear most susceptible( 65) to damage. Over time, capillaries regenerate, and the alveolar 
epithelium is repopulated by type 11 cells (surfactant-producing cells). If the injury is severe, 
damage to other non-dividing materials of the lung, such as proteins and polysaccharides, takes 
place. This results in functional derangement and scar formation. Many factors are critical to the 
development of radiation pneumonitis but the most important is the volume of lung tissue that is 
irradiated and the dose of radiation. Radiation pneumonitis seldom occurs with doses of less than 
2,000 cOy but is highly likely when doses exceed 6,000 cOy(66) for external beam radiation 
therapy. 
The histo-pathologic changes of radiation pneumonitis can be divided into early, .. 
intermediate, and late stages based on the time, course, and the absorbed dose of radiation (67) . 
Early changes (0-2 months after radiation) are characterised by injury to small vessels and 
capillaries with the development of vascular congestion and increased capillary permeability(68). 
At this stage, a fibrin-rich exudate is present in the alveolar spaces. Hyaline membranes form on 
the alveoli, probably from condensation of the intra-alveolar fibrin. The intermediate stage (2-9 
months after radiation) is characterised by obstruction of pulmonary capillaries by platelets, 
fibrin, and collagen. Alveolar-lining cells become hyperplastic, and the alveolar walls become 
infiltrated with fibroblasts. The changes of early and intermediate stage · may be reversed with · 
,-
time but when the injury is severe, a chronic phase (9 months or more after radiation) ensues that 
may persist or progress for months or years. The histo-pathologic appearance then is dominated 
by dense fibrosis, thickening of the alveolar walls, vasc~lar subintimal fibrosis, and luminal 
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, narrowing. The lung may shrink to less than half its original size with a thickened adherent pleura 
and scarred hilar structures. 
Symptoms of radiation pneumonitis usually develop 2 to 3 months after radiotherapy, 
depending on the dose and volume of lung irradiated. The cardinal symptom is dyspnoea and a 
dry· cough (67). Frank haemoptysis is rare but has been reported (69). Other uncommon symptoms 
include chest pain and fever. On physical examination, signs are minimal for early or mild cases. 
Occasionally, rales or a pleural friction rub or small amount of pleural effusion may be detected. 
- . 
In severe cases, tachypnoea and cyanosis may be present, and occasionally evidence of acute cor 
pulmonale appears which is usually fatal. 
Radiologic abnormalities are invariably found at presentation. Early changes include a 
ground-glass opacification, diffuse haziness, or indistinctness of the normal pulmonary markings 
over the irradiated area(70). Later, the CXR may show alveolar infiltrates or dense consolidation 
with or without air bronchograms. As the pneumonitis progresses to fibrosis, the radiographic 
appearance changes to that of linear streaks radiating from the area of pneumonitis and of 
contraction toward the hilar, the permediastinal, or the apical areas. The abnormality ill 
pulmonary function test is mainly a restrictive pattern of ventilatory dysfunction and impaired gas 
exchange parameters(71). The diagnosis of radiation pneumonitis can usually be made on the 
timing of irradiation in relation to symptoms and the typical CXR findings. Differentiation from 
recurrent malignancy or infection often poses a problem, and then lung biopsy is necessary. 
Most of the clinical studies on radiation pneumonitis came from external beam irradiation. 
Radiation pneumonitis from internal _irradiation has not been reported before. Internal radiation 
.' 
with intra-arterial 90Yttrium-microspheres can damage the lungs with leaked radiolabeled-
micro spheres to the pulmonary circulation and cause radiation pneumonitis. Therefore, the 
method of using Tc-MAA scan to predict lung-shunting was devised which is crucial in order to 
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prevent radiation pneumonitis(45-47,64). Patients with lung-shunting percentage of less than 15% 
{, are selected for SIR treatment with 90Yttrium-microspheres. However, some patients with 
marginally high percentage shunting were still treated out of protocol, or entered into another 
protocol on the use of ivalon partiale,mbolisation to reduce lung-shunting percentage. Therefore, 
there were a few patients who had high lung-shunting percentages who had received SIR therapy 
as well. Five patients are reported here who had developed the complication of radiation 
pneumonitis. 
Patients 
Five patients developed radiation pnuemonitis after SIR treatment with 90Yttrium-
microspheres. Four of the patients had inoperable HCC and one had metastatic liver tumours due 
to carcinoma of colon. Radiation pneumonitis is defined by the following criteria: 
1. Previous treatment with 90Yttrium-microspheres SIR treatment 
2. Deteriorating pulmonary function both clinically and by pulmonary function tests 
3. Other causes of deteriorating pulmonary function confidently excluded or found 
not to be significant: heart failure, chest infection, pulmonary embolisation, pleural 




The characteristics of these five patients are listed in Table 4.18. 
Table 4.18. Characteristics of 5 Patients Having Radiation 'Pneumonitis 
No. Sex! Diagnosis % lung- Date(s) of Dose of Response Survival 
Age shunting SIR-Rx 90y (GBq) to 90y (months) 
1 - M/59 Metastatic 14.8 28/11/91 5 PR 16.5 
Ca colon 28/5/92 3.4 
2 M/26 Inoperable 15.7 9/4/93 4 PR 8 
HCC 
3 M/60 Inoperable 23.7 10/6/93 4 PR 3 
HCC 
4 M/48 Inoperable 36.5 23/6/93 4 PR 4 
HCC 
5 F/52 Inoperable 45.6 9/9/93 5 SD 1 
HCC 
Patient 1 was male, 59 years old, had metastatic carcinoma of colon to the liver who failed 
systemic chemotherapy with 5-FU and high dose folinic acid. The local disease in the colon was 
under control and there was no extrahepatic disease documented. The liver secondaries were too 
multiple for surgical resection. He had no history of chronic lung or heart disease and he was a 
non-smoker as well. HAG was performed with an intent for SIR treatment. The lung-shunting 
percentage was 14.8% and the TIN ratio by T~-MAA was 2.1. He was then treated with 5 GBq of 
90Y-microspheres at laparotomy. The treatment was uneventful. He responded very well initially. 
The CEA level dropped from 11,300nglL to 188 nglL in 2 -months' time. Repeat CT scan at 2 
months post-treatment confirmed partial response. The disease progressed 6 months after the fjrst 
SIR. A second treatment of SIR with 3.4 GBq 90y -microspheres percutaneously through the 
Port-A-Catheter which was inserted at first operation. The disease responded the second _time to 
treatment with reduction of CEA level and also regression of tumour volume radiologically. He 
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:, . was admitted 5 months after the second treatment because of dry cough, exertional dyspnoea but 
~! .. 
ri,', without a temperature. The CXR on admission showed·, extensive patchy consolidations. 
~: 
~. Pulmonary function tests showed a restrictive pattern. He was extensively investigated for a cause 
of the changes in the lungs. There was ,no positive culture to suggest an infection. A 
bronchoscopy was done which was essentially negative. His exercise tolerance gradually 
deteriorated. He was treated with steroids and had improvement in symptoms. He was maintained 
on the steroids until he succumbed 5 months later. Before he died, there was already progressive 
disease due to the colon cancer invading into the second part of the duodenum. He died of 
malignant cachexia due to disseminated malignancy. 
Patient 2, male 26 years old, had inoperable HCC at prese!ltation because of bi-Iobar 
disease. He was treated with 4 GBq 90Y-microspheres through HAG percutaneously. He has no 
significant previous medical history, particularly no history of pulmonary disease. The lung-
shunting percentage calculated from the Tc-MAA scan was 15.7%. In view of his young age and 
lack of any alternative treatment, it was decided to proceed with SIR. The HCC responded very 
well to 90Y-microspheres and the AFP dropped from 211,090J.lg/L to the lowest 9,730J.lg/L in 1 
month's time. The tumour also regressed and the overall response was partial remission. He 
presented with dry cough and progressive dyspnoea 2 months after SIR. The CXR findings were 
similar to the previous patient. Infective causes were excluded after extensive investigations. The 
pulmonary function tests showed restrictive ventilatory defect with decreased gas exchange 
parameters. An open lung biopsy was carried out which revealed features of radiation 
pneumonitis. His symptom of dyspnoea was well controlled with steroids for 5 months. However, 
his HCC progressed following control for half a year. He was seen by a surgeon from another 
hospital who attempted a resection of the tumour. Unfortunately, the patient died post-operatively 
due to respiratory failure. ' 
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Patient 3, male 60 years old, had inoperable HCC at presentation. He had a 23.7% lung-
shunting on Tc-MAA scan and a TIN ratio of 8. In view of his high lung-shunting from pre-
operatively Tc-MAA scan, partial embolisation with ivalon particles was done before the SIR 
treatment. He was treated with 4 G~q of 90Y-microspheres during HAG. The ivalon particles 
managed to bring down the lung-shunting percentage 'to from 23.7% to 5.3%. However, he still 
developed radiation pneumonitis about 2 months after 90Y-microspheres treatment. At that time, 
he complained of dyspnoea, coughing and CXR revealed left mid and lower zone haziness. A 
thoracoscopic biopsy of the left lung was done which confirmed radiation pneumonitis. His 
pulmonary function test was of the restrictive defect type. He succumbed 1 month later due to 
respiratory failure. This patient had only a modest decrease of AFP from 1,058Jlg/L to the lowest 
792Jlg/L after SIR. 
Patient 4, male 48 years old, also had inoperable HCC on presentation. He had no 
previous pulmonary or heart disease and a normal pulmonary function test before SIR. The lung-
shunting percentage was 36.5% and TIN ratio was 4 from the pre-treatment Tc-MAA scan. 
Again, in view of the high lung-shunting, he was given partial embolisation with ivalon particles 
before SIR treatment. The ivalon managed to bring down the lung-shunting from 36.5% to 
12.8%. He was then treated with 4 GBq 90Y-microspheres during HAG. The HCC responded 
very well to 90y -micro spheres treatment. T~e AFP decreased from 65690Jlg/L to 13Jlg/L in 3 
months time. The overall response was a partial remission. Three months later, he presented with 
cough and dyspnoea without fever. The CXR findings were compatible with radiation 
pneumonitis. An infective cause could not be found after extensive investigation. An open lung 
" 
biopsy was carried out which confirmed the diagnosis histologically. He had progressive 




The last patient was a 52 year old lady 'who had inoperable HCC at presentation. She had 
no previous of lung or heart disease and she was a non-smoker. The HCC was not previously 
treated. HAG and Tc-MAA scan showed that she had a high lung-shunting percentage of 45.6%. 
Despite the high lung-shunting, she w:as given SIR after partial embolisation with ivalon particles 
to reduce lung-shunting to 10.1 %. The dose of 90y w~s 5 GBq. She first noticed the symptom of 
dyspnoea shortly after SIR therapy. The chest X-ray and pulmonary function test findings were 
similar to the previous 4 patients. Radiation pneumonitis was diagnosed after excluding other 
causes. She did not respqnd to steroid treatment and succumbed 1 month after the SIR treatment 
due to respiratory failure. The survival duration was so short that evaluation of response was not 
carried out. 
Pathological and Radiological Findings 
All the patients had histological confirmation either through bronchoscopy or open lung 
biopsy. They all shared similar histological findings. Typical microscopic pictures under low and 
high power are shown in Figure 4.47. The lung tissue showed dense fibrosis and acute 
inflammation with fibrin. Scattered microspheies are also visible. 
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Fig 4.47a 90Y-Microspheres in Lung TIssue having 
Radiation Pneumonitis (Low power) 
Fig 4.47b 90Y-Microspheres in Lung Tissue having 




Chest X-rays of patient 2 and 4 snowed a typical pattern of extensive peripheral 
consolidation with a very well defined lateral margin (Fig ;4.48). This was particularly well 
demonstrated on CT scan in patient 2 (Fig 4.49) which confirms that the areas of opacification lie 
mostly peripherally within the lungs. ,The lateral edge of the shadowing is seen to run parallel to 
the lung edge and fissures. Air bronchograms are clearly visible indicating that there is air-space 
shadowing. The peripheral location of the consolidation is thought to be due to lodging of the 
micro spheres in distal pulmonary arterioles which are ' too small to allow them to travel further. 
Chest X-rays of patient -:l, 3 and 5 showed more localised pulmonary abnormalities, consisting of 
smaller areas of patchy consolidation, again lying peripherally within the lungs. 
In the cases (patient 1 and 2) where sufficient follow up_ was possible, changes of 
widespread severe fibrosis were seen on the plain film between 7 and 11 months following SIR 
therapy (Fig 4.50). Again this time scale is consistent with chest X-ray changes of radiation 
fibrosis following external radiation(72). 
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Fig 4.48 CXR of a Patient having Radiation Pneumonitis 
Fig 4.49 er Scan of a Patient having Ra~ation Pneumonitis 
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These 5 patients illustrated an important complication' after SIR with 90Y-microspheres. 
They all shared a similar predisposing factor which is high lung-shunting. Partial embolisation 
with ivalon particles ' in 3 patients was tried which did manage to bring down lung-shunting 
percentage to below 15%. However, this did not prevent the complication~ Therefore, it is clearly 
shown here that the ivalon particles can only stop the Tc-MAA from passing through the 
arteriovenous shunts but not the radio-Iabeled microspheres. It is thought that . the Tc-MAA might 
stick to the ivalon particles. Another explanation might be due ,to the higher density of the 
micro spheres compared with Tc-MAA so that the momentum carried by the fast moving 
microspheres opens up the blocked arteriovenous shunts. 
However, reviewing all the patients who received SIR treatment with 90Y-microspheres, 
there is no patient apart from patient 1 in this series, who had a lung-shunting percentage below 
15% and none of them developed radiation pneumonitis. Therefore, SIR therapy should be 
avoided in patients with lung-shunting percentages more than 15%. This also stressed the 
importance of pre-treatment Tc-MAA scan to document lung-shunting percentage. 
Corticosteroids are used in treatment of radiation pneumonitis and can reduce the degree 
of inflammation. Ruben and Casarett(73) collected data from eight studies on humans and 
categorised them according to whether corticosteroids were used prophylactic ally or 
therapeutically. Steroids given prophylactic ally failed to prevent radiation pneumonitis, but when 
they were given as clinical pneumonitis occurred, an objective response was seen. The treatment 
did not improve the situation in 3 patients who had a lung-shunting percentage of more than 20%. ' 
The first two patients had improvement after steroid treatment and both of them had lung-




The radiological appearances are those of air-space shadowing. Theoretically, any cause 
of pulmonary consolidation could cause such opacification" but the distribution is unusual for 
other aetiologies. Infection would be the most likely differential diagnosis, but tends to conform 
to anatomical boundaries. Eosinophilic pneumonia is typically peripheral in location and does not 
subscribe to normal segmental boundaries. However the opacities usually lie against the chest 
wall, unlike those seen in the cases which do not extend to the periphery. Pulmonary oedema 
frequently causes air-space shadowing, but the abnormality is usually central, and there are no 
other features to support cardiac failure. Pulmonary haemorrhage can also result in lung 
consolidation, but again the clinical picture does not support this diagnosis and the distribution 
would be very atypical. 
The plain radiographic changes of radiation pneumonitis are usually seen between 2 and 6 
months following completion of treatment(72). All of the cases showed consolidation on the chest 
film between ' 2 and 4 months following SIR therapy. eT scanning is more sensitive to subtle 
changes in attenuation, and radiation pneumonitis rnay be detected earlier by eT, as well as being 




Conclusion to Part III 
~ It has been shown that despite previous belief that 'HCC is radioresistant, it is actually 
sensitive to radiation if an adequate dose can be delivered. Both intraarterial Lipiodol-Iodine131 
and Yttrium90 micro spheres are effective because a tumouricidal dose of radiation can be 
delivered. Radiation to non-tumourous liver can be kept below the maximum tolerable level. 
Systemic toxicities are avoided because both substances stay within the liver tumour. Hence, the 
new novel treatment is feasible, effective and safe for the treatment of inoperable HCC. 
Selection of patients for such treatment is important. Tc-MAA scanning has been shown 
to be useful as simulation for selective internal radiation therapy to predict TIN ratio and 
pulmonary shunting. It can predict TIN ratio better than can plain angiography. Complications of 
radiation pneumonitis are reported and can be avoided by careful patient selection. 
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Conclusion of the Thesis 
,-, This thesis tests the hypothesis that "improvement in loco-regional control of HCC by a 
new treatment, selective internal radiation, is feasible, effective, safe and can significantly 
improve outlook of patients with inoperable HCC". 
From the background study in Part I, the global and regional problems of HCC are 
outlined. Basic facts of the disease are discussed. Local data are presented and the current status 
of treatment and progI?-_?sis are defined. It is concluded that HCC is a serious global and local 
health problem. The prognosis is generally dismal. Part 11 describes the results of conventional 
treatment for inoperable HCC from both the literature and author's own studies. Results from 
conventional treatment are still unsatisfactory and patients' progno'sis is not changed. Median 
survival is about 10 to 12 weeks even for selected cases. The tumour response rate in various 
phase 11 chemotherapy studies was 10% at the best. These results establish the status of treatment 
by conventional methods and are to be compared with treatment results from the new treatment of 
selective internal radiation, in Part Ill. 
Part III gives an account of selective internal radiation therapy which is the tested novel 
modality. On the basis of the bio-distribution study of 131Iodine-Lipiodol and the early phase 11 
studies of 90Yttrium-microspheres, the treatment has been shown to be safe. HCC was 
preferentially irradiated with tumouricidal dose while non-tumourous tissues only received 
relatively low radiation dose, below the maximum tolerance limit. Both treatments also produced 
dramatic tumour regression without undue toxicity. Durable local tumour control is now possible. 
However, case selection is important and it has been shown that Tc-MAA scanning is a crucial 
pretreatment investigation. Its' . power to predict the absorbed radiation dose makes the 
percutaneous administration of SIR feasible and safe, thus avoiding an operation and simplifying 
the technique while maintaining the same high degree of tumour response. The duration of 
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hospital stay has become shorter with percutaneous treatment. Thus, it has been shown that 
selective internal radiation treatment is feasible, effective, safe and improves loco-regional 
control of the disease. Based on an historical control group, survival appears prolonged as 
compared with previous conventional treatment. The research hypothesis is therefore likely to be 
true. 
Concerning future direction of research, further study should be aimed at improvement of 
the technique further by fractionation of the radiation dose and earlier repeat treatment. A 
... ~ ,; 
prospective randomised study is also indicated based on the phase 11 data. At present, internal 
radiation can only be performed in a selected group of patients. Patients with extrahepatic disease, 
high lung-shunting and poor TIN ratio are not suitable. Future studie~ should look into methods to 
reduce lung-shunting and improve TIN ratio. Partial arterial embolisation and the use of 
vasoconstrictors or vasodilators are worthy of study in this respect. The prediction of dose has 
always been difficult in 90y -micro spheres treatment because of the ~ radiation. Single Photon 
Emission Computer Tomography is a better tool to quantify the secondary X-ray (Bremstahlung 
effect) so that some form of dosimetric measurement can be carried out. This should be compared 
with Tc-MAA scan in a prospective trial. Although 131Iodine-Lipiodol is not as powerful as 
90Yttrium-microspheres in terms of energy, it is satisfactory for small tumours, and perhaps 
microscopic disease. Hence, further study with 131I-L as a form of adjuvant treatment after 
surgical resection is currently underway. 
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A P P E N D I X 
I. W.H.O. Recommendations for Grading of Acute and Subacute Toxicity 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
HAEMATOLOGIC 
(ADULTS) 
Haemoglobin (g/lOOml) > 11.0 9.5 -10.9 8.0 - 9.4 6.5 - 7.9 < 6.5 
Leukocytes 1000/mm3 >4.0 3.0-3.9 2.0-2.9 1.0- 1.9 <1.0 
Granulocytes 1000/mm3 >2.0 1.5-1.9 1.0-1.4 0.5-0.9 <0.5 
Platelets 1000/mm3 > 100 75-99 50-74 25-49 <25 
Haemorrhage none petechiae mild blood gross blood debilitating 
loss loss 
GASTROINTESTINAL ::: 
Bilirubin < 1.25xN* 1.26-2.5 xN 2.6-5 xN 5.1-10xN >10xN 
SGOT/SGPT <1.25xN 1.26-2.5 xN 2.6-5 xN 5.1-10xN >10xN 
Alkaline phosphatase <1.25xN 1.26-2,5 xN 2.6-5 xN 5.1-10xN >10xN 
Oral none soreness/ erythema/ulcers ulcers, requires alimentation 
erythema can eat solids liquid diet only not possible 
Nausea/vomiting none nausea transient vomiting intractable 
vomiting requiring Rx vomiting 
Diarrhoea none transient tolerable but intolerable haemorrhagic, 
> 2 days requiring Rd dehydration 
RENAL, BLADDER 
BUN or blood urea <1.25xN 1,26-2.5 xN 2.6-5 xN 5 - 1 0 x N >10xN 
Creatinine <1.25xN 1.26 - 2.5 xN 2.6-5 xN 5 - 1 0 x N >10xN 
Proteinuria none 1+, < 0.3g/100ml 2 - 3+, 0.3 -1.0 4+, > l.Og/lOOml nephrotic 
syndrome 
Haematuria none microscopic gross gross + clots obstructive 
uropathy 
Pulmonary none mild symptoms exertional dyspnoea at rest complete bed 
dyspnoea rest needed 
Fever-drug none fever<38°C fever 38-40°C fever >40°C fever with 
hypertension 
Allergic none oedema bronchospasm, bronchospasm, anaphylaxis 
’" no parenteral parenteral Rx 
therapy needed required 
Cutaneous none erythema dry moist exfoliative 
desquamation desquamation dermatitis 
ulceration necrosis 
Hair none minimal hair moderate, complete non-reversible 
loss patchy alopecia alopecia 
alopecia but reversible 
Infection none minor infection moderate major infection major 
(specify site) infection infection 
with 
hypotension 
nnnnnrLrLrLrLrLrLfWUinrLnmWUWinAnJVWWVtfWWWVWVVWWWWVWWWWWWVVVWVVVVWVVVVV^ W^WWWWWWWWWWWWWWWWWVWVWWWVtfCviwWWWVVVWWVWWWWVVWWWWVWWV^  
/WVWWWVWWWVWVWMVWWWWWWWWWVWVWVWWWWWWVWWWWWWWVWWWWVWWWWWWWWWWWWWWWVVWVWUUIJ•……•… 
* Upper limit of normal 
316 
Grade 0 Grade 1 Grade 2 
CARDIAC 
Rhythm none sinus unifocal PVC 
tachycardia atrial arrhythmia 
> 100 at rest 
Function none asymptomatic transient 
but symptomatic 
abnormal dys~ction, no 
cardiac therapy required 
sign 
Pericarditis none asymptomatic symptomatic, no 
effusion tap required 
NEUROTOXICITY 
State of consciousness alert transient somnolence < 50% 
lethargy of waking hours 
Peripheral none paraesthesia severe paraesthesia 
and/ and/or mild 
or decreased weakness 
tendon reflexes 
Constipation * mild moderate none 
PAIN* ,none mild moderate 
* Constipation does not include constipation resulting from narcotics. 











of waking hours 
intolerable 
paraesthesia and/ 






















ll. Tumour Response criteria 
1. Complete Response (CR) 
The disappearance of all known lesions on radiological ground and normalization 
of AFP level for at least 4 weeks 
2. Partial Response (PR) 
Decrease of 50% or more in the maximum diameter of the largest tumor nodule 
with a decrease of AFP level for at least 4 weeks. There should be no new 
appearance of lesions or progression of lesions. 
3. No Change (NC) 
Less than 50% decrease or not more than 25% increase in the maximum diameter 
of the largest tumor nodule. 
4. Progressive Disease (PD) 
More than 25% increase in the maximum diameter of the largest tumor nodule or 
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